UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 

 

Date of report (Date of earliest event reported):   November 11, 2016 (November 7, 2016)

 

MAKKANOTTI GROUP CORP.

(Exact name of registrant as specified in its charter)

 

Nevada

 

333-204857

 

37-1765151

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

1620 Beacon Place, Oxnard, California

 

93033

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code (805) 824-0410

 

Larnakos Avenue, Ap. 402, Nicosia, Cyprus 1046

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨

Pre-commencement communications pursuant to 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 
 
 

Forward Looking Statements

 

This Form 8-K and other reports filed by the registrant from time to time with the Securities and Exchange Commission (collectively the “Filings”) contain or may contain forward looking statements and information that are based upon beliefs of, and information currently available to, the registrant’s management as well as estimates and assumptions made by the registrant’s management. When used in the filings the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan” or the negative of these terms and similar expressions as they relate to the registrant or the registrant’s management identify forward looking statements. Such statements reflect the current view of the registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the registrant’s industry, its operations and results of operations and any businesses that may be acquired by the registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

 

Although the registrant believes that the expectations reflected in the forward looking statements are reasonable, the registrant cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, the registrant does not intend to update any of the forward-looking statements to conform these statements to actual results. The following discussion should be read in conjunction with the registrant’s pro forma financial statements and the related notes filed with this Form 8-K.

 

Item 1.01 Entry into a Material Definitive Agreement

 

On November 7, 2016, the registrant, in a reverse take-over transaction, acquired a specialty pharmaceutical and bioscience company based in California that specializes in drug delivery technologies, by executing a Share Exchange Agreement and Conversion Agreement (“Exchange Agreement”) by and among the registrant and a holder of a majority of the issued and outstanding capital stock of the registrant prior to the closing (the “Majority Stockholder”), on the one hand, and Cure Pharmaceutical Corporation, a California corporation (“Cure Pharmaceutical”), all of the shareholders of Cure Pharmaceutical’s issued and outstanding share capital (the “Cure Pharm Shareholders”) and the holders of certain convertible promissory notes of Cure Pharmaceutical (“Cure Pharm Noteholders”), on the other hand. Hereinafter, this share exchange transaction is described as the “Share Exchange.”

 

The following is a brief description of the terms and conditions of the Exchange Agreement and the transactions contemplated thereunder that are material to the registrant:

 

· Share Exchange and Share Cancellations . The registrant shall issue 9,010,000 restricted shares of its common stock, $0.001 par value per share (“Common Stock”), to the Cure Pharm Shareholders in the aggregate, in exchange for 2,718,253 shares of Cure Pharmaceutical's common stock held by them, representing 100% of the then issued and outstanding common stock of Cure Pharmaceutical (the “Share Exchange”). In connection with the Share Exchange, the Majority Stockholder agreed to cancel 16,181,400 shares of Common Stock of the registrant in exchange for a warrant (the “Majority Stockholder Warrant”) to purchase up to 1,640,305 shares of Common Stock of the registrant at an exercise price of $2.00 per share and with an exercise period of four years commencing on the date of issuance of the warrant. In addition, one other shareholder of the registrant entered into a share cancellation agreement with the registrant whereby such shareholder agreed to cancel 652,390 shares of the registrant's common stock at the closing of the Share Exchange in order to induce Cure Pharmaceutical to enter into the Exchange Agreement.

 

 

· Conversion . The registrant shall issue 6,106,463 restricted shares of Common Stock to the Cure Pharm Noteholders in the aggregate, by converting the convertible promissory notes of Cure Pharmaceutical held by the Cure Pharm Noteholders in the aggregate principal amount of $6,106,463, at a conversion price of $1.00 per share.

 

 

· Change in Management . Michael Hlavsa, the registrant’s sole director and executive officer immediately prior to the closing of the Exchange Agreement, shall resign, and Robert Davidson, William Yuan and Charles Berman shall be appointed to the registrant’s board of directors (the “Board”). Robert Davidson, Edward Maliski, Wayne Nasby and Mark Udell shall be appointed as the new chief executive officer, president and chief scientific officer, chief operating officer, and chief financial officer and secretary, respectively, effective at the closing of the Exchange Agreement. Additional information regarding the above-mentioned directors and executive officers is set forth below in Item 2.01 and Item 5.02.

 

As a result of the Share Exchange, Cure Pharmaceutical became a wholly owned subsidiary of the registrant, and the Cure Pharm Shareholders and Cure Pharm Noteholders became the controlling shareholders of the registrant.

 

The closing of the transactions contemplated under the Exchange Agreement (the “Closing”) took place on November 7, 2016 (the “Closing Date”). As a result, the registrant had a total of 23,266,733 shares of common stock issued and outstanding at the Closing Date, with the Cure Pharm Shareholders and Noteholders collectively owning approximately 64.97% of the registrant’s issued and outstanding Common Stock.

 

 
2
 

 

Except for the Exchange Agreement and the transactions contemplated thereunder, neither the registrant nor its sole officer and director serving prior to the consummation of the Share Exchange had any material relationship with Cure Pharmaceutical or its shareholders.

 

A copy of the Exchange Agreement is included as an exhibit to this Current Report on Form 8-K.

 

Item 2.01 Completion of Acquisition or Disposition of Assets

 

On November 7, 2016, the registrant acquired Cure Pharmaceutical, a fully integrated specialty pharmaceutical/bioscience company with a focus in drug delivery technologies, and its business operations in the Share Exchange. Reference is made to Item 1.01, which is incorporated herein, which summarizes the terms of the Share Exchange.

 

The registrant was incorporated in the state of Nevada on May 15, 2014 and was previously engaged in the business of manufacturing food paper bags in Nicosia, Cyprus for use in supermarkets, fruit kiosks, bakeries, cafés and similar businesses. The registrant previously had two Agreements for Sale of Goods with “Epidorpio Confectionery” Bakery and “A&G Kokkinou Ltd”, which the registrant cancelled on July 1, 2016. On August 19, 2016, the registrant sold all of its equipment relating to its manufacturing of food paper bags business.

 

As of the date immediately prior to the Closing Date, the Company had nominal operations and minimal assets. As a result of the Share Exchange, Cure Pharmaceutical became the registrant’s wholly-owned subsidiary, and the registrant’s principal business is now that of Cure Pharmaceutical. The information provided hereinafter in this Item 2.01 with respect to Cure Pharmaceutical is intended to comply with the disclosure requirements of Form 10 prescribed under the Exchange Act.

 

Except as otherwise indicated by the context, references to “we”, “us” or “our” hereinafter in this Item 2.01 are to the business of Cure Pharmaceutical, except that references to “our common stock”, “our shares of common stock” or “our capital stock” or similar terms shall refer to the common stock of the registrant.

 

DESCRIPTION OF BUSINESS

 

Overview

 

Our wholly owned subsidiary and operating business, Cure Pharmaceutical, located in Oxnard, California was originally incorporated in July 2011 as a developer of advanced oral thin film (“OTF”) for the delivery of nutraceutical, Over-The-Counter (“OTC”) and prescription products for human and veterinary markets. We utilize drug delivery technologies to develop and commercialize new applications of proven therapeutics through our CureFilm™ technology, as well as through sublingual and transdermal applications. Our exclusive micro encapsulation of drug actives allows for a higher volume of an active and if required, multiple actives to be produced on a single OTF strip. We expect this technology will allow us to produce a broad spectrum of pharmaceutical, OTC and nutraceutical products.

 

We are currently focused on partnering with pharmaceutical and biotech companies seeking to deliver drug actives utilizing and benefitting from our proprietary CureFilm™, sublingual and transdermal applications and when preferable to take our own products from clinical process to commercialization. We manufacture our products in our Current Good Manufacturing Practice (“cGMP”) and U.S. Food and Drug Administration (“FDA”) registered manufacturing facility.

 

Background

 

According to IBIS World’s Global Pharmaceuticals & Medicine Manufacturing Market Research Report (2013), the worldwide pharmaceutical market alone represents $1 trillion in revenue and has had an average annual growth of 3.7% from 2008 to 2013. This growth has resulted from the rising demand for healthcare and medications worldwide, especially from emerging economies. Higher healthcare standards and greater emphasis on illness prevention have given pharmaceuticals a higher significance among consumers, driving sales and overall industry growth, which is expected to continue

 

The pet industry is also forecasted to grow exponentially. As domestic pets increasingly become members of the family, pet owners are spending more and more on pet care, resulting in continued future growth. According to the American Pet Products Association (“APPA”), the pet industry is forecasted to reach $62.5 billion by 2016. The most lucrative segment of the pet care industry is pet health care, with health and wellness solutions gaining pace across the industry and with significant opportunities for manufacturers allocating larger research and development budgets, and implementing product innovation and marketing to exploit them. The APPA estimated that $14.98 billion is spent in the OTC pet medicine markets in the United States alone. We intend to utilize our CureFilm™ Technology to develop products marketed towards the veterinarian market.

 

 
3
 

 

Though in its infancy stage (10 years old), OTF Technology is experiencing a major surge in acceptance and adoption by pharmaceutical and biotech companies as they search for new and better ways to deliver drug actives. We believe there are only a handful of pharmaceutical and biotech companies capable of producing OTF strips, limiting competition. In addition, we believe that our proprietary and patented technology creates opportunities within the targeted marketplaces far surpassing the capability of these companies to compete.

 

CureFilm Technology and Value Proposition

 

Typical forms of drug delivery that consumers have been familiar with over the years, include tablets, capsules, chewable, gummies, and more recent developments, such as melts and sublingual drops and sprays. We believe that we are one of the companies at the forefront of OTF drug delivery technology. Our OTF product is about the size of a postage stamp using a matrix that maximizes the amount of “active” drug that can be delivered via OTF.

 

Our CureFilm™ Technology consists of patented, patent pending and trade secrets in two areas: OTF – Core Technology, Sublingual Technology and Transdermal (skin) Technology.

 

Our proprietary multi-layer CureFilm™ allows dosages of many pharmaceutical, OTC and nutraceutical products to be put onto a small strip applied to the cheek (buccal), under the tongue (sublingual). We believe that what sets us apart from the competition is our proprietary patented CureFilm™ Technology, multi-layer systems and formulation technologies that:

 

· Consists of two components - a liquid-based film layer that contains and stabilizes the active ingredients, and a powder matrix layer.

 

 

· Provides improved stability as well as delivery of active ingredients.

 

 

· Contains functional qualities to include extra flavoring ingredients, pliability enhancers, and mucosal permeation enhancers.

 

In a two layer strip, the layers are designed to work together, in combination with the powder composition. The powder composition can be varied, as can the muco-adhesion properties of the strips, to alter the dissolution and absorption rates of the medicament. A complete multilayer system allows for increased stability, higher loading of active ingredients, and increased taste and palatability.

 

Another recent advancement in our CureFilm™ Technology utilizes micro-encapsulation of selected active ingredients. In the micro-encapsulation process, microscopic particles or droplets envelop the active ingredients to protect and shield them. The technique used in the micro-encapsulation process depends on various factors including the physical and chemical properties of the active ingredients. This micro-encapsulation technology has allowed the delivery of higher dosing with better flavor masking.

 

We believe that our CureFilm™ Technology has the following competitive advantages over other drug delivery technologies:

 

· With our proprietary formulations we can put more drugs per cm 2 on a single strip than any of our competitors while still maintaining a positive patient experience.

 

 

· Ability to put multiple actives on one OTF.

 

 

· More stable, durable and quicker to dissolve than other oral deliveries.

 

 

· Improves the onset of action, lower dosing and enhance the efficacy thereby widening the therapeutic index.

 

 

· Differentiation within large therapeutic categories and potentially improves patient compliance.

 

 

· Ability to deliver actives on a single strip through both buccal and gastrointestinal tract, thereby allowing for sustained release.

 

 

· Enters the blood stream directly making it fast acting and more effective.

 

 

· Easy to use, transport and no liquid needed to administer.

 

 

· Ideal for children, elderly patients and patients who have trouble swallowing.

 

 

· Palatable in terms of taste.

 

 
4
 

 

Product Portfolio

 

We have various types of CureFilm ™ dietary supplement products that are being commercialized and developed. These include:

 

Commercialized:

 

· MacuStrip Vitamin complex (eye health product)

 

 

· ID Life Sleep melatonin

 

 

· Electrolyte (Adult and Pediatric)

 

 

· E6 Berry Caffeine

 

 

· Hang-Over Relief

 

In Development:

 

· Aspirin

 

 

· Loratadine

 

 

· Tadalifil

 

 

· Sildenafil

 

 

· Loperamide

 

 

· Vitamin B12

 

 

· Vitamin D3

 

 

· Folic Acid

 

Clinical Development

 

We partner with pharmaceutical companies looking for new methods to deliver drug actives. Under Section (505)(b)(2) of the Food, Drug, and Cosmetic Act, ("(505)(b)(2)") the FDA may grant market exclusivity for a term of up to three years of exclusivity following approval of a listed drug that contains previously approved active ingredients but is approved in a new dosage, dosage form, route of administration or combination. The 505(b)(2) pathway is also the regulatory approach to be followed if an applicant intends to file an application for a product containing a drug that is already approved by the FDA for a certain indication and for which the applicant is seeking approval for a new indication or for a new use, the approval of which is required to be supported by new clinical trials, other than bioavailability studies. We have implemented a strategy under which we actively look for such so-called “repurposing opportunities” and determine whether our proprietary CureFilm™ Technology adds value to the product.

 

We currently have five such drug repurposing projects in our development pipeline, although there can be no assurance that such projects will be fully developed. The companies we partner with are typically responsible for managing the regulatory approval process of the product with the FDA and/or other regulatory bodies, as well as for the marketing and distribution of the products. On a case-by-case basis, we may be responsible for providing all or part of the documentation required for the regulatory submission.

 

In addition to pursuing partnering arrangements that provide for the full funding of a drug development project, we may undertake development of selected product opportunities until the marketing and distribution stage. We would first assess the potential and associated costs for successful development of a product, and then determine at which stage it would be most prudent to seek a partner, balancing costs against the potential for higher returns later in the development process. We currently have five of such potential drug candidates in our product pipeline, all of which are in the formulation development and pre-clinical phase of development. However, there can be no assurance that we will be able to fully develop, market and distribute OTF products for these drug candidates.

 

 
5
 

 

Competition

 

We face competition from other companies, academic institutions, governmental agencies and other public and private research organizations for collaborative arrangements with pharmaceutical and biotechnology companies, in recruiting and retaining highly qualified scientific and management personnel and for licenses to additional technologies. Many of our competitors, including Monosol, BioDelivery Sciences International, IntelGenx and LTS Lohmann, will have substantially greater financial, technical and human resources than we have. Our success will be based in part on our ability to build, obtain regulatory approval for and market acceptance of, and actively manage a portfolio of drugs that addresses unmet medical needs and creates value in patient therapy.

 

The OTF manufacturing industry is relatively new, having only emerged over the last ten years. Although currently there are just a handful of current players within this industry, we expect that we will be subject to competition from numerous other companies that currently operate or are planning to enter the markets in which we compete. To date, among manufacturers of OTF, some medications that either are or have been available by OTF manufacturers in the marketplace include:

 

· Zuplenz (the first oral soluble film approved by the FDA as a prescription medication)

 

 

· Benadryl (diphenhydramine product and anti-histamine used for allergies and mild sedative)

 

 

· Gas-X (simethicone product for bloating, gas, and gastrointestinal complaint)

 

 

· Melatonin PM (hormonal product sold as a "dietary supplement" marketed for insomnia)

 

 

· Orajel Kids (benzocaine product for dental pain)

 

 

· Suboxone (buprenorphine and naloxone fixed dosage combination product for opioid addiction)

 

 

· Subutex (buprenorphine product for opioid addiction)

 

 

· Sudafed (phenylephrine or pseudoephedrine product for nasal congestion)

 

 

· TheraFlu (combination product of pain reliever, anti-pyretic and decongestant)

 

 

· Triaminic (children's anti-tussive product)

 

The barriers to enter this market are the “know how’s” of developing and formulating consumer desired products which taste great. Also, the high cost of entry by companies who have no expertise in the market makes entry by competitors risky since the technology to develop product is expensive and proprietary. The key factors affecting the development and commercialization of our drug delivery products are likely to include, among other factors:

 

· The safety and efficacy of our products;

 

 

· The relative speed with which we can develop products;

 

 

· Generic competition for any product that we develop;

 

 

· Our ability to defend our existing intellectual property and to broaden our intellectual property and technology base;

 

 

· Our ability to differentiate our products;

 

 

· Our ability to develop products that can be manufactured on a cost effective basis;

 

 

· Our ability to manufacture our products in compliance with cGMP and any other regulatory requirements; and

 

 

· Our ability to obtain financing.

 

In order to establish ourselves as a viable industry partner, we plan to continue to invest in our research and development activities and in our manufacturing technology expertise, in order to further strengthen our technology base and to develop the ability to manufacture our CureFilm™ products ourselves, at competitive costs. Our failure to compete effectively could have a material adverse effect on our business.

 

 
6
 

 

Research and Development

 

Research and development (“R&D”) is the cornerstone for Cure Pharmaceutical’s initiatives with drug and brand partners. Our first step in partnering with its target market is to implement their actives and drugs into OTF via the R&D process. Therefore, we are investing heavily in the development of new delivery system technology advancements. Formulation of OTFs involves a specific combination of ingredients such as film-forming polymers, plasticizers, active pharmaceutical ingredients, sweeteners, saliva stimulating agents, flavoring agents, coloring agents, stabilizers and thickening agents. Each active ingredient requires a specific combination of these ingredients to yield the optimum film dissolution and taste that is tailored to each client company’s product/brand. OTF’s can be different colors and be embossed just like pills (e.g. Benadryl strips can be pink and imprinted), and the process of tailoring our services to client needs continues through our manufacturing and packaging operations that allows clients the option to provide single sachets of OTF to cassettes holding multiple OTFs.

 

We continue to make significant advances in OTF technology to include certain microencapsulation and nano-encapsulation technologies, taste masking systems, composition formulations, stability systems, primary packaging advances and production methodologies. Our technological advances allow the offering of highly effective products that contain controlled levels of active ingredients as well as multiple active ingredients in great tasting OTFs.

 

Our R&D expenses, net of R&D tax credits, for the year ended December 31, 2015 was $681,699, compared with $663,899 for the year ended December 31, 2014. The increase in R&D expenditure is explained in the section of this report entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations”.

 

Intellectual Properties and Licenses

 

We strive to protect and enhance the proprietary technologies that we believe are important to our business and seek to obtain and maintain patents for any patentable aspects of our products and any other inventions that are important to the development of our business. Our success will depend on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business, to defend and enforce our patents, to maintain our licenses to use intellectual property owned by third parties, to preserve the confidentiality of our trade secrets and to operate without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on continuing technological innovation and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in the fields targeted by our diagnostic products and services.

 

We continue to strengthen our patent portfolio and intellectual property (“IP”). We currently have four (4) issued patents and we also have ten (10) pending patent applications. The patents expire 20 years after submission of the initial application.

 

We also have a significant portfolio of intellectual property, such as trade secrets, technical expertise, and proprietary processes and information, which we maintain and protect. Measures of protection are a combination of contractual provisions, company policies, intellectual property laws and other measures, which cover OTF components: film compositions, polymers, taste formulations, process engineering and packaging.

 

Marketing Strategy

 

Cure Pharmaceutical acts as the technology partner for providing OTF products into the marketplace by strategically partnering with pharmaceutical and manufacturing companies looking for new methods to deliver drug actives. Partners will be developed through the business development efforts of our executive management team, trade associations, shows and conferences.

 

We either have existing partners or are actively seeking partners in the following areas:

 

· Pharmaceutical Partners (drug delivery technology)

 

 

· Consumer Product Brand Extensions (consumables)

 

 

· Non-governmental Organizations (NGO)

 

 

· Emerging markets (pharmaceutical & nutraceutical)

 

 

· Leading children’s hospitals and schools of veterinary medicine for clinical research

 

We also intend to join and attend trade groups, such as:

 

· Pharmaceutical (Interphex, Partnership Opportunities in Drug Delivery Forum/PODD)

 

 

· OTC (Consumer Health Products Association)

 

 

· Nutraceutical (Supply Side East and West)

 

 

· Veterinary (Veterinary Dental Forum, American Veterinary Medical Association)

 

Manufacturing – Capabilities and Regulatory Registrations

 

We operate a top rated manufacturing facility for cGMP and FDA registered manufacturing plant/processes for the current and future manufacture of our CureFilm™ products. “cGMP" is a term recognized worldwide for the regulation, control and management of manufacturing and quality control and quality assurance of pharmaceutical, dietary supplement and food products under regulations set forth by the U.S. Food and Drug Administration.

 

 
7
 

 

We are one of only a handful of manufacturers that can produce OTF products. We believe that this (1) represents a profitable business opportunity, (2) will reduce our dependency upon third-party contract manufacturers, thereby protecting our manufacturing process know-how and intellectual property, and (3) allows us to offer our development partners a full service from product conception to supply of the finished product.

 

We offer a total solution utilizing our cGMP and FDA registered plant and processes ranging product ideation, formulation, package design, and fulfillment via a leased, fully operational, 25,000-square-foot cGMP registered manufacturing plant capable of producing diverse consumer products based on the company’s proprietary technology. This facility also houses complete R&D operations and product commercialization operations. The formulation, manufacturing, packaging, labeling, advertising, distribution and sale of products are subject to regulation by one or more federal agencies, principally the FDA and the Federal Trade Commission (“FTC”), and to a lesser extent, the Consumer Product Safety Commission (“CPSC”), the U.S. Department of Agriculture, and the Environmental Protection Agency (“EPA”). Our activities are also regulated by various governmental agencies for the states and localities in which our products are sold, as well as by governmental agencies in certain countries outside the U.S. in which Cure Pharmaceutical products are sold.

 

Cure Pharmaceutical’s manufacturing operations are designed to perform robust and repeatable processes to meet specific, measurable quality and performance standards. The company’s cGMP compliant quality system provides a set of formalized standard operating procedures and policies that drive the production process and ensures high quality, safe, profitable and effective products.

 

Our cutting and packaging operation can be optimized to meet the specific requirements and budgets of individual clients. The labeling equipment offers a range of labeling options, including a tamper resistant seal and full wrap-around application. Technologically advanced blister card machinery enables us to offer retail-ready packaging, blister card single and multipacks, and flow-wrap individual products. We also offer a number of innovative packaging solutions, including space saving packaging design development.

 

Our Suppliers

 

We do not have any current contractual relationships for the manufacture of raw materials for our CureFilm™ products. Our product partners, however, may purchase significant quantities of raw materials, some of which may have long lead times. If raw materials cannot be supplied to our manufacturing partners in a timely and cost effective manner, our manufacturing partners may experience delays in production that may lead to reduced supplies of commercial products being available for sale or distribution. Such shortages could have a detrimental effect on sales of the products and a corresponding reduction on our royalty revenues earned.

 

Governmental Regulations

 

The pharmaceutical industry is highly regulated. The products we participate in developing require certain regulatory approvals. In the United States, drugs are subject to rigorous regulation by the Department of Public Health, FDA and possibly the Drug Enforcement Agency (“DEA”). The U.S. Federal Food, Drug, and Cosmetic Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, record keeping, packaging, labeling, adverse event reporting, advertising, promotion, marketing, distribution, and import and export of pharmaceutical products and dietary supplements. Failure to comply with applicable regulatory requirements may subject a company to a variety of administrative or judicially-imposed sanctions and/or the inability to obtain or maintain required approvals or to market drugs. The steps ordinarily required before a new pharmaceutical product may be marketed in the United States include:

 

· Preclinical laboratory tests, animal studies and formulation studies under FDA’s good laboratory practices regulations, or GLPs;

 

 

· The submission to the FDA of an investigational new drug application, or IND, which must become effective before human clinical trials may begin;

 

 

· The completion of adequate and well-controlled clinical trials according to good clinical practice regulations, or GCPs, to establish the safety and efficacy of the product for each indication for which approval is sought;

 

 

· After successful completion of the required clinical testing, submission to the FDA of a new drug application (“NDA”), or an Abbreviated New Drug Application (“ANDA”), for generic drugs. In certain cases, an application for marketing approval may include information regarding safety and efficacy of a proposed drug that comes from studies not conducted by or for the applicant. Such applications, known as a 505(b)(2) NDA, are permitted for new drug products that incorporate previously approved active ingredients, even if the proposed new drug incorporates an approved active ingredient in a novel formulation or for a new indication;

 

 

· Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMPs to assure that the facilities, methods and controls are adequate to preserve the drug’s identity, strength, quality and purity; and

 

 

· FDA review and approval of the NDA or ANDA.

 

 
8
 

 

The cost of complying with the foregoing requirements, including preparing and submitting an NDA or ANDA, may be substantial. Accordingly, we typically rely upon our partners in the pharmaceutical industry to spearhead and bear the costs of the FDA approval process. We also seek to mitigate regulatory costs by focusing on 505(b)(2) NDA opportunities. By applying our drug delivery technology to existing drugs, we seek to develop products with lower R&D expenses and shorter time-to-market timelines as compared to regular NDA products.

 

None of our products under development has been approved for marketing in the United States or elsewhere. We may not be able to obtain regulatory approval for any of our products under development. If we do not obtain the requisite governmental approvals or if we fail to obtain approvals of the scope we request, we or our licensees or strategic alliance or marketing partners may be delayed or precluded entirely from marketing our products, or the commercial use of our products may be limited. Such events would have a material adverse effect on our business, financial condition and results of operations.

 

All of our current commercialized products are deemed dietary supplements under the FDA. The FDA issued a final rule called “Statements Made for Dietary Supplements Concerning the Effect of the Product on the Structure or Function of the Body,” which includes regulations requiring companies, their suppliers and manufacturers to meet cGMPs in the preparation, packaging, storage and shipment of their products. Management is committed to meeting or exceeding the standards set by the FDA.

 

The Dietary Supplement Health and Education Act of 1994 (“DSHEA”) revised the existing provisions of the U.S. Federal Food, Drug, and Cosmetic Act, concerning the composition and labeling of dietary supplements and defined dietary supplements to include vitamins, minerals, herbs, amino acids and other dietary substances used to supplement diets. DSHEA generally provides a regulatory framework to help ensure safe, quality dietary supplements and the dissemination of accurate information about such products. The FDA is generally prohibited from regulating active ingredients in dietary supplements as drugs unless product claims, such as claims that a product may heal, mitigate, cure or prevent an illness, disease or malady, trigger drug status.

 

Other Healthcare Laws and Regulations

 

If we obtain regulatory approval for any of our current or future product candidates, we may also be subject to healthcare regulation and enforcement by the federal government and the states and foreign governments in which we conduct our business. These laws may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:

 

· the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs;

 

 

· federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent;

 

 

· federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;

 

 

· the federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare & Medicaid Services information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members;

 

 

· Health Insurance Portability and Accountability Act of 1996, as amended by Health Information Technology for Economic and Clinical Health Act of 2009, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; and

 

 

· state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.

 

 
9
 

 

If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, the exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to operate our business and impact our financial results.

 

Employees

 

As of November 8, 2016, we have 16 full time employees and no part-time employees. In addition, we use advisors and consultants for research and development, clinical, regulatory, legal and administrative activities. We plan to hire additional staff as we expand research, production, business development, and sales and marketing programs. None of our employees are represented by a labor union.

 

Compliance with Environmental Laws

 

Our operations require the use of hazardous materials which subject us to a variety of federal, provincial and local environmental and safety laws and regulations. Some of the regulations under the current regulatory structure provide for strict liability, holding a party potentially liable without regard to fault or negligence. We believe that we are in compliance with state and federal environmental regulations applicable to our manufacturing facility. However, we could be held liable for damages and fines as a result of our, or others’, business operations should contamination of the environment or individual exposure to hazardous substances occur. We cannot predict how changes in laws or development of new regulations will affect our business operations or the cost of compliance.

 

CORPORATE INFORMATION

 

Our principal executive office is located at 1620 Beacon Place, Oxnard, California 93033. Our main telephone number is (805) 824-0410, and our fax number is (805) 487-7163.

 

WHERE YOU CAN FIND MORE INFORMATION

 

The registrant is subject to the requirements of the Exchange Act, and files reports, proxy statements and other information with the SEC. You may read and copy these reports, proxy statements and other information at the public reference room maintained by the Securities and Exchange Commission (“SEC”) at its Public Reference Room, located at 100 F Street, N.E. Washington, D.C. 20549. You may obtain information on the operation of the public reference room by calling the SEC at (800) SEC-0330. In addition, we are required to file electronic versions of those materials with the SEC through the SEC’s EDGAR system. The SEC also maintains a web site at http://www.sec.gov, which contains reports, proxy statements and other information regarding registrants that file electronically with the SEC.

 

  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of the results of operations and financial condition of Cure Pharmaceutical Corporation, a California corporation for the three and six months ended June 30, 2016, should be read in conjunction with the financial statements of Cure Pharmaceutical Corporation, and the notes to those financial statements that are included elsewhere in this Form 8-K. This discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as Cure Pharmaceutical Corporation’s plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under the Business sections in this Form 8-K. Words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions are used to identify forward-looking statements.

 

Overview

 

We are a specialty pharmaceutical and bioscience company with a focus in drug delivery technologies. We leverage novel drug delivery technologies to develop and commercialize new applications of proven therapeutics through OTF via our proprietary patented CureFilm™ Technology as well as through transdermal applications. Our micro encapsulation of drug actives in our CureFilm™ Technology allows for a higher volume of an active and if required, multiple actives to be produced on a single oral thin film strip.

 

 
10
 

 

We are currently focused on partnering with pharmaceutical and biotech companies seeking to deliver drug actives utilizing and benefitting from our proprietary OTF and transdermal applications and when preferable to take our own products from clinical process to commercialization. We are focused on both the human and veterinary prescription, OTC and nutraceutical markets. We believe that Cure Pharmaceutical represents the complete solution to OTF drug delivery therapeutics from inception to finished product utilizing our cGMP/FDA registered manufacturing facility and processes.

 

Results of Operations

 

Three and Six Months Ended June 30, 2016 Compared with Three and Six Months Ended June 30, 2015  

 

Revenues

 

Revenues have decreased by $10,524 and $74,760 in the three and six months ended June 30, 2016, respectively, compared to the three and six months ended June 30, 2015, respectively. As the Company continues to move in the direction of working with more pharmaceutical and bioscience companies, we experienced a corresponding decrease in revenues. In addition, the Company did not see re-orders from two nutraceutical customers during the three and six months ended June 30, 2016 and as a result, we had lower revenues generated during this period.

 

Cost of Goods Sold

 

Cost of goods sold decreased by $8,446 and $46,735 in the three and six months ended June 30, 2016, respectively, compared to the three and six months ended June 30, 2015, respectively. As the Company generated less revenue in the three and six months ended June 30, 2016 compared to the three and six months ended June 30, 2015, we also had a corresponding decrease in our cost of goods sold during the same periods in 2016 compared to same periods in 2015.

 

Research and Development Expenses

 

For the three months ended June 30, 2016, research and development expenses slightly increased to $171,447 compared to the three months ended June 30, 2015 of $171,098. The Company was able to raise funds during the 2016 fiscal year by issuing convertible promissory notes and as a result, was able to continue to focus on spending on improving our intellectual property. However, for the six months ended June 30, 2016, research and development expenses decreased by $86,171 compared to the six months ended June 30, 2015. This was due to the Company’s decrease in expenses to further develop potential partnerships with pharmaceutical and bioscience companies and new OTC products.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses for the three and six months ended June 30, 2016 amounted to $296,098 and $579,463, respectively, and for the three and six months ended June 30, 2015 amounted to $226,933 and $429,076, respectively. For the three and six months ended June 30, 2016 and 2015, selling, general and administrative expenses were mainly comprised of amortization, commission, insurance, payroll, consulting and rent expenses. The increase in both the three and six months ended June 30, 2016 compared to the three and six months period ended June 30, 2015 was due to incurred commission associated with the fund raise in 2016 and consulting fees that were not present in the same periods in 2015.

 

Other Income/Expense

 

Other income amounted to $45 and $412 for the three and six months ended June 30, 2016, respectively, and $145,406 and $145,406 of other income for the three and six months ended June 30, 2015, respectively. Other income generated in 2015 is mainly a result of 21 st Century Brands, LLC agreeing to forgive the remaining deposit amount of $145,606 for future OTF products after deducting costs incurred by the Company for purchasing raw materials that were never used and expired. The Company did not incur this type of transaction in the same period for 2016. Other expense amounted to $136,094 and $203,278 for the three and six months ended June 30, 2016, respectively and $54,611 and $97,421, for the three and six months ended June 30, 2015, respectively. Other expenses in 2016 and 2015 were mainly from interest expense and commissions relating to convertible promissory notes and other note payables.

 

 
11
 

 

Year Ended December 31, 2015 Compared with Year Ended December 31, 2014

 

Revenues

 

Revenues have decreased from $1,242,630 in 2014 to $183,430 in 2015. The majority of the decrease was mainly due to the conclusion of Cure’s consulting services, which generated approximately $900,000 in consulting revenues in 2014 and $0 in 2015, and the decrease in product sales in 2015 compared to 2014 caused by a decrease in melatonin orders by one of its main customers and the need to further develop our OTF Aspirin product.

 

In addition, Cure started focusing more on research and development to improve our OTF technology and looking to partner with pharmaceutical and bioscience companies who are looking to deliver drug actives utilizing our proprietary OTF and transdermal applications. As a result, we saw a corresponding decrease in our revenues from 2015 compared to 2014.

 

Cost of Goods Sold

 

Cost of goods sold amounted to $205,117 in 2014 and $117,012 in 2015. The decrease in cost of goods sold from 2014 to 2015 is mainly due to the decrease in product revenues incurred in 2015. With two of the Company’s major customers decreasing their orders in 2015, we had a corresponding decrease in cost of goods sold. In addition, with the Company focused on improving our OTF technology and efficacy of our OTF, we had more costs being attributed to research and development rather than cost of goods sold.

 

Research and Development Expenses

 

Research and development expenses amounted to $663,899 in 2014 and $681,699 in 2015. The increase in research and development expenses from 2014 to 2015 was due to the Company continuing to advance its OTF technology by performing clinical trials and studies as well as developing new encapsulation methods for various molecules. In addition, as we were focused on partnering with pharmaceutical and bioscience companies, the Company believed it necessary to invest in further research to identify various molecules that would best suit our proprietary CureFilm™ technology.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses amounted to $914,736 in 2014 and $920,247 in 2015. In 2015 and 2014, the Company mainly incurred expenses relating to insurance, payroll, consulting services, legal expenses, office rent, amortization and depreciation expenses. The Company experienced an increase in insurance, consulting services, travel and non-management and sales payrolls as the company looked to decrease costs as revenues decreased in 2015 compared to 2014. The deferred officer salaries were converted into convertible promissory notes as of December 31, 2015.

 

Other Income/Expense

 

Other income/expense is comprised of $47,303 and $178,091 of other income in 2014 and 2015, respectively, and $171,020 and $245,624 of other expense in 2014 and 2015, respectively. Other income generated in 2015 is mainly a result of 21 st Century Brands, LLC agreeing to forgive the remaining deposit amount of $145,605 for future OTF products after deducting costs incurred by the Company for purchasing raw materials that were never used and expired. The Company did not incur this type of transaction in 2014. Other expense in 2015 and 2014 is mainly from interest expense relating to convertible promissory notes and other note payables. The increase in interest expense is related to the additional convertible notes and notes payable of $763,009 issued in 2015 compared to 2014.

 

Liquidity and Capital Resources

 

For the six months ended June 30, 2016

 

As of June 30, 2016, our total assets were $4,578,840 comprised of cash of $2,025,787, restricted cash of $99,980, accounts receivable of $228, note receivable of $36,238, inventory of $178,490, prepaid expenses and other assets of $741,960, net property equipment of $373,275, net intangibles of $953,920, and other assets of $168,962. Our total liabilities were $9,485,455 comprised of accounts payable of $348,568, accrued expenses of $344,728, current portion of loan and note payables of $130,809, current portion of capital lease payable of $12,072, current portion of related party convertible promissory notes of $412,212, current portion of convertible promissory notes of $7,486,852, deferred revenue of $186,980, license fees of $560,000 and capital lease payable of $3,234.

 

As of June 30, 2016, our stockholders’ deficit was $4,906,615 comprised of common stock of $200, additional paid in capital of $2,727,531 and accumulated deficit of $7,634,346.

 

 
12
 

 

Cash flows used in operating activities

 

For the six months ended June 30, 2016, operating activities consumed $1,972,119 of cash. This was primarily the result of a net loss of $1,073,112, offset by depreciation and amortization of $75,394 as well as the changes in prepaid expenses of $703,838, accounts payable of $265,682 and accrued expenses of $46,823. 

 

Cash flows used in investing activities

 

Investment activities used an additional $92,647 of cash during the six months ended June 30, 2016, primarily as a result of payments for patents and costs associated in the development and improvement of our intellectual property of $25,527, payment for a note receivable of $18,290 and acquisition of property and equipment of $48,830.

 

Cash flows provided by financing activities

 

Financing activities provided $4,077,201 of cash for the six months ended June 30, 2016, primarily as the result of proceeds from the issuance of convertible promissory notes of $4,371,963 and repayments of loan and notes payables of $289,253.

 

For the year ended December 31, 2015

 

As of December 31, 2015, our total assets were $1,822,149 comprised of cash of $13,352, restricted cash of $49,980, accounts receivable of $1,907, note receivable of $17,948, inventory of $191,465, prepaid expenses and other assets of $38,122, net property equipment of $381,830, net intangibles of $949,725, and other assets of $177,820. Our total liabilities were $5,655,652 comprised of accounts payable of $614,250, accrued expenses of $297,905, current portion of loan and note payables of $420,062, current portion of capital lease payable of $11,362, current portion of related party convertible promissory notes of $412,212, current portion of convertible promissory notes of $3,114,889, deferred revenue of $215,519, license fees of $560,000 and capital lease payable of $9,453.

 

As of December 31, 2015, our stockholders’ deficit was $3,833,503 comprised of common stock of $200, additional paid in capital of $2,727,531 and accumulated deficit of $6,561,234.

 

Cash flows used in operating activities

 

For the year ended December 31, 2015, operating activities consumed $402,092 of cash. This was primarily the result of a net loss of $1,603,061, offset by depreciation and amortization of $157,546 as well as the changes in accounts receivable of $112,891, other assets of $108,384, accounts payable of $291,585, accrued expenses of $348,810 and license fees of $360,000.

 

Cash flows used in investing activities

 

Investment activities used an additional $270,374 of cash during the year ended December 31, 2015, primarily as a result of payments for patents and costs associated in the development and improvement of our intellectual property of $66,031, payment for a note receivable of $17,948 and acquisition of property and equipment of $186,395.

 

Cash flows provided by financing activities

 

Financing activities provided $681,612 of cash for the year ended December 31, 2015, primarily as the result of proceeds from the issuance of convertible promissory notes of $813,009 and repayments of loan payables of $121,333.

 

Off-Balance Sheet Arrangements

 

We had no off-balance sheet arrangements as of June 30, 2016.

 

Inflation

 

We do not believe that inflation has had a material effect on our Company’s results of operations.

 

 
13
 

 

Critical Accounting Policies and Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles of the United States (“U.S. GAAP”) requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities in the financial statements and accompanying notes. The SEC has defined a company’s critical accounting policies as the ones that are most important to the portrayal of the company’s financial condition and results of operations, and which require the company to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Based on this definition, we have identified the critical accounting policies and judgments addressed below. We also have other key accounting policies, which involve the use of estimates, judgments, and assumptions that are significant to understanding our results. For additional information, see Note 2 – “Summary of Significant Accounting Policies”. Although we believe that our estimates, assumptions, and judgments are reasonable, they are based upon information presently available. Actual results may differ significantly from these estimates under different assumptions, judgments, or conditions.

 

Long-lived assets

 

Long-lived assets include equipment and intangible assets other than those with indefinite lives. We assess the carrying value of our long-lived asset groups when indicators of impairment exist and recognize an impairment loss when the carrying amount of a long-lived asset is not recoverable when compared to undiscounted cash flows expected to result from the use and eventual disposition of the asset.

 

Indicators of impairment include significant underperformance relative to historical or projected future operating results, significant changes in our use of the assets or in our business strategy, loss of or changes in customer relationships and significant negative industry or economic trends. When indications of impairment arise for a particular asset or group of assets, we assess the future recoverability of the carrying value of the asset (or asset group) based on an undiscounted cash flow analysis. If carrying value exceeds projected, net, undiscounted cash flows, an additional analysis is performed to determine the fair value of the asset (or asset group), typically a discounted cash flow analysis, and an impairment charge is recorded for the excess of carrying value over fair value.

 

Going concern

 

 The Company’s financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it establishes a revenue stream and becomes profitable. The Company is continually analyzing its current costs and is attempting to make additional cost reductions where possible. We expect that we will continue to generate losses from operations throughout 2016.

 

In order to continue as a going concern and to develop a reliable source of revenues, and achieve a profitable level of operations the Company will need, among other things, additional capital resources. Management’s plans to continue as a going concern include raising additional capital through borrowing and/or sales of equity and debt securities. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.

 

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.

 

DESCRIPTION OF PROPERTY

 

We rent approximately 25,000 square feet for our office and laboratory space in 1620 Beacon Place, Oxnard, California 93033 under a lease that provides for an annual rent payment of $232,980 per year for our development, production, warehouse and distribution of nutraceutical OTC products, pharmaceuticals, and veterinary mendicants, and related office activities from George Stern. We are finalizing an amended lease with George Stern and anticipate it to be completed prior to the end of the calendar year. This lease may be terminated by either party if the other party fails to perform their obligations under the lease, and then fails to cure such default within the applicable cure period.

 

We also lease approximately 6,547 square feet of a larger concrete tilt-up building located at 1610 and 1612 Fiske Place, Oxnard, California 93033 from Fiske Industrial LLC for storage and potential manufacturing purposes. We pay an annual rent payment of $51,960 per year for this month to month lease.

 

We believe that our facility is sufficient to meet our current needs and we will look for suitable additional space as and when needed.

 

 
14
 

 

SECURITY OWNERSHIP OF CERTAIN

BENEFICIAL OWNERS AND MANAGEMENT

 

Security Ownership After Change Of Control

 

The following table sets forth information regarding the beneficial ownership of our common stock for each of the following persons, after giving effect to the transaction under the Exchange Agreement:

 

· each of our incoming directors and each of the executive officers in the “Management—Executive Compensation” section of this report;

 

 

· all directors and executive officers as a group; and

 

 

· each person who is known by us to own beneficially five percent or more of our common stock.

 

 
15
 

 

Named Executives Officers and Directors (1)

 

Number of Shares
Beneficially

Owned (2)

 

 

Percent of

Class (3)

 

Robert Davidson (4)

 

 

657,624

 

 

 

2.83 %

Edward Maliski

 

 

471,131

 

 

 

2.02

 

Wayne Nasby

 

 

522,619

 

 

 

2.25

 

Mark Udell

 

 

442,632

 

 

 

1.90 %

William Yuan

 

 

-

 

 

 

-

Charles Berman

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

All Executive Officers and Directors as a group (6 person)

 

 

2,094,006

 

 

 

9.00 %

 

 

 

 

 

 

 

5% Shareholders

 

 

 

 

 

 

 

 

The Branstetter Group (5)

 

 

2,754,626

 

 

 

11.83

Climate Change Investigation, Innovation and Investment Company, LLC (6)

 

 

3,000,000

 

 

 

12.89

 

Aureus Fiduciary Nevis Limited (7)

 

 

 3,458,905

 

 

 

 13.89

 

______________ 

(1)

Unless otherwise noted, the address for each of the named beneficial owners is: 1620 Beacon Place, Oxnard, California 93035.

(2)

 

 

Beneficial ownership is determined in accordance with the rules of the Commission generally includes voting or investment power with respect to securities. Under the rules of the Commission, a person (or group of persons) is deemed to be a “beneficial owner” of a security if he or she, directly or indirectly, has or shares a power to vote or to direct the voting of such security. Accordingly, more than one person may be deemed to be a beneficial owner of the same security. In accordance with Commission rules, shares of Common Stock that may be acquired upon exercise of stock options or warrants which are currently exercisable or which become exercisable within 60 days of the date of the table are deemed beneficially owned by the optionees. Subject to community property laws, where applicable, we believe the persons or entities named in the table above have sole voting and investment power with respect to all shares of the Common Stock indicated as beneficially owned by them.

(3) 

In determining percentage of outstanding, we included shares issued and outstanding, shares obligated to be issued and the securities identified (if consisting of derivative securities) as if issued. As of November 9, 2016, we had 23,266,733 shares of common stock.

(4)

535,469 of these shares are held by Robert Davidson as an individual and 122,155 of the shares are held in the name of Ronick, Inc. Robert Davidson is a director of Ronick, Inc. and may be deemed to have dispositive and voting power over such shares.

(5)

The address for this shareholder is 271 North Sepulveda, California 90266.

(6)

The address for this shareholder is 12 San Rafael Avenue, Belvedere, California 94920.

(7)

Includes 1,818,600 shares of common stock and a warrant to purchase up to 1,640,305 shares of common stock at an exercise price of $2.00 per share and with an exercise period of four years commencing on the date issuance of the warrant. The address for this shareholder is Toedistrasse 53, 8002 Zurich, Switzerland.

 

DIRECTORS AND EXECUTIVE OFFICERS

 

Appointment of New Directors and Officers

 

In connection with the Share Exchange, at Closing, Michael Hlavsa resigned from our Board, and we appointed three new directors to replace him. Michael Hlavsa also resigned as our sole officer, and we appointed four new executive officers to replace them. Descriptions of our newly appointed directors and officers can be found below in the section titled “ Current Management .”

 

Current Management

 

The following table sets forth the names and ages of the incoming directors and executive officers:

 

Name

 

Age

 

Positions Held

Robert Davidson*

 

49

 

Chairman of the Board, Chief Executive Officer

Edward Maliski*

 

67

 

Chief Scientific Officer, President

Wayne Nasby*

 

55

 

Chief Operating Officer

Mark Udell*

 

39

 

Chief Financial Officer, Treasurer and Secretary

William Yuan

 

56

 

Director

Charles Berman

 

73

 

Director

____________ 

* Denotes an executive officer.

 

Biographical Information

 

The following is a brief account of the education and business experience of the incoming directors and executive officers during at least the past five years, indicating the person's principal occupation during the period, and the name and principal business of the organization by which he or she was employed.

 

Robert Davidson, Chairman of the Board and Chief Executive Officer

 

Robert Davidson has served as the Chairman of the Board and Chief Executive Officer of Cure Pharmaceutical since July 2011. Prior to his role at Cure Pharmaceutical, Mr. Davidson served as President and Chief Executive Officer of InnoZen Inc., Chief Executive Officer of Gel Tech LLC Chief Executive Officer of Bio delivery Technologies Inc., and Director of HealthSport Inc. Mr. Davidson was responsible for the development of several drug delivery technologies and commercial brand extensions. He has worked with brands such as Chloraseptic™, Suppress™, as well as Pediastrip™, a private label electrolyte oral thin film sold in major drug store chains. Mr. Davidson is also considered an industry expert leader in OTF technology. Mr. Davidson received his B.S. degree with a concentration in Biological Life Sciences from the University of the State of New York, Excelsior College. He has a Masters Certificate in Applied Project Management from Villanova University, Masters of Public Health from American Military University, Virginia and a Masters in Health and Wellness from Liberty University, Virginia. Mr. Davidson is also a Certified Performance Enhancement Specialist and Fitness Nutrition Specialist through the National Academy of Sports Medicine and attended Post-Graduate Studies at the University of Cambridge. Mr. Davidson’s experience as our Chief Executive Officer and Chairman, and his extensive knowledge of OTF and drug delivery technologies qualifies him to serve on our Board.

 

 
16
 

 

Edward Maliski, PhD – President and Chief Science Officer

 

Dr. Edward Maliski has served as the President, Chief Science Officer and Director of Cure Pharmaceutical since July 2011. Dr. Maliski is an accomplished research scientist with 30 years of experience in the development of pharmaceutical and biotechnology products. As an executive leader and strategist, Dr. Maliski contributed his expertise in project management and chemical research to facilitate the transfer of new discoveries into pharmaceutical products for the Sterling Winthrop Research Institute, Glaxo Research Institute, Merck & Co., and Amgen Inc. Additionally, Dr. Maliski has worked with several successful start-up companies.

 

Wayne Nasby – Chief Operating Officer

 

Wayne Nasby has served as the Chief Operating Officer and director of Cure Pharmaceutical since July 2011. He has over 30 years of experience in the healthcare industry and has been recognized by industry and regulatory leaders for his proven track record in cGMP pharmaceutical regulatory compliance and innovation. Prior to Cure Pharmaceutical, Mr. Nasby served as the Vice President of Operations at InnoZen, Inc. He also served in various management positions at Amgen Inc. within quality assurance, supply chain, and corporate project management. During his twenty year tenure at Amgen, Inc., Mr. Nasby also established and directed distribution of pharmaceutical products to Asia, Australia, Europe and Puerto Rico.

 

Mark Udell, CPA – Chief Financial Officer and Treasurer

 

Mark Udell has served as the Chief Financial Officer, Treasurer and Secretary of Cure Pharmaceutical since July 2011. He is a Certified Public Accountant with over 17 years of experience in finance and accounting. Prior to Cure Pharmaceutical, Udell served as InnoZen, Inc.’s Chief Accounting Officer and Controller. He has also held the position as Auditing Manager at Green Hasson & Janks, LLP in Los Angeles. Mr. Udell received his B.A. in Business Economics with a concentration in accounting from the University of California, Santa Barbara.

 

William Yuan – Director

 

William Yuan was most recently Chairman and CEO of Fortress Hill Holdings, an Asian-based investment banking firm. With 23 years in global finance experience, he has served as a key strategist and advisor to international institutions. U.S. companies advised by Mr. Yuan include Amgen Corp., Biogen, GE Capital, Warner Brothers Studios, and Fox News. He has also guided such leading Asian institutions as Sina.com, Shanghai Petrochemicals, Jinlia Pharmaceutical and Tsingtao Beer Corp. In 1995, Mr. Yuan led Merrill Lynch Asset Management Asia, and managed one of the largest pension/retirement funds in the world, with a $488 billion portfolio under his leadership. Simultaneously, he was chairman and portfolio manager of the $1.2 billion AmerAsia Hedge Fund. In 1993, he was the founder and managing director of the Corporate Institutional Services Group at Merrill Lynch Asset Management. Prior to that, Mr. Yuan served as a senior-vice president and co-manager at Morgan Stanley Smith Barney's Portfolio Management Corporation with dual functions as co-head of the Capital Markets Derivative team, and Chairman of the Technology Investment Management and Executive Policy Committee. He began his finance career at Goldman Sachs in 1983 as an investment banker in Mergers & Acquisitions. Mr. Yuan is a member of the International Who’s Who of Finance, Technology, Media and Telecom. Mr. Yuan holds a Bachelor of Science degree in Economics from Cornell University and attended Harvard University's John F. Kennedy School as a Mason Fellow. Mr. Yuan’s extensive finance, investment banking and corporate strategy background as well as his experience advising large pharmaceutical companies such as Amgen, Biogen and Jinlia Pharmaceutical qualify him to serve on our Board.

 

Charles Berman - Director

 

Formerly a partner at Oppenheimer, Wolff & Donnelly, Charles Berman has focused his practice in patent work for more than 20 years. His clients include both major corporations and smaller companies, which he represents within the U.S. and internationally. He has a degree in electrical engineering and a law degree from the University of Witwatersrand in Johannesburg, where he also started his legal career, concentrating in patent work. In 1978 Berman joined Lyon & Lyon's Los Angeles office as an associate, and he has remained in the U.S. ever since. He is admitted to practice before the U.S. and South African Patent and Trademark Offices, the U.S. District Court, Central District of California and the South African Supreme Court. From 1996-2000, he served as president, secretary and treasurer of the Los Angeles Intellectual Property Law Association (“LAIPLA”), and has represented LAIPLA and the California State Bar Intellectual Property Section before the U.S. Bar/European Patent Office- Liaison Council and the U.S. Bar/Japanese Patent Office- Liaison Council since 1990. Berman also has been a member of the Editorial Board of Managing Intellectual Property magazine since 1992. A board member of the American Intellectual Property Association from 1995 to 1998, he was a founding fellow of the AIPLA and currently serves as vice chair of the fellows. Mr. Berman’s extensive work experience as a patent attorney providing legal services to major corporations and smaller companies, both within the U.S. and internationally, qualifies him to serve on our Board.

 
 
17
 

 

Family Relationships

 

There are no family relationships between or among any of the incoming directors or executive officers.

 

Involvement in Certain Legal Proceedings

 

There are no orders, judgments, or decrees of any governmental agency or administrator, or of any court of competent jurisdiction, revoking or suspending for cause any license, permit or other authority to engage in the securities business or in the sale of a particular security or temporarily or permanently restraining any of our incoming officers or directors from engaging in or continuing any conduct, practice or employment in connection with the purchase or sale of securities, or convicting such person of any felony or misdemeanor involving a security, or any aspect of the securities business or of theft or of any felony. Nor are any of the officers or directors of any corporation or entity affiliated with us so enjoined.

 

Board of Directors

 

Effective upon the Closing Date, the registrant’s Board will be comprised of three (3) members. All directors serve in this capacity until their terms expire or until their successors are duly elected and qualified. The registrant’s bylaws provide that the authorized number of directors shall be one or more, as fixed from time to time by resolution of the Board; provided, however, that the number of directors shall not be reduced so as to shorten the tenure of any director at the time in office.

 

Board Committees; Director Independence

 

Our Board has not established a separate standing audit committee within the meaning of Section 3(a)(58)(A) of the Exchange Act or separate standing nominating or compensation committees, or committees performing similar functions, nor has it adopted charters for any such committee. Due to the present and prior size of our Board, our Board believes that it is not necessary to have separate standing audit, nominating or compensation committees at this time because the functions of each such committee are adequately performed by our full Board. However, it is anticipated that our Board will form separate standing audit, nominating and compensation committees, with the audit committee including an audit committee financial expert and the audit and compensation committees consisting solely of independent directors, if and when our Board determines that the establishment of such committees is advisable as we seek to further develop our business and operations and potentially expand the size of our Board.

 

We look to our directors to guide us through our next phase as a public company and continue and manage our growth. Our directors bring leadership experience from a variety of corporate, technology and professional backgrounds which we require to continue to grow and to add shareholder value. Our directors also have worked with startup through public companies and bring depth of knowledge in building shareholder value, growing a company from inception, developing leading edge products, and navigating mergers and acquisitions and the public company process.

 

We currently act with three directors, consisting of Robert Davidson, William Yuan and Charles Berman. Our common stock is quoted on the OTC Pink quotation system, operated by OTC Markets Group Inc. OTC Markets Group Inc. is neither a stock exchange nor self-regulatory organization, and it does not impose director independence requirements on companies quoted on the OTC Pink quotation system. However, under NASDAQ rule 5605(a)(2), a director is not independent if he or she is also an executive officer or employee of a company, or any parent or subsidiary of such company, or was, at any time during the past three years, employed by the company, or any parent or subsidiary of such company. Also a director is not independent if a director is a family member of an individual who is, or at any time during the past three years was, employed by us as an executive officer. Using this definition of independent director, we have two independent directors.

 

Committees and Insider Participation

 

No interlocking relationship exists between the Board and the board of directors or compensation committee of any other company, nor has any interlocking relationship existed in the past. Currently, we do not have standing audit, nominating, or compensation committees of our board of directors, or committees performing similar functions and, therefore, our Board performs such functions. Our common stock is not currently listed on any national exchange and we are not required to maintain such committees by any self-regulatory agency. We do not believe it is necessary for our Board to appoint such committees because the volume of matters that currently and historically has come before our Board (and that of the operating company) for consideration permits each director to give sufficient time and attention to such matters to be involved in all decision making. Following the Closing Date, and as we grow our business, we may undertake a review of the need for some or all of these committees.

 
 
18
 

 

EXECUTIVE COMPENSATION

 

Director Compensation

 

Effective upon the Closing Date, our former sole director Michael Hlavsa resigned as a director after appointing William Yuan and Charles Berman as our directors and Robert Davidson as the Chairman of the Board of Directors.

 

The table below summarizes all compensation earned by each of our directors for services performed during our fiscal year ended December 31, 2014 and 2015.

 

Name

 

Fiscal Year

Ended

 

Salary ($)

 

 

Bonus ($)

 

 

Stock

Awards ($)

 

 

Non-qualified Deferred Comp Earnings ($)

 

 

All Other

Comp ($)

 

 

Total ($)

 

Anna Ioannou (1)

 

2014

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

 

2015

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Michael Hlavsa (2)

 

2014

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

 

2015

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

______________ 

(1) Anna Ioannou resigned as the Company’s director on June 28, 2016.

 

 

(2) Michael Hlavsa resigned as the Company’s director on November 7, 2016.

 

Executive Compensation

 

The following executive compensation disclosure reflects all compensation for the periods ended December 31, 2015 and 2014, received by our principal executive officer, principal financial officer, and most highly compensated executive officers. We refer to these individuals in this Current Report as “named executive officers.”

 

Name

 

Fiscal Year Ended

 

Salary ($)

 

 

Bonus ($)

 

 

Stock

Awards ($)

 

 

Non-Equity Incentive Plan Comp ($)

 

 

Non-qualified Deferred Comp Earnings ($)

 

 

All Other

Comp ($)

 

 

Total ($)

 

Robert Davidson (1)

 

2015

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

 

2014

 

$ 62,813

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ 62,813

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Edward

 

2015

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

Maliski (1)

 

2014

 

$ 33,750

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ 33,750

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Wayne

 

2015

 

$ 3,125

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ 3,125

 

Nasby (1)

 

2014

 

$ 62,813

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ 62,813

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Mark Udell (1)

 

2015

 

$ 75,000

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ 75,000

 

 

 

2014

 

$ 77,500

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ 77,500

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Michael Hlavsa (2)

 

2015

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

 

2014

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Anna Ioannou (3)

 

2015

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

 

2014

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

______________ 

(1)

Executive Compensation was assumed by us as of the Closing Date. This does not include convertible promissory notes issued to such executive in connection with accrued payroll as described in “Certain Relationships and Related Transactions” under Item 2.01 “Completion of Acquisition or Disposition of Assets”, which is incorporated herein by reference.

 

(2)

Michael Hlavsa resigned as the Company’s president, chief executive and treasurer on November 7, 2016.

 

(3)

Anna Ioannou resigned as the Company’s president, chief executive and treasurer on June 28, 2016.

  

 
19
 

 

Employment Agreements

 

None.

 

Potential Payments Upon Termination or Change-in-Control

 

We currently have no contract, agreement, plan or arrangement, whether written or unwritten, that provides for payments to a named executive officer at, following, or in connection with any termination, including without limitation resignation, severance, retirement or a constructive termination of a named executive officer, or a change in control of the registrant or a change in the named executive officer’s responsibilities, with respect to each named executive officer.

 

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

 

On October 3, 2014, Cure Pharmaceutical obtained a short-term loan from Jonathan Turman, Cure Pharmaceutical’s Chief Engineering Officer, in the amount of $1,000. This loan is non-interest bearing, unsecured and has no fixed terms of repayment.

 

On October 22, 2014, Cure Pharmaceutical obtained another short-term loan from Jonathan Turman in the amount of $1,000. This loan is non-interest bearing, unsecured and has no fixed terms of repayment.

 

On various dates from October 31, 2014 to February 2, 2015, Cure Pharmaceutical issued convertible promissory notes to Ronick, Inc., (“Ronick”) totaling $89,000 that were due on February 25, 2016, but Ronick has agreed to extended the due date to August 31, 2016. Robert Davidson, our Chief Executive Officer and director, is a shareholder of Ronick. Interest is payable at 3% per annum and is secured by technology and patent rights. Principal and accrued interest is convertible into common stock at $4.00 per share. This conversion is subject to an adjustment if Cure Pharmaceutical sells stock or grants conversion rates at a lower price; however, Ronick has subsequently agreed to waive these conversion rights and will convert at $4.00 per share. As of October 6, 2016, Ronick has converted $35,260 of principal and unpaid accrued interest into 8,815 of common stock shares of Cure Pharmaceutical. As of October 6, 2016, Ronick converted $35,290 of principal and unpaid accrued interest into 8,822 of common stock shares of Cure Pharmaceutical.

 

On April 15, 2015, Cure Pharmaceutical obtained a short-term loan from Jonathan Turman in the amount of $20,000. This loan is non-interest bearing, unsecured and has no fixed terms of repayment.

 

On May 6, 2015, Cure Pharmaceutical obtained a short-term loan from Jonathan Turman in the amount of $4,000. This loan is non-interest bearing, unsecured and has no fixed terms of repayment.

 

On December 31, 2015, Cure Pharmaceutical converted $100,150 of accrued payroll for Robert Davidson into a convertible promissory note. As of October 6, 2016, Robert Davidson has converted $38,415 of principal and unpaid accrued interest into 9,604 of common stock shares of Cure Pharmaceutical. On October 17, 2016, Robert Davidson transferred his convertible promissory note to Ronick. On that same date, Ronick converted $38,449 of principal and unpaid accrued interest into 9,612 of common stock shares of Cure Pharmaceutical.

 

On December 31, 2015, Cure Pharmaceutical converted $94,312 of accrued payroll for Wayne Nasby, our Chief Operating Officer, into a convertible promissory note. As of October 6, 2016, Wayne Nasby has converted $48,241 of principal and unpaid accrued interest into 12,060 of common stock shares of the Cure Pharmaceutical. As of October 17, 2016, Wayne Nasby converted $48,284 of principal and unpaid accrued interest into 12,071 of common stock shares of Cure Pharmaceutical.

 

On December 31, 2015, Cure Pharmaceutical converted $77,250 of accrued payroll for Edward Maliski, our President and Chief Science Officer, into a convertible promissory note. As of October 6, 2016, Edward Maliski has converted $39,514 of principal and unpaid accrued interest into 9,878 of common stock shares of Cure Pharmaceutical. As of October 17, 2016, Edward Maliski converted $39,549 of principal and unpaid accrued interest into 9,887 of common stock shares of Cure Pharmaceutical.

 

On December 31, 2015, Cure Pharmaceutical converted $51,500 of accrued payroll for Jonathan Turman into a convertible promissory note. As of October 6, 2016, Jonathan Turman has converted $26,343 of principal and unpaid accrued interest into 6,586 of common stock shares of Cure Pharmaceutical. As of October 17, 2016, Jonathan Turman converted $26,366 of principal and unpaid accrued interest into 6,591 of common stock shares of Cure Pharmaceutical.

 

At December 31, 2015, two of our executive officers, Robert Davidson and Mark Udell, had $50,772 and $12,377, respectively, due to them and are included in accounts payable. At December 31, 2014, Robert Davidson had $24,126 due to him and is included in accounts payable.

 

LEGAL PROCEEDINGS

 

We are not currently involved in any material legal proceedings, nor have we been involved in any such proceedings that have had or may have a significant effect on our company. We are not aware of any other material legal proceedings pending against us.

 
 
20
 

 

MARKET PRICE OF AND DIVIDENDS ON COMMON EQUITY

AND RELATED SHAREHOLDER MATTERS

 

Market Information

 

The registrant’s common stock is not listed on any stock exchange, and is quoted for trading on the OTC Pink quotation system operated by OTC Markets Group Inc. under the symbol “MKKN.” However, there has been no active trading with respect to our shares of common stock to date.

 

Holders

 

As of November 8, 2016, there were approximately 80 shareholders of record of the registrant’s common stock based upon the records of the shareholders provided by the registrant’s transfer agent. The registrant’s transfer agent is Globex Transfer, LLC, and whose telephone number is (813) 344-4490.

 

Dividends

 

The registrant has never paid cash dividends on its common stock. We intend to keep future earnings, if any, to finance the expansion of our business, and we do not anticipate that any cash dividends will be paid in the foreseeable future. The registrant’s future payment of dividends will depend on the registrant’s earnings, capital requirements, expansion plans, financial condition and other relevant factors that the registrant’s board of directors may deem relevant. The registrant’s retained earnings deficit currently limits the registrant’s ability to pay dividends.

 

RECENT SALES OF UNREGISTERED SECURITIES

 

Reference is made to Item 3.02 of this Current Report on Form 8-K for a description of recent sales of unregistered securities, which is hereby incorporated by reference.

 

DESCRIPTION OF SECURITIES

 

The following information describes the registrant’s capital stock and provisions of the registrant’s articles of incorporation and the registrant’s bylaws, all as in effect upon the Closing of the Share Exchange. This description is only a summary. You should also refer to the registrant’s articles of incorporation, bylaws and articles of amendment which have been incorporated by reference or filed with the SEC as exhibits to this Current Report on Form 8-K.

 

As of the Closing Date, our authorized capital stock consists of 75,000,000 shares of common stock, par value $0.001 per share, of which 23,266,733 shares are issued and outstanding.

 

Under our Articles of Incorporation, the shares of our common stock are identical in all respects, and each share entitles the holder to the same rights and privileges as are enjoyed by other holders and is subject to the same qualifications, limitations, and restrictions as apply to other shares.

 

Our common stock is the only class of voting securities issued and outstanding. Holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders. Holders of our common stock do not have cumulative voting rights.

 

Holders of our common stock are entitled to dividends when and if declared by our Board from legally available funds. We have never declared a dividend and do not intend to do so in the foreseeable future. Holders of our common stock are also entitled to share pro rata in any distribution to stockholders upon our liquidation or dissolution.

 

INDEMNIFICATION OF DIRECTORS AND OFFICERS

 

The Nevada Private Corporation Law and our Articles of Incorporation allow us to indemnify our officers and directors from certain liabilities and our Bylaws state that we shall indemnify every present or former director or officer of ours (each an “Indemnitee”).

 

Our Bylaws provide that we shall indemnify an Indemnitee against all costs, charges and expenses, including amounts paid to settle an action or satisfy a judgment, actually and reasonably incurred by such Indemnitee.

 

 
21
 

 

Other than discussed above, none of our Bylaws, or Articles of Incorporation includes any specific indemnification provisions for our officers or directors against liability under the Securities Act. Additionally, insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

 

Item 3.02   Unregistered Sales of Equity Securities

 

As more fully described in Items 1.01 and 2.01 above, in connection with the Exchange Agreement, on the Closing Date, we issued an aggregate of 15,116,463 shares of our common stock to the Cure Pharm Shareholders and Cure Pharm Noteholders in exchange for 100% of the capital stock of Cure Pharmaceutical. Reference is made to the disclosures set forth under Items 1.01 and 2.01 of this Current Report on Form 8-K, which disclosures are incorporated herein by reference. The issuance of the common stock to the Cure Pharm Shareholders and Cure Pharm Noteholders pursuant to the Exchange Agreement as well as the issuance of the Majority Stockholder Warrant to the Majority Stockholder exempt from registration under the Securities Act pursuant to Section 4(a)(2) and Regulation D or S thereof. We made this determination based on the representations of the Cure Pharm Shareholders, Cure Pharm Noteholders and the Majority Stockholder which included, in pertinent part, that such shareholders were "accredited investors" within the meaning of Rule 501 of Regulation D promulgated under the Securities Act or sophisticated investors within the meaning of Rule 506 of Regulation D promulgated under the Securities Act that were provided full information regarding the Company’s business and operations, and that such shareholders were acquiring our common stock, for investment purposes for their own respective accounts and not as nominees or agents, and not with a view to the resale or distribution thereof, and that each member understood that the shares of our common stock may not be sold or otherwise disposed of without registration under the Securities Act or an applicable exemption therefrom.

 

Item 5.01   Changes in Control of Registrant.

 

As more fully described in Items 1.01 and 2.01 above, on November 7, 2016, in a reverse acquisition, we acquired a business engaged in the development of drug delivery technologies, by executing the Exchange Agreement by and among the registrant, Cure Pharmaceutical and the Cure Pharm Shareholders.

 

Under the Exchange Agreement, on the Closing Date, we acquired all of the issued and outstanding shares of Cure Pharmaceutical through the issuance of 15,116,463 restricted shares of our common stock to the Cure Pharm Shareholders and Noteholders. Immediately prior to the Exchange Transaction, we had 24,984,000 shares of common stock issued and outstanding. Immediately after the issuance of the shares to the Cure Pharm Shareholders and Cure Pharm Noteholders and the Share Cancellations described in Item 1.01 above, we had shares of common stock issued and outstanding.

 

As a result of this Exchange Transaction, the Cure Pharm Shareholders became our controlling shareholders and Cure Pharmaceutical became our wholly owned subsidiary.

 

In connection with the Closing of the Share Exchange, and as explained more fully in Item 2.01 above under the section titled “Management” and in Item 5.02 below, on the Closing Date, Michael Hlavsa will resign as our chief executive officer, president, chief financial officer, secretary and treasurer, and Robert Davidson shall become the Company’s chief executive officer, Edward Maliski shall become the registrant’s president and Chief Scientific Officer, Wayne Nasby shall become the registrant’s Chief Operating Officer and Mark Udell shall become the registrant’s Secretary, Treasurer and Chief Financial Officer. Additionally, Robert Davidson, William Yuan, and Charles Berman shall be appointed to the Board effective at the Closing, and Michael Hlavsa, who is also the registrant’s sole director immediately prior to the Share Exchange, shall resign from such position, and Robert Davidson shall be appointed as Chairman of the Board.

 

The closing of the transaction under the Exchange Agreement, which resulted in the change of control of the registrant, occurred on November 7, 2016. A copy of the Exchange Agreement is included as Exhibit 2.1to this Current Report on Form 8K.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

 On November 7, 2016, Michael Hlavsa resigned as our sole officer and director. Also on that date, Robert Davidson shall become the Company’s chief executive officer, Edward Maliski shall become the registrant’s president and Chief Scientific Officer, Wayne Nasby shall become the registrant’s Chief Operating Officer and Mark Udell shall become the registrant’s Secretary, Treasurer and Chief Financial Officer. Additionally, Robert Davidson, Edward Maliski, Wayne Nasby and Mark Udell shall be appointed as the new chief executive officer, president and chief scientific officer, chief operating officer and chief financial officer, respectively and Robert Davidson, William Yuan, and Charles Berman shall be appointed to the registrant’s Board, with Robert Davidson serving as the Chairman of the Board. See “Directors and Executive Officers” and “Executive Compensation” each under Item 2.01 “Completion of Acquisition or Disposition of Assets” above.

 

 
22
 

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On November 7, 2016, the Board of Directors of the registrant adopted the following resolutions by unanimous written consent to:

 

· change in fiscal year end from March 31 to December 31, effective immediately as of the effective date of the Share Exchange.

 

 

· Amended Section I, Subsection .01 (Annual Meeting) of our Bylaws such that Annual shareholders meeting shall now be held on such date and at such time as is fixed by the Board of Directors and stated in the notice of the meeting rather than the fixed date of the first week of December of each year.

 

 

· Amended Section I, Subsection .02 (Special Meeting) of our Bylaws to add the Chief Executive Officer as an additional Company officer that can call special meetings of shareholders.

 

 

· Amended Section I, Subsection .03 (Notice of Meeting) of our Bylaws to allow notice of shareholder meetings to be given no more than sixty (60) days (was previously fifty (50) days) prior to the date of meeting as allowed under Nevada Revised Statutes section 78.350.

 

 

· Amended Section I, Subsection .07 (Voting of Shares) of our Bylaws to add “as of the record date” language to clarify that every shareholder of record shall have the right at every shareholder's meeting to one (1) vote for every share standing in his/her name on the books of the Corporation as of the record date.

 

 

· Added Section I, Subsection .09 (Record Date) of our Bylaws that allows the Board to fix in advance, a record date, which shall be not more than sixty (60) nor less than ten (10) days before the date of any stockholder meeting, nor more than sixty (60) days prior to any other action.

 

 

· Amended and restated Section III (Actions by Written Consent) of our Bylaws to allow any action required or permitted to be taken at a meeting of the shareholders to be taken without a meeting if, before or after the action, a written consent thereto is signed by shareholders holding at least a majority of the voting power, except that if a different proportion of voting power is required for such an action at a meeting, then that proportion of written consents shall be required.

 

 

· Amended Section IV, Subsections .01, .02 and .03 (Officers) of our Bylaws to add Chief Executive Officer, Chief Financial Officer, Chief Operating Officer and Chief Scientific Officer as additional designated Officers of the Company and added descriptions of the powers and duties of each added designated Company Officer.

 

 

· Amended Section V, Subsection .01 (Form and Execution of Certificates) of our Bylaws to add the Chief Executive Officer as an authorized signatory for the Company’s stock certificates.

 

 

· Added Section XIII (Acquisition of Controlling Interest) of our Bylaws whereby the Company elected not to be governed by Nevada Revised Statutes Sections 78.378 through 78.3793 relating to acquisition of a controlling interest in the Company.

 

The above summary of the Bylaws’ amendments is qualified in its entirety by reference to the complete text of the Amendments to the Bylaws, which is attached hereto as Exhibit 3.3 and incorporated herein by reference.

 

Item 5.06 Change in Shell Company Status.

 

As explained more fully in Item 2.01 above, the registrant was a “shell company” (as such term is defined in Rule 12b-2 under the Exchange Act) immediately before the closing of the Exchange. The registrant believes that as a result of the Exchange, however, it has ceased to be a shell company. For information about the Exchange, please see the information set forth above under Items 1.01 and 2.01, which information is incorporated herein by reference.

 

Item 9.01   Financial Statement and Exhibits.

 

Reference is made to the reverse acquisition transaction under the Exchange Agreement, as described in Item 1.01, which is incorporated herein by reference. In the reverse acquisition transaction, the registrant is the accounting acquiree and Cure Pharmaceutical is the accounting acquirer. Accordingly, the financial statements of Cure Pharmaceutical are presented.

 

(a) Financial Statements of the Business Acquired

 

The audited financial statements of Cure Pharmaceutical as of and for the years ended December 31, 2015 and 2014, including the notes to such financial statements, are incorporated herein by reference to Exhibit 99.1 of this Current Report.

 

 
23
 

 

The unaudited financial statements of Cure Pharmaceutical as of and for the six months ended June 30, 2016 and 2015, including the notes to such financial statements, are incorporated herein by reference to Exhibit 99.2 of this Current Report.

 

(b) Pro Forma Financial Information

 

Incorporated by reference to Exhibit 99.3 attached hereto.

 

(d) Exhibits

 

Exhibit Number

 

Description

2.1

Share Exchange and Conversion Agreement, dated November 7, 2016*

3.1

 

Articles of Incorporation (1)

3.2

 

By-Laws (1)

3.3

Amendments to the Bylaws*

10.1

 

Agreement for the Sale of Assets, dated August 19, 2016 (2)

10.2

Form of Share Cancellation Agreement, dated November 7, 2016*

10.3

Form of Warrant, dated November 7, 2016*

21.1

Subsidiaries of the Registrant*

99.1

Audited consolidated financial statements of Cure Pharmaceutical for the year ended December 31, 2015*

99.2

 

Unaudited consolidated financial statements for the three and six months ended June 30, 2016 and 2015, and accompanying notes to consolidated financial statements*

99.3

Unaudited pro forma combined financial statements of the combined entity as of June 30, 2016, and for the year ended, December 31, 2015, and accompanying notes to unaudited pro forma consolidated financial statements*

____________ 

(1)

Incorporated by reference from the registrant's Registration Statement on Form S-1 filed on June 10, 2015.

(2)

Incorporated by reference from the registrant's Current Report on Form 8-K filed on August 26, 2016.

*

Filed herewith.

**

Management contract or compensatory plan or arrangement.

***

Confidential treatment has been requested for a portion of this document.

 

 
24
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

MAKKANOTTI GROUP CORP.
(Registrant)

     
Date: November 14, 2016 By: /s/ Robert Davidson

 

Name:

Robert Davidson  
  Title: Chief Executive Officer  

 

 

25

 

EXHIBIT 2.1

 

SHARE EXCHANGE AND CONVERSION AGREEMENT

 

by and among

 

MAKKANOTTI GROUP CORP. (“PUBCO”),

a Nevada corporation

 

and

 

THE MAJORITY STOCKHOLDER OF PUBCO

 

on the one hand;

 

and

 

CURE PHARMACEUTICAL CORPORATION (“PRIVECO”),

a California corporation

 

and

 

THE STOCKHOLDERS OF PRIVECO

 

and

 

THE NOTEHOLDERS OF PRIVECO

 

on the other hand

 

Dated as of November 7, 2016

 

 
1
 

 

SHARE EXCHANGE AND CONVERSION AGREEMENT

 

THIS SHARE EXCHANGE AND CONVERSION AGREEMENT (this “ Agreement ”), dated as of November 7, 2016, is made and entered into by and among Makkanotti Group Corp., a Nevada corporation (“ Pubco ”), Aureus Fiduciary Nevis Limited, a Nevis limited company and the majority stockholder of Pubco (“ Pubco Stockholder ”), on the one hand, and Cure Pharmaceutical Corporation, a California corporation (“ Priveco ”), the stockholders of Priveco identified on the attached Signature Pages of Priveco Stockholders (together referred to herein as “ Priveco Stockholders ,” each a “ Priveco Stockholder ”), and the holders of Priveco’s convertible promissory notes identified on the attached Signature Pages of Priveco Noteholders (together referred to herein as “ Priveco Noteholders ,” each a “ Priveco Noteholder ”), on the other hand. Each party to this Agreement is individually referred to herein as a “ Party ” and collectively, as the “ Parties .”

 

RECITALS

 

WHEREAS , on October 28, 2016, the board of directors of Pubco adopted resolutions approving Pubco’s acquisition of the equity interests of Priveco held by Priveco Stockholders by means of a share exchange with Priveco Stockholders (the “ Share Exchange ”), and the conversion of convertible promissory notes of Priveco held by Priveco Noteholders (each a “ Note ”, and collectively, the “ Notes ”) into shares of Pubco’s common stock (the “ Conversion ”), upon the terms and conditions hereinafter set forth in this Agreement;

 

WHEREAS , each Priveco Stockholder owns the amount of equity interests (in shares of capital stock or otherwise) of Priveco set forth on such Priveco Stockholder’s Signature Page of Priveco Stockholders (collectively, the “ Priveco Shares ”);

 

WHEREAS , Priveco Stockholders desire to sell and transfer their respective holdings of the Priveco Shares in exchange for shares of Pubco pursuant to the terms and conditions of this Agreement, and will enter into this Agreement for the purpose of making certain representations, warranties, covenants and agreements;

 

WHEREAS , each Priveco Noteholder owns a Note in the principal amount set forth on such Priveco Noteholder’s Signature Page of Priveco Noteholders;

 

WHEREAS , concurrently with closing of the Share Exchange, the Notes shall convert into shares of Pubco pursuant to the terms and conditions of this Agreement, and Priveco Noteholders will enter into this Agreement for the purpose of making certain representations, warranties, covenants and agreements;

 

WHEREAS , concurrently with the execution of this Agreement, Pubco and two Pubco stockholders (includes Pubco Stockholder and hereinafter collectively referred to as the “ Cancelling Stockholders ”) shall each enter into Share Cancellation Agreements, dated as of the date of this Agreement, in substantially the forms attached hereto as Exhibit A and Exhibit B (collectively, the “ Cancellation Agreements ”), pursuant to which two Pubco stockholders have agreed to cancel an aggregate 16,833,790 shares of Pubco’s common stock held by them (the “ Cancellation Shares ”) representing approximately 67.38% of the issued and outstanding capital stock of Pubco immediately prior to the transactions contemplated under this Agreement (such shares cancellations are hereinafter collectively referred to as the “ Shares Cancellations ”);

 

 
2
 

 

WHEREAS , Pubco Stockholder will enter into this Agreement for the purpose of making certain representations, warranties, covenants and agreements;

 

WHEREAS , upon consummation of the transactions contemplated by this Agreement, Priveco will become a 100% wholly-owned subsidiary of Pubco; and

 

WHEREAS , it is intended that the terms and conditions of this Agreement comply in all respects with Section 368(a)(1)(B) and/or Section 351 of the Internal Revenue Code of 1986, as amended and in effect on the date of this Agreement (the “ Code ”) and the regulations corresponding thereto, so that the Exchange shall qualify as a tax free reorganization under the Code, and that the share exchange transaction contemplated by this Agreement shall qualify as a transaction in securities exempt from registration or qualification under the Securities Act of 1933, as amended and in effect on the date of this Agreement.

 

AGREEMENT

 

NOW, THEREFORE , in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth herein, and intending to be legally bound hereby, the Parties agree as follows:

 

ARTICLE 1

SHARE EXCHANGE AND CONVERSION

 

1.1 Share Exchange . Upon the terms and subject to the conditions hereof, at the Closing (as hereinafter defined), Pubco and Priveco Stockholders shall do the following in connection with the Share Exchange:

 

(a) Priveco Stockholders will each sell, convey, assign, transfer and deliver to Pubco the stock certificates representing the Priveco Shares held by each Priveco Stockholder as set forth in such Priveco Stockholder’s Signature Page of Priveco Stockholders attached hereto, which in the aggregate shall constitute 100% of the issued and outstanding equity interests of Priveco, each accompanied by a properly executed and authenticated stock power, instrument of transfer or other instrument of like tenor.

 

(b) As consideration in exchange for the acquisition of the Priveco Shares, Pubco will issue to each Priveco Stockholder or its designees, in exchange for such Priveco Stockholder’s portion of the Priveco Shares, the number of shares of Pubco common stock set forth in such Priveco Stockholder’s Signature Page of Priveco Stockholders attached hereto. The 9,010,000 shares of the Common Stock to be issued in the aggregate by Pubco to all Priveco Stockholders, shall hereinafter be referred to as the “ Exchange Shares .”

 

 
3
 

 

1.2 Conversion . Upon the terms and subject to the conditions hereof, at the Closing, Pubco and Priveco Noteholders shall do the following in connection with the Conversion:

 

(a) Each Priveco Noteholder will each deliver to Pubco for cancellation the Note held by such Priveco Noteholder, in the principal amount as set forth in such Priveco Noteholder’s Signature Page of Priveco Noteholders attached hereto.

 

(b) As consideration for the surrender of the Notes, Pubco will issue to each Priveco Noteholder or its designees, the number of shares of common stock set forth in such Priveco Noteholder’s Signature Page of Priveco Noteholders attached hereto. The 6,106,463 shares of the Common Stock to be issued in the aggregate by Pubco to all Priveco Noteholders shall hereinafter be referred to as the “ Conversion Shares .”

 

1.3 Closing Date . The closing of the Share Exchange and the Conversion (the “ Closing ”) shall take place as soon as practicable upon signing of this Agreement, and on or prior to November 14, 2016, or on such other date as may be mutually agreed upon in writing by the Parties. Such date is referred to herein as the “ Closing Date .”

 

1.4 Taking of Necessary Action; Further Action . If, at any time after the Closing, any further action is necessary or desirable to carry out the purposes of this Agreement, Priveco Stockholders, Priveco Noteholders, Priveco, Pubco Stockholder and/or Pubco (as applicable) will take all such lawful and necessary action.

 

1.5 Tax Consequences . It is intended that the terms and conditions of this Agreement comply in all respects with Section 368(a)(1)(B) and/or Section 351 of the Code and the regulations corresponding thereto, so that the Share Exchange and Conversion shall qualify as a tax-free reorganization under the Code.

 

1.6 Certain Definitions . In addition to the capitalized terms defined elsewhere in this Agreement, the following capitalized terms as used in this Agreement shall have the respective definitions:

 

Affiliate ” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

Common Stock ” means the common stock of Pubco, par value $0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.

 

Contract ” means any contract, lease, license, indenture, note, bond, agreement, permit, concession, franchise or other instrument.

 

Exchange Act ” means the Securities Exchange Act of 1934, as amended.

 

FINRA ” means Financial Industry Regulatory Authority.

 

 
4
 

 

GAAP ” means United States generally accepted accounting principles.

 

Governmental Authority ” means any federal or national, state or provincial, municipal or local government, governmental authority, regulatory or administrative agency, governmental commission, department, board, bureau, agency or instrumentality, political subdivision, commission, court, tribunal, official, arbitrator or arbitral body, in each case whether U.S. or non-U.S.

 

Knowledge ” means the actual knowledge of the officers, directors or advisors of the referenced party after reasonable inquiry.

 

Laws ” means, with respect to any Person, any U.S. or non-U.S. federal, national, state, provincial, local, municipal, international, multinational or other law (including common law), constitution, statute, code, ordinance, rule, regulation or treaty applicable to such Person.

 

Liens ” means a lien, charge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

 

Material Adverse Effect ” means an adverse effect on either referenced party or the combined entity resulting from the consummation of the transaction contemplated by this Agreement, or on the financial condition, results of operations or business, before or after the consummation of the transaction contemplated in this Agreement, which as a whole is or would be considered material to an investor in the referenced party.

 

Non-U.S. Person ” means any person who is not a U.S. Person or is deemed not to be a U.S. Person under Rule 902(k)(2).

 

Order ” means any award, decision, injunction, judgment, order, ruling, subpoena, or verdict entered, issued, made, or rendered by any Governmental Authority.

 

Organizational Documents ” means (a) the articles or certificate of incorporation and the by-laws or code of regulations of a corporation; (b) any other document performing a similar function to the documents specified in clause (a) adopted or filed in connection with the creation, formation or organization of a Person; and (c) any and all amendments to any of the foregoing.

 

Permitted Liens ” means (a) Liens for Taxes not yet payable or in respect of which the validity thereof is being contested in good faith by appropriate Proceedings and for the payment of which the relevant party has made adequate reserves; (b) Liens in respect of pledges or deposits under workmen’s compensation laws or similar legislation, carriers, warehousemen, mechanics, laborers and materialmen and similar Liens, if the obligations secured by such Liens are not then delinquent or are being contested in good faith by appropriate Proceedings conducted and for the payment of which the relevant party has made adequate reserves; (c) statutory Liens incidental to the conduct of the business of the relevant party which were not incurred in connection with the borrowing of money or the obtaining of advances or credits and that do not in the aggregate materially detract from the value of its property or materially impair the use thereof in the operation of its business; and (d) Liens that would not have a Material Adverse Effect.

 

 
5
 

 

Person ” means any individual, corporation, partnership, joint venture, trust, business association, organization, governmental authority or other entity.

 

Priveco Common Stock Equivalents ” means any securities of Priveco which would entitle the holder thereof to acquire at any time such entities capital stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive shares of such entities capital stock.

 

Priveco Indemnified Parties ” means Priveco, Priveco Stockholders and Priveco Noteholders and their respective Affiliates and the officers, directors and representatives of such Persons; provided that (i) Pubco shall be a member of Priveco Indemnified Parties after the Closing and (ii) none of Pubco Stockholder nor any of Pubco Stockholder’s Affiliates shall be members of Priveco Indemnified Parties at any time.

 

Proceeding ” means any action, arbitration, audit, hearing, investigation, litigation, or suit (whether civil, criminal, administrative or investigative) commenced, brought, conducted, or heard by or before, or otherwise involving, any Governmental Authority.

 

“Pubco Common Stock Equivalents ” means any securities of Pubco which would entitle the holder thereof to acquire at any time such entities capital stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive shares of such entities capital stock.

 

SEC ” means the United States Securities and Exchange Commission or any other federal agency then administering the Securities Act and the Exchange Act.

 

Securities Act ” means the Securities Act of 1933, as amended.

 

Subsidiary ” means any entity, whether or not capitalized, in which the referenced party, owns, directly or indirectly, an equity interest of more than fifty percent (50%).

 

Tax Returns ” means all federal, state, local and foreign returns, estimates, information statements and reports relating to Taxes.

 

Tax ” or “ Taxes ” means any and all applicable central, federal, provincial, state, local, municipal and foreign taxes, including, without limitation, gross receipts, income, profits, sales, use, occupation, value added, ad valorem, transfer, franchise, withholding, payroll, recapture, employment, excise and property taxes, assessments, governmental charges and duties together with all interest, penalties and additions imposed with respect to any such amounts and any obligations under any agreements or arrangements with any other person with respect to any such amounts and including any liability of a predecessor entity for any such amounts.

 

 
6
 

 

Trading Day ” means a day on which the principal Trading Market is open for trading.

 

Trading Market ” means the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE Amex Exchange, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market, the New York Stock Exchange, the OTCQB and OTC Pink quotation tiers of OTC Markets Group, Inc. or the OTC Bulletin Board.

 

Transaction ” means the transactions contemplated by this Agreement, including the Share Exchange and the Conversion.

 

Transaction Documents ” means this Agreement, all exhibits and schedules thereto and hereto, the Cancellation Agreements and any other documents or agreements executed in connection with the transactions contemplated hereunder.

 

United States ” means and includes the United States of America, its territories and possessions, any State of the United States, and the District of Columbia.

 

U.S. Person as defined in Regulation S means: (i) a natural person resident in the United States; (ii) any partnership or corporation organized or incorporated under the laws of the United States; (iii) any estate of which any executor or administrator is a U.S. Person; (iv) any trust of which any trustee is a U.S. Person; (v) any agency or branch of a foreign entity located in the United States; (vi) any nondiscretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. Person; (vii) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated and (if an individual) resident in the United States; and (viii) a corporation or partnership organized under the laws of any foreign jurisdiction and formed by a U.S. Person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, owned, by accredited investors (as defined in Rule 501(a) under the Securities Act) who are not natural persons, estates or trusts).

 

ARTICLE 2

REPRESENTATIONS AND WARRANTIES OF PRIVECO

 

Except as otherwise disclosed herein or in a disclosure schedule (“ Schedule ”) attached hereto, Priveco hereby represents and warrants to Pubco and Pubco Stockholder as of the date hereof and as of the Closing Date (unless otherwise indicated) as follows:

 

2.1 Organization . Priveco is duly incorporated, validly existing and in good standing under the laws of the State of California, has all requisite authority and power (corporate and other), governmental licenses, authorizations, consents and approvals to carry on its business as presently conducted, and to own, hold and operate its properties and assets as now owned, held and operated by it. Priveco is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in a Material Adverse Effect, and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.

 

 
7
 

 

2.2 Subsidiaries . As of the Closing, Priveco has no direct or indirect Subsidiaries.

 

2.3 Organizational Documents . True, correct and complete copies of the Organizational Documents of Priveco have been delivered to Pubco prior to the execution of this Agreement, and no action has been taken to amend or repeal such Organizational Documents since such date of delivery. Priveco is not in violation or breach of any of the provisions of its Organizational Documents.

 

2.4 Authorization and Validity of this Agreement . Priveco has all requisite authority and power (corporate and other), authorizations, consents and approvals to enter into this Agreement and each of the Transaction Documents to which Priveco is a party, to consummate the transactions contemplated by this Agreement and each of the Transaction Documents to which Priveco is a party, to perform its obligations under this Agreement and each of the Transaction Documents to which Priveco is a party, and to record the transfer of the Shares and the delivery of the new certificates representing the Shares registered in the name of Pubco. The execution, delivery and performance by Priveco of this Agreement and each of the Transaction Documents to which Priveco is a party have been duly authorized by all necessary corporate action and do not require from Priveco’s board of directors, Priveco Stockholder or Priveco Noteholder any consent or approval that has not been validly and lawfully obtained. The execution, delivery and performance by Priveco of this Agreement and each of the Transaction Documents to which Priveco is a party requires no authorization, consent, approval, license, exemption of or filing or registration with any Governmental Authority or other Person.

 

2.5 No Violation . Neither the execution nor the delivery by Priveco of this Agreement or any Transaction Document to which Priveco is a party, nor the consummation or performance by Priveco of the transactions contemplated hereby or thereby will, directly or indirectly, (a) contravene, conflict with, or result in a violation of any provision of the Organizational Documents of Priveco; (b) contravene, conflict with, constitute a default (or an event or condition which, with notice or lapse of time or both, would constitute a default) under, or result in the termination or acceleration of, or result in the imposition or creation of any Lien under, any agreement or instrument to which Priveco is a party or by which the properties or assets of Priveco are bound; (c) contravene, conflict with, or result in a violation of, any Law or Order to which Priveco, or any of the properties or assets owned or used by Priveco, may be subject; or (d) contravene, conflict with, or result in a violation of, the terms or requirements of, or give any Governmental Authority the right to revoke, withdraw, suspend, cancel, terminate or modify, any licenses, permits, authorizations, approvals, franchises or other rights held by Priveco or that otherwise relate to the business of, or any of the properties or assets owned or used by, Priveco, except, in the cases of clauses (b), (c) and (d), for any such contraventions, conflicts, violations, or other occurrences as would not have a Material Adverse Effect.

 

 
8
 

 

2.6 Binding Obligations . Assuming this Agreement and the Transaction Documents have been duly and validly authorized, executed and delivered by the parties hereto and thereto other than Priveco, this Agreement and each of the Transaction Documents to which Priveco is a party are duly authorized, executed and delivered by Priveco and constitute the legal, valid and binding obligations of Priveco, enforceable against Priveco in accordance with their respective terms, except as such enforcement is limited by general equitable principles, or by bankruptcy, insolvency and other similar laws affecting the enforcement of creditors rights generally.

 

2.7 Capitalization . Priveco has authorized capital stock consisting of a total of 10,000,000 shares of common stock (the “ Priveco Capital Stock ”). Priveco has 2,718,253 shares of Priveco Capital Stock currently issued and outstanding. The Priveco Shares are not subject to any preemptive or subscription right, any voting trust agreement or other contract, agreement, arrangement, option, warrant, call, commitment or other right of any character obligating or entitling Priveco to issue, sell, redeem or purchase any of its securities. Except as set forth in Schedule 2.7 , there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire any shares of Priveco Capital Stock, or Contracts, commitments, understandings or arrangements by which Priveco is or may become bound to issue additional shares of Priveco Capital Stock or Priveco Common Stock Equivalents.

 

2.8 Priveco Stockholders and Noteholders . The attached Signature Pages of Priveco Stockholders contain the names of the record and beneficial holders of all of the outstanding capital stock of the Priveco. The attached Signature Pages of the Priveco Noteholders contain the names of the record and beneficial holders of all of the outstanding Notes of Priveco. Except as expressly provided in this Agreement, no holder of Priveco Shares, Notes or any other security of the Priveco or any other Person is entitled to any preemptive right, right of first refusal or similar right as a result of the issuance of the shares or otherwise.

 

2.9 Compliance with Laws and Other Instruments . Except for those that would not have a Material Adverse Effect, the business and operations of the Priveco have been and are being conducted in accordance with all applicable Laws and Orders. Except as would not have a Material Adverse Effect, Pubco has not received notice of any violation (or any Proceeding involving an allegation of any violation) of any applicable Law or Order by or affecting Priveco and, to the knowledge of Priveco, no Proceeding involving an allegation of violation of any applicable Law or Order is threatened or contemplated. Except for those that would not have a Material Adverse Effect, Priveco is, and is not alleged to be, in violation of, or (with or without notice or lapse of time or both) in default under, or in breach of, any term or provision of its Organizational Documents or of any indenture, loan or credit agreement, note, deed of trust, mortgage, security agreement or other material agreement, lease, license or other instrument, commitment, obligation or arrangement to which Priveco is a party or by which any of Priveco’s properties, assets or rights are bound or affected. Priveco is not subject to any obligation or restriction of any kind or character, nor is there, to the knowledge of Priveco, any event or circumstance relating to Priveco that materially and adversely affects in any way its business, properties, assets or prospects or that prohibits Priveco from entering into this Agreement or would prevent or make burdensome its performance of or compliance with all or any part of this Agreement or the consummation of the transactions contemplated hereby or thereby.

 

 
9
 

 

2.10 Legal Proceedings . There is no pending Proceeding that has been commenced against Priveco and that challenges, or may have the effect of preventing, delaying, making illegal, or otherwise interfering with, any of the transactions contemplated in this Agreement. To the Knowledge of Priveco, no such Proceeding has been threatened. No current officer, director or Person known to Priveco to be the record or beneficial owner in excess of 5% of Priveco’s outstanding capital stock, is a party adverse to Priveco or has a material interest adverse to Priveco in any material pending Proceeding.

 

2.11 Certain Fees . Except as set forth in Schedule 2.11 , no brokerage or finder’s fees or commissions are or will be payable by Priveco to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by this Agreement.

 

2.12 Title to and Condition of Properties . Except as would not have a Material Adverse Effect, Priveco owns (with good and marketable title in the case of real property) or holds under valid leases or other rights to use all real property, plants, machinery and equipment necessary for the conduct of the business of Priveco as presently conducted, free and clear of all Liens, except Permitted Liens. The material buildings, plants, machinery and equipment necessary for the conduct of the business of Priveco as presently conducted are in good operating condition and repair and are adequate for the uses to which they are being put, in each case, taken as a whole.

 

2.13 Board Recommendation . Priveco’s board of directors has, by unanimous written consent, determined that this Agreement and the transactions contemplated by this Agreement, are advisable and in the best interests of the Priveco, Priveco Stockholders and Priveco Noteholders.

 

2.14 Liabilities . Except as indicated in the financial statements and those incurred in the ordinary business hereto, since June 30, 2016, Priveco has not incurred any external liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) which, individually or in the aggregate, are reasonably likely to cause a Material Adverse Effect.

 

2.15 Disclosure . The representations and warranties and statements of fact made by Priveco in this Agreement are, as applicable, accurate, correct and complete and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements and information contained herein not false or misleading.

 

 
10
 

 

ARTICLE 3

REPRESENTATIONS AND WARRANTIES OF PRIVECO STOCKHOLDERS

 

Except as otherwise disclosed herein or in a Schedule attached hereto, each Priveco Stockholder hereby represents and warrants to Pubco and Pubco Stockholder as of the date hereof and as of the Closing Date (unless otherwise indicated) as follows:

 

3.1 Ownership of the Priveco Shares . Each Priveco Stockholder owns, beneficially and of record, good and marketable title to the amount of the Priveco Shares set forth in such Priveco Stockholder’s Signature Page of Priveco Stockholders attached hereto, free and clear of all security interests, liens, adverse claims, encumbrances, equities, proxies, options or voting agreements. Each Priveco Stockholder represents that they have no right or claims whatsoever to any equity interests of Priveco, other than the Priveco Shares set forth in such Priveco Stockholder’s Signature Page of Priveco Stockholders attached hereto, and does not have any options, warrants or any other instruments entitling him to exercise or purchase or convert into additional equity interests of Priveco. At the Closing, Priveco Stockholders will convey to Pubco good and marketable title to the Priveco Shares, free and clear of any security interests, liens, adverse claims, encumbrances, equities, proxies, options, stockholders’ agreements or restrictions.

 

3.2 Authority Relative to this Agreement . This Agreement has been duly and validly executed and delivered by Priveco Stockholders and constitutes a valid and binding agreement of such Person, enforceable against such Person in accordance with its terms, except as such enforcement may be limited by bankruptcy, insolvency or other similar laws affecting the enforcement of creditors’ rights generally or by general principles of equity.

 

3.3 Purchase of Restricted Securities for Investment . Each Priveco Stockholder acknowledges that the Exchange Shares will not be registered pursuant to the Securities Act or any applicable state securities laws, that the Exchange Shares will be characterized as “restricted securities” under federal securities laws, and that under such laws and applicable regulations the Exchange Shares cannot be sold or otherwise disposed of without registration under the Securities Act or an exemption therefrom. In this regard, each Priveco Stockholder is familiar with Rule 144 promulgated under the Securities Act, as currently in effect, and understands the resale limitations imposed thereby and by the Securities Act. Further, each Priveco Stockholder acknowledges and agrees that:

 

(a) Each Priveco Stockholder is acquiring the Exchange Shares for investment for such Priveco Stockholder’s own account and not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and each Priveco Stockholder has no present intention of selling, granting any participation in, or otherwise distributing the same. Each Priveco Stockholder further represents that he, she or it does not have any Contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participation to such person or to any third person, with respect to any of the Exchange Shares.

 

(b) Each Priveco Stockholder understands that the Exchange Shares are not registered under the Securities Act on the ground that the sale and the issuance of securities hereunder is exempt from registration under the Securities Act pursuant to Section 4(a)(2) thereof, and that Pubco’s reliance on such exemption is predicated on the each Priveco Stockholder’s representations set forth herein.

 

 
11
 

 

3.4 Status of Stockholder . Each of Priveco Stockholders hereby makes the representations and warranties in either paragraph (a), (b) or (c) of this Section 3.4 , as indicated on the signature page of such Priveco Stockholder which is attached and part of this Agreement:

 

(a) Accredited Investor Under Regulation D . The Priveco Stockholder is an “ Accredited Investor ” as that term is defined in Rule 501 of Regulation D promulgated under the Securities Act, an excerpt of which is included in the attached Annex I , and such Priveco Stockholder is not acquiring its portion of the Exchange Shares as a result of any advertisement, article, notice or other communication regarding the Exchange Shares published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general solicitation or general advertisement.

 

(b) Sophisticated Investor as Described in Rule 506(b)(2)(ii) . The Priveco Stockholder is a “sophisticated investor” as that term is described in Rule 506(b)(2)(ii) promulgated under the Securities Act that (i) has such experience in business and financial matters that it is capable of evaluating the merits and risk of an investment in Pubco; (ii) is not acquiring its portion of the Exchange Shares as a result of any advertisement, article, notice or other communication regarding the Exchange Shares published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general solicitation or general advertisement; (iii) is aware of and has had the opportunity to review Pubco’s SEC Reports as filed on www.sec.gov, (iv) has, prior to the date of this Agreement, had the opportunity to ask questions of and receive answers from, or obtain additional information from Pubco and Priveco and their respective officers and directors (or any Person acting on their behalf) concerning the financial and other affairs of Pubco and Priveco, and to the extent deemed necessary in light of such Priveco Stockholder’s personal knowledge of the Pubco’s and Priveco’s affairs, such Priveco Stockholder has asked such questions and received answers to the full satisfaction of such Priveco Stockholder, (v) has, prior to the date of this Agreement, had access to and has acquired information, documents, records and books regarding Pubco and Priveco that such Priveco Stockholder deems sufficient to reach an informed and knowledgeable decision to acquire the Exchange Shares being acquired; and (vi) is not relying on any oral representation of Pubco, Priveco or any other Person, nor any written representation or assurance from Pubco or Priveco in connection with such Priveco Stockholder’s acceptance of the Exchange Shares and investment decision in connection therewith.

 

(c) Non-U.S. Person Under Regulation S . The Priveco Stockholder:

 

(i) is not a “U.S. person” as defined by Rule 902 of Regulation S promulgated under the Securities Act, was not organized under the laws of any U.S. jurisdiction, and was not formed for the purpose of investing in securities not registered under the Securities Act;

 

(ii) at the time of Closing, such Priveco Stockholder was located outside the United States;

 

(iii) no offer of the Exchange Shares was made to such Priveco Stockholder within the United States;

 

 
12
 

 

(iv) such Priveco Stockholder is either (a) acquiring the Exchange Shares for its own account for investment purposes and not with a view towards distribution, or (b) acting as agent for a principal that has signed this Agreement or has delivered representations and warranties substantially similar to this Section 3.4(c) ;

 

(v) all subsequent offers and sales of the Exchange Shares by such Priveco Stockholder will be made outside the United States in compliance with Rule 903 or Rule 904 of Regulation S, pursuant to registration of the Exchange Shares under the Securities Act, or pursuant to an exemption from such registration; such Priveco Stockholder understands the conditions of the exemption from registration afforded by section 4(a)(l) of the Securities Act and acknowledges that there can be no assurance that it will be able to rely on such exemption.

 

(vi) such Priveco Stockholder will not resell the Exchange Shares to U.S. Persons or within the United States until after the end of the one (1) year period commencing on the date of Closing (the “ Restricted Period ”);

 

(vii) such Priveco Stockholder shall not and hereby agrees not to enter into any short sales with respect to the Common Stock of Pubco at any time after the execution of this Agreement by such Priveco Stockholder and prior to the expiration of the Restricted Period;

 

(viii) such Priveco Stockholder understands that the Exchange Shares are being offered and sold to it in reliance on specific provisions of federal and state securities laws and that Pubco is relying upon the truth and accuracy of the representations, warranties, agreements, acknowledgments and understanding of such Priveco Stockholder set forth herein in order to determine the applicability of such provisions. Accordingly, such Priveco Stockholder agrees to notify Pubco of any events which would cause the representations and warranties of such Priveco Stockholder to be untrue or breached at any time after the execution of this Agreement by such Priveco Stockholder and prior to the expiration of the Restricted Period;

 

(ix) in the event of resale of the Exchange Shares to non-U.S. Persons outside of the United States during the Restricted Period, such Priveco Stockholder shall provide a written confirmation or other written notice to any distributor, dealer, or person receiving a selling concession, fee, or other remuneration in respect of the Exchange Shares stating that such purchaser is subject to the same restrictions on offers and sales that apply to the undersigned, and shall require that any such purchase shall provide such written confirmation or other notice upon resale during the Restricted Period;

 

(x) such Priveco Stockholder has not engaged, nor is it aware that any party has engaged, and it will not engage or cause any third party to engage in any “directed selling” efforts (as such term is defined in Regulation S) in the United States with respect to the Exchange Shares;

 

(xi) such Priveco Stockholder is not a “distributor” as such term is defined in Regulation S, and it is not a “dealer” as such term is defined in the Securities Act;

 

 
13
 

 

(xii) such Priveco Stockholder has not taken any action that would cause any of the Parties to be subject to any claim for commission or other or remuneration by any broker, finder, or other person; and

 

(xiii) such Priveco Stockholder hereby represents that it has satisfied fully observed of the laws of the jurisdiction in which it is located or domiciled, in connection with the acquisition of the Exchange Shares or this Agreement, including (A) the legal requirements of such Priveco Stockholder’s jurisdiction for the purchase and acquisition of the Exchange Shares, (B) any foreign exchange restrictions applicable to such purchase and acquisition, (C) any governmental or other consents that may need to be obtained, and (D) the income tax and other tax consequences, if any, which may be relevant to the purchase, holding, redemption, sale, or transfer of the Exchange Shares; and further, such Priveco Stockholder agrees to continue to comply with such laws as long as it shall hold the Exchange Shares.

 

3.5 Investment Risk . Each Priveco Stockholder is able to bear the economic risk of acquiring the Exchange Shares pursuant to the terms of this Agreement, including a complete loss of such Priveco Stockholder’s investment in the Exchange Shares.

 

3.6 Restrictive Legends . Each Priveco Stockholder acknowledges that the certificate(s) representing such Priveco Stockholder’s pro rata portion of the Exchange Shares shall each conspicuously set forth on the face or back thereof a legend in substantially the following form, corresponding to the stockholder’s status as set forth in Section 3.4 and the signature pages hereto:

 

REGULATION D OR RULE 506(B)(2)(ii) LEGEND:

 

 

“THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR PURSUANT TO AN EXEMPTION FROM REGISTRATION OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.”

 

 

REGULATION S LEGEND:

 

 

“THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“SECURITIES ACT”), AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S PROMULGATED UNDER THE SECURITIES ACT, PURSUANT TO REGISTRATION UNDER THE SECURITIES ACT, OR PURSUANT TO ANOTHER AVAILABLE EXEMPTION FROM REGISTRATION; HEDGING TRANSACTIONS INVOLVING THE SHARES REPRESENTED HEREBY MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.”

 

 

 
14
 

 

3.7 Disclosure . The representations and warranties and statements of fact made by Priveco Stockholders in this Agreement are, as applicable, accurate, correct and complete and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements and information contained herein not false or misleading.

 

ARTICLE 4

REPRESENTATIONS AND WARRANTIES OF PRIVECO NOTEHOLDERS

 

Except as otherwise disclosed herein or in a Schedule attached hereto, each Priveco Noteholder hereby represents and warrants to Pubco and Pubco Stockholder as of the date hereof and as of the Closing Date (unless otherwise indicated) as follows:

 

4.1 Ownership of the Notes . Each Priveco Noteholder owns, beneficially and of record, good and marketable title to the Note in the principal amount set forth in such Priveco Noteholder’s Signature Page of Priveco Noteholders attached hereto, free and clear of all security interests, liens, adverse claims, encumbrances, equities, proxies, options or voting agreements. Each Priveco Noteholder represents that they have no right or claims whatsoever to any equity interests of Priveco, other than pursuant to the Note held by such Priveco Noteholder, and does not have any options, warrants or any other instruments entitling him to exercise or purchase or convert into additional equity interests of Priveco. At the Closing, Priveco Noteholders will convey to Pubco good and marketable title to the Notes, free and clear of any security interests, liens, adverse claims, encumbrances, equities, proxies, options, Noteholders’ agreements or restrictions.

 

4.2 Authority Relative to this Agreement . This Agreement has been duly and validly executed and delivered by Priveco Noteholders and constitutes a valid and binding agreement of such Person, enforceable against such Person in accordance with its terms, except as such enforcement may be limited by bankruptcy, insolvency or other similar laws affecting the enforcement of creditors’ rights generally or by general principles of equity.

 

4.3 Purchase of Restricted Securities for Investment . Each Priveco Noteholder acknowledges that the Conversion Shares will not be registered pursuant to the Securities Act or any applicable state securities laws, that the Conversion Shares will be characterized as “restricted securities” under federal securities laws, and that under such laws and applicable regulations the Conversion Shares cannot be sold or otherwise disposed of without registration under the Securities Act or an exemption therefrom. In this regard, each Priveco Noteholder is familiar with Rule 144 promulgated under the Securities Act, as currently in effect, and understands the resale limitations imposed thereby and by the Securities Act. Further, each Priveco Noteholder acknowledges and agrees that:

 

(c) Each Priveco Noteholder is acquiring the Conversion Shares for investment for such Priveco Noteholder’s own account and not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and each Priveco Noteholder has no present intention of selling, granting any participation in, or otherwise distributing the same. Each Priveco Noteholder further represents that he, she or it does not have any Contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participation to such person or to any third person, with respect to any of the Conversion Shares.

 

 
15
 

 

(d) Each Priveco Noteholder understands that the Conversion Shares are not registered under the Securities Act on the ground that the sale and the issuance of securities hereunder is exempt from registration under the Securities Act pursuant to Section 4(a)(2) thereof, and that Pubco’s reliance on such exemption is predicated on the each Priveco Noteholder’s representations set forth herein.

 

4.4 Status of Noteholder . Each of Priveco Noteholders hereby makes the representations and warranties in either paragraph (a) or (b) of this Section 4.4 , as indicated on the signature page of such Priveco Noteholder which is attached and part of this Agreement:

 

(a) Accredited Investor Under Regulation D . Such Priveco Noteholder is an “ Accredited Investor ” as that term is defined in Rule 501 of Regulation D promulgated under the Securities Act, an excerpt of which is included in the attached Annex I , and such Priveco Noteholder is not acquiring its portion of the Conversion Shares as a result of any advertisement, article, notice or other communication regarding the Conversion Shares published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general solicitation or general advertisement.

 

(b) Non-U.S. Person Under Regulation S . Such Priveco Noteholder:

 

(i) is not a “U.S. person” as defined by Rule 902 of Regulation S promulgated under the Securities Act, was not organized under the laws of any U.S. jurisdiction, and was not formed for the purpose of investing in securities not registered under the Securities Act;

 

(ii) at the time of Closing, such Priveco Noteholder was located outside the United States;

 

(iii) no offer of the Conversion Shares was made to such Priveco Noteholder within the United States;

 

(iv) such Priveco Noteholder is either (a) acquiring the Conversion Shares for its own account for investment purposes and not with a view towards distribution, or (b) acting as agent for a principal that has signed this Agreement or has delivered representations and warranties substantially similar to this Section 4.4(b) ;

 

(v) all subsequent offers and sales of the Conversion Shares by such Priveco Noteholder will be made outside the United States in compliance with Rule 903 or Rule 904 of Regulation S, pursuant to registration of the Conversion Shares under the Securities Act, or pursuant to an exemption from such registration; such Priveco Noteholder understands the conditions of the exemption from registration afforded by section 4(a)(l) of the Securities Act and acknowledges that there can be no assurance that it will be able to rely on such exemption.

 

 
16
 

 

(vi) such Priveco Noteholder will not resell the Conversion Shares to U.S. Persons or within the United States until after the end of the Restricted Period;

 

(vii) such Priveco Noteholder shall not and hereby agrees not to enter into any short sales with respect to the Common Stock of Pubco at any time after the execution of this Agreement by such Priveco Noteholder and prior to the expiration of the Restricted Period;

 

(viii) such Priveco Noteholder understands that the Conversion Shares are being offered and sold to it in reliance on specific provisions of federal and state securities laws and that Pubco is relying upon the truth and accuracy of the representations, warranties, agreements, acknowledgments and understanding of such Priveco Noteholder set forth herein in order to determine the applicability of such provisions. Accordingly, such Priveco Noteholder agrees to notify Pubco of any events which would cause the representations and warranties of such Priveco Noteholder to be untrue or breached at any time after the execution of this Agreement by such Priveco Noteholder and prior to the expiration of the Restricted Period;

 

(ix) in the event of resale of the Conversion Shares to non-U.S. Persons outside of the United States during the Restricted Period, such Priveco Noteholder shall provide a written confirmation or other written notice to any distributor, dealer, or person receiving a selling concession, fee, or other remuneration in respect of the Conversion Shares stating that such purchaser is subject to the same restrictions on offers and sales that apply to the undersigned, and shall require that any such purchase shall provide such written confirmation or other notice upon resale during the Restricted Period;

 

(x) such Priveco Noteholder has not engaged, nor is it aware that any party has engaged, and it will not engage or cause any third party to engage in any “directed selling” efforts (as such term is defined in Regulation S) in the United States with respect to the Conversion Shares;

 

(xi) such Priveco Noteholder is not a “distributor” as such term is defined in Regulation S, and it is not a “dealer” as such term is defined in the Securities Act;

 

(xii) such Priveco Noteholder has not taken any action that would cause any of the Parties to be subject to any claim for commission or other or remuneration by any broker, finder, or other person; and

 

(xiii) such Priveco Noteholder hereby represents that it has satisfied fully observed of the laws of the jurisdiction in which it is located or domiciled, in connection with the acquisition of the Conversion Shares or this Agreement, including (A) the legal requirements of such Priveco Noteholder’s jurisdiction for the purchase and acquisition of the Conversion Shares, (B) any foreign exchange restrictions applicable to such purchase and acquisition, (C) any governmental or other consents that may need to be obtained, and (D) the income tax and other tax consequences, if any, which may be relevant to the purchase, holding, redemption, sale, or transfer of the Conversion Shares; and further, such Priveco Noteholder agrees to continue to comply with such laws as long as it shall hold the Conversion Shares.

 

 
17
 

 

4.5 Investment Risk . Each Priveco Noteholder is able to bear the economic risk of acquiring the Conversion Shares pursuant to the terms of this Agreement, including a complete loss of such Priveco Noteholder’s investment in the Conversion Shares.

 

4.6 Restrictive Legends . Each Priveco Noteholder acknowledges that the certificate(s) representing such Priveco Noteholder’s pro rata portion of the Conversion Shares shall each conspicuously set forth on the face or back thereof a legend in substantially the form set forth in Section 3.6 , corresponding to the Noteholder’s status as set forth in Section 4.4 and the signature pages hereto.

 

4.7 Disclosure . The representations and warranties and statements of fact made by Priveco Noteholders in this Agreement are, as applicable, accurate, correct and complete and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements and information contained herein not false or misleading.

 

ARTICLE 5

REPRESENTATIONS AND WARRANTIES OF PUBCO

AND PUBCO STOCKHOLDER

 

Except as otherwise disclosed herein or in a Schedule attached hereto, Pubco and Pubco Stockholder hereby, jointly and severally, represent and warrant, to Priveco and Priveco Stockholders as of the date hereof and as of the Closing Date (unless otherwise indicated), as follows:

 

5.1 Organization and Qualification . Pubco is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority (corporate and other), governmental licenses, authorizations, consents and approvals to carry on its business as presently conducted, and to own, hold and operate its properties and assets as now owned, held and operated by it. Pubco is neither in violation nor default of any of the provisions of its Organizational Documents. Pubco is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in a Material Adverse Effect, and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.

 

5.2 Authorization; Enforcement . Pubco has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder. The execution and delivery of this Agreement by Pubco and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary action on the part of Pubco and no further action is required by Pubco, its board of directors or stockholders in connection therewith other than in connection with the Required Approvals, as defined in Section 5.4 . This Agreement has been (or upon delivery will have been) duly executed by Pubco and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of Pubco enforceable against Pubco in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

 

 
18
 

 

5.3 No Conflicts . The execution, delivery and performance by Pubco of this Agreement and the consummation by Pubco of the other transactions to which it is a party and as contemplated hereby do not and will not: (i) conflict with or violate any provision of Pubco’s Organizational Documents, (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of Pubco, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Pubco debt or otherwise) or other understanding to which Pubco is a party or by which any property or asset of Pubco is bound or affected, or (iii) subject to the Required Approvals, as defined by Section 5.4 , conflict with or result in a violation of any Law, Order, judgment, injunction, decree or other restriction of any court or Governmental Authority to which Pubco is subject (including federal and state securities laws and regulations), or by which any property or asset of Pubco is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.

 

5.4 Filings, Consents and Approvals . Pubco is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by Pubco of this Agreement, other than the filing of a Current Report on Form 8-K and Form D (if applicable) with the SEC and such filings as are required to be made under applicable state securities laws (collectively, the “ Required Approvals ”).

 

5.5 Issuance of the Exchange Shares and Conversion Shares; Exemptions from Registration . The Exchange Shares and Conversion Shares are duly authorized and, when issued and paid for in accordance with this Agreement, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed on or by Pubco other than restrictions on transfer provided for in this Agreement. Pubco has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant to this Agreement. All of Pubco’s issued and outstanding shares of Common Stock were issued pursuant to an exemption from the registration requirements of the Securities Act as set forth in Schedule 5.5 , which Schedule shall set forth the exemption pursuant to which the shares were issued.

 

 
19
 

 

5.6 Capitalization . The capitalization of Pubco is as set forth on Schedule 5.6 of the disclosure schedules hereto. Priveco has been provided with a stockholder register from Pubco’s transfer agent as of the date hereof which includes the names and owners of the shares of Common Stock of Pubco and the amounts owned. Pubco has not issued any capital stock since its most recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by this Agreement. There are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire any shares of the Common Stock, or Contracts, commitments, understandings or arrangements by which Pubco is or may become bound to issue additional shares of the Common Stock or Pubco Common Stock Equivalents. The issuance of the Exchange Shares and Conversion Shares will not obligate Pubco to issue shares of the Common Stock or other securities to any Person (other than Priveco Stockholders) and will not result in a right of any holder of Pubco securities to adjust the exercise, conversion, exchange or reset price under any of such securities. All of the outstanding shares of capital stock of Pubco are validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder or Pubco’s board of directors is required for the issuance of the Exchange Shares and Conversion Shares. There are no stockholders agreements, voting agreements or other similar agreements with respect to Pubco’s capital stock to which Pubco is a party or, to the Knowledge of Pubco, between or among any of Pubco’s stockholders.

 

5.7 SEC Reports; Financial Statements . Pubco has filed all reports, schedules, forms, statements and other documents required to be filed by Pubco under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as Pubco was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the “ SEC Reports ”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act, the Exchange Act and Sarbanes-Oxley Act of 2002 (the “ Sarbanes-Oxley Act ”), as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The financial statements of Pubco included in the SEC Reports (the “ Financial Statements ”) comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with GAAP, except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of Pubco as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.

 

 
20
 

 

5.8 Material Changes . Since the date of the latest audited financial statements included within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof or in connection herewith: (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) Pubco has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in Pubco’s financial statements pursuant to GAAP or disclosed in filings made with the SEC, (iii) Pubco has not altered its method of accounting, (iv) Pubco has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) Pubco has not issued any equity securities to any officer, director or Affiliate. Pubco does not have pending before the SEC any request for confidential treatment of information. Except for the issuance of the Exchange Shares and Conversion Shares contemplated by this Agreement, no event, liability or development has occurred or exists with respect to Pubco or its business, properties, operations or financial condition, that would be required to be disclosed by Pubco under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least one (1) Trading Day prior to the date that this representation is made.

 

5.9 Litigation . There is no action, suit, inquiry, notice of violation, Proceeding or investigation pending or, to the Knowledge of Pubco, threatened against or affecting Pubco or any of its properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an “ Action ”) which: (i) adversely affects or challenges the legality, validity or enforceability of this Agreement, the Exchange Shares or Conversion Shares, or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither Pubco nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the Knowledge of Pubco, there is not pending or contemplated, any investigation by the SEC or FINRA involving Pubco or any current or former director or officer of Pubco. The SEC has not issued any stop order or other order suspending the effectiveness of any registration statement filed by Pubco under the Securities Act.

 

5.10 Labor Relations . No labor dispute exists or, to the Knowledge of Pubco, is imminent with respect to any of the employees of Pubco which could reasonably be expected to result in a Material Adverse Effect. None of Pubco’s employees is a member of a union that relates to such employee’s relationship with Pubco, and Pubco is not a party to a collective bargaining agreement, and Pubco believes that its relationships with their employees are good. No executive officer, to the Knowledge of Pubco, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other Contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject Pubco to any liability with respect to any of the foregoing matters. Pubco is in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

 
21
 

 

5.11 Compliance . Pubco: (i) is not in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by Pubco under), nor has Pubco received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is not in violation of any order of any court, arbitrator or governmental body, or (iii) is not or has not been in violation of any statute, rule or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws applicable to its business and all such laws that affect the environment, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect.

 

5.12 Regulatory Permits . Pubco possesses all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct its business, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (“ Material Permits ”), and Pubco has not received any notice of Proceedings relating to the revocation or modification of any Material Permit.

 

5.13 Title to Assets . Pubco has good and marketable title in all personal property owned by it that is material to the business of, in each case free and clear of all Liens, except for Liens that do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by Pubco and Liens for the payment of Taxes, the payment of which is neither delinquent nor subject to penalties. Pubco does not own any real property. Any real property and facilities held under lease by Pubco, if any is held by Pubco under valid, subsisting and enforceable leases with which Pubco is in compliance.

 

5.14 Transactions with Affiliates and Employees . Except as set forth in the SEC Reports and in Schedule 5.14 of the disclosure schedules hereto, none of the officers or directors of Pubco and, to the Knowledge of Pubco, none of the employees of Pubco is presently a party to any transaction with Pubco (other than for services as employees, officers and directors), including any Contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the Knowledge of Pubco, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner, in each case in excess of $120,000, other than for: (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of Pubco and (iii) other employee benefits.

 

 
22
 

 

5.15 Sarbanes-Oxley; Internal Accounting Controls . Pubco is in material compliance with all provisions of the Sarbanes-Oxley Act of 2002 which are applicable to it as of the Closing Date. Pubco maintains a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Pubco has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for Pubco and designed such disclosure controls and procedures to ensure that information required to be disclosed by Pubco in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Pubco’s certifying officers have evaluated the effectiveness of Pubco’s disclosure controls and procedures as of the end of the period covered by Pubco’s most recently filed periodic report under the Exchange Act (such date, the “ Evaluation Date ”). Pubco presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in Pubco’s internal control over financial reporting (as such term is defined in the Exchange Act) that has materially affected, or is reasonably likely to materially affect, Pubco’s internal control over financial reporting.

 

5.16 Certain Fees . Except as set forth in Schedule 5.16, no brokerage or finder’s fees or commissions are or will be payable by Pubco to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by this Agreement.

 

5.17 Issuance of Exchange Shares and Conversion Shares . Assuming the accuracy of Priveco Stockholders’ representations and warranties set forth under Article 3 , and Priveco Noteholders’ representations and warranties set forth under Article 4 , no registration under the Securities Act is required for the offer and issuance of the Exchange Shares to Priveco Stockholders and the Conversion Shares to Priveco Noteholders by Pubco as contemplated hereby. The issuance of the Exchange Shares and Conversion Shares hereunder does not contravene the rules and regulations of the applicable Trading Market.

 

5.18 Investment Company . Pubco is not, and is not an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended.

 

5.19 Listing and Maintenance Requirements . The Common Stock is currently quoted on the OTC Market Group Inc.’s OTC Pink quotation system (“ OTC Pink ”) and Pubco has not, in the twenty four (24) months preceding the date hereof, received any notice from the OTC Market Group, Inc. or FINRA or any trading market on which the Common Stock is or has been listed or quoted to the effect that Pubco is not in compliance with the quoting, listing or maintenance requirements of the OTC Pink quotation system or such other trading market. Pubco is, and has no reason to believe that it will not, in the foreseeable future continue to be, in compliance with all such quoting, listing and maintenance requirements. Trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or any other state authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of Priveco Stockholders and Priveco Noteholders, makes it impracticable or inadvisable to acquire the Exchange Shares and Conversion Shares at the Closing.

 

 
23
 

 

5.20 Application of Takeover Protections . Pubco has taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under Pubco’s Organizational Documents or the laws of its state of incorporation that is or could become applicable to Priveco Stockholders and Priveco Noteholders as a result of Priveco Stockholders, Priveco Noteholders and Pubco fulfilling their obligations or exercising their rights under this Agreement, including without limitation as a result of Pubco’s issuance of the Exchange Shares and Conversion Shares, Priveco Stockholders’ ownership of the Exchange Shares and Priveco Noteholders’ ownership of the Conversion Shares.

 

5.21 No Integrated Offering . Assuming the accuracy of Priveco Stockholders’ representations and warranties set forth under Article 3 , and Priveco Noteholders’ representations and warranties set forth under Article 4 , neither Pubco, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Exchange Shares and Conversion Shares to be integrated with prior offerings by Pubco for purposes of (i) the Securities Act which would require the registration of any such securities under the Securities Act, or (ii) any applicable stockholder approval provisions of any Trading Market on which any of the securities of Pubco are listed or designated.

 

5.22 Tax Status . Except as set forth in Schedule 5.22, Pubco has timely filed all necessary Tax Returns and has paid or accrued all Taxes shown as due thereon, and Pubco has no Knowledge of a tax deficiency which has been asserted or threatened against Pubco.

 

5.23 No General Solicitation . Neither Pubco nor any Person acting on behalf of Pubco has offered or sold any of the Exchange Shares or Conversion Shares by any form of general solicitation or general advertising.

 

5.24 Foreign Corrupt Practices . Neither Pubco, nor to the Knowledge of Pubco, any agent or other person acting on behalf of Pubco, has: (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by Pubco (or made by any person acting on its behalf of which Pubco is aware) which is in violation of law or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended.

 

5.25 Accountants . Pubco’s accounting firm is set forth on Schedule 5.25 of the disclosure schedules hereto. To the Knowledge of Pubco, such accounting firm: (i) is a registered public accounting firm as required by the Exchange Act and (ii) expressed its opinion with respect to the financial statements for the period ended March 31, 2016 included in Pubco’s Annual Report on Form 10-K, filed with the SEC on June, 24, 2016.

 

 
24
 

 

5.26 No Disagreements with Accountants and Lawyers . There are no disagreements of any kind, including but not limited to any disagreements regarding fees owed for services rendered, presently existing, or reasonably anticipated by Pubco to arise, between Pubco and the accountants and lawyers formerly or presently employed by Pubco which could affect Pubco’s ability to perform any of its obligations under this Agreement, and Pubco is current with respect to any fees owed to its accountants and lawyers.

 

5.27 Regulation M Compliance . Pubco has not, and to the Knowledge of Pubco no Person acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of Pubco to facilitate the sale or resale of any of the Exchange Shares or Conversion Shares, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the securities of Pubco, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of Pubco.

 

5.28 Money Laundering Laws . The operations of Pubco are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the money laundering statutes of all U.S. and non-U.S. jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental body (collectively, the “ Money Laundering Laws ”) and no action, suit or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving Pubco with respect to the Money Laundering Laws is pending or, to the Knowledge of Pubco, threatened.

 

5.29 Minute Books . The minute books of Pubco made available to Priveco and Priveco Stockholders contain a complete summary of all meetings and written consents in lieu of meetings of directors and stockholders since the time of incorporation.

 

5.30 Employee Benefits . Pubco has not (nor for the two years preceding the date hereof has) had any plans which are subject to ERISA.

 

5.31 Business Records and Due Diligence . Prior to the Closing, Pubco delivered to Priveco all records and documents relating to Pubco, which Pubco and possesses, including, without limitation, books, records, government filings, Tax Returns, Organizational Documents, corporate records, stock records, consent decrees, orders, and correspondence, director and stockholder minutes, resolutions and written consents, stock ownership records, financial information and records, and other documents used in or associated with Pubco.

 

5.32 Contracts . Except as set forth in the SEC Reports, there are no Contracts that are material to the business, properties, assets, condition (financial or otherwise), results of operations or prospects of Pubco taken as a whole. Pubco is not in violation of or in default under (nor does there exist any condition which upon the passage of time or the giving of notice would cause such a violation of or default under) any Contract to which it is a party or by which it or any of its properties or assets is bound, except for violations or defaults that would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.

 

 
25
 

 

5.33 No Undisclosed Liabilities . Except as otherwise disclosed in Schedule 5.33 or in Pubco’s financial statements included with Pubco’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 that was filed with the SEC on November [●], 2016, and except for those liabilities incurred by Pubco in the ordinary course of business after September 30, 2016, Pubco has no other undisclosed liabilities whatsoever, either direct or indirect, matured or unmatured, accrued, absolute, contingent or otherwise. Pubco represents that at the Closing Date, Pubco shall have no liabilities or obligations whatsoever, either direct or indirect, matured or unmatured, accrued, absolute, contingent or otherwise.

 

5.34 No SEC or FINRA Inquiries or Trading Suspensions . Neither Pubco nor any of its past or present officers or directors is, or has ever been, the subject of any formal or informal inquiry or investigation by the SEC or FINRA. Trading in the Common Stock is, and has not previously been, suspended by the SEC or FINRA.

 

5.35 DTC Program . Pubco employs a transfer agent for its Common Stock that is a participant in the Depositary Trust Company’s (“ DTC ”) Fast Automated Securities Transfer Program. Pubco’s Common Stock is fully transferable pursuant to such program (“ DTC Eligible ”), and the DTC has not given Pubco any formal or informal notice to the effect that the Common Stock is not or may not continue to be DTC Eligible.

 

5.36 No Disqualification Events . None of Pubco, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of Pubco participating in the transactions hereunder, any beneficial owner of 20% or more of Pubco's outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with Pubco in any capacity at the time of the Closing (each, an “ Issuer Covered Person ”) is subject to any of the “ Bad Actor ” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a “ Disqualification Event ”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). Pubco has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. Pubco has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to Priveco Stockholders a copy of any disclosures provided thereunder.

 

5.37 Shell Company . As of the Closing Date, Pubco is deemed to be a "shell company" as defined in Rule 405 as promulgated pursuant to the Securities Act.

 

5.38 Subsidiaries . Immediately prior to the Closing, Pubco shall have no direct or indirect Subsidiaries.

 

5.39 Disclosure . The representations and warranties and statements of fact made by Pubco and Pubco Stockholders in this Agreement are, as applicable, accurate, correct and complete and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements and information contained herein not false or misleading.

 

 
26
 

 

ARTICLE 6

REPRESENTATIONS AND WARRANTIES OF PUBCO STOCKHOLDER

 

Pubco Stockholder . Pubco Stockholder hereby represents and warrants to Priveco and Priveco Stockholders as of the date hereof and as of the Closing Date (unless otherwise indicated), as follows:

 

6.1 Organization and Qualification . Pubco Stockholder is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority (corporate and other), governmental licenses, authorizations, consents and approvals to carry on its business as presently conducted, and to own, hold and operate its properties and assets as now owned, held and operated by it. Pubco Stockholder is neither in violation nor default of any of the provisions of its Organizational Documents. Pubco Stockholder is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in a Material Adverse Effect, and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.

 

6.2 Ownership of Pubco Capital Stock . Pubco Stockholder owns, beneficially and of record, good and marketable title to 16,181,400 Cancellation Shares, free and clear of any security interests, liens, adverse claims, encumbrances, equities, proxies, options or stockholders’ agreements, and has no right or claims whatsoever to any other shares of Pubco capital stock and does not have any options, warrants or any other instruments entitling it to exercise to purchase or convert into shares of Pubco capital stock.

 

6.3 Authority Relative to this Agreement . This Agreement has been duly and validly executed and delivered by Pubco Stockholder and constitutes a valid and binding agreement of it, enforceable against Pubco Stockholder in accordance with its terms, except as such enforcement may be limited by bankruptcy, insolvency or other similar laws affecting the enforcement of creditors’ rights generally or by general principles of equity.

 

6.4 Disclosure . The representations and warranties and statements of fact made by Pubco Stockholder in this Agreement are, as applicable, accurate, correct and complete and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements and information contained herein not false or misleading.

 

 
27
 

 

ARTICLE 7

SURVIVAL OF REPRESENTATIONS; INDEMNIFICATION

 

7.1 Survival . Notwithstanding provision in this Agreement to the contrary, the representations and warranties given or made by Parties under this Agreement shall survive the date hereof for a period of twenty four (24) months from and after the Closing Date (the last day of such period is herein referred to as the “ Expiration Date ”), except that any written claim for breach thereof made and delivered prior to the Expiration Date to the party against whom such indemnification is sought shall survive thereafter and, as to any such claim, such applicable expiration will not affect the rights to indemnification of the party making such claim; provided , however , that any representations and warranties that were fraudulently made shall not expire on the Expiration Date and shall survive indefinitely, and claims with respect to fraud by Pubco, Pubco Stockholder, Priveco, Priveco Stockholders or Priveco Noteholders may be made at any time. All covenants and agreements herein shall survive the Closing Date until performance is completed under the terms of such covenants and agreements. Nothing in this Article 7 shall impair or alter any covenant or agreement of the Parties which by its terms contemplates performance after the Closing Date.

 

7.2 Indemnification by the Pubco Stockholder . From and after the Closing Date until the Expiration Date, the Pubco Stockholder shall indemnify and hold harmless the Priveco Indemnified Parties, from and against any all costs or expenses (including attorneys’ fees), judgments, fines, losses, claims, damages, liabilities and amounts paid in settlement (collectively, “ Damages ”) arising, directly or indirectly, from or in connection with: (a) any breach (or alleged breach) of any representation or warranty made by Pubco Stockholder or Pubco in this Agreement or any Transaction Document or in any certificate delivered by Pubco Stockholder or Pubco pursuant to this Agreement; or (b) any breach (or alleged breach) by Pubco Stockholder or Pubco of any covenant, agreement or obligation of Pubco Stockholder or Pubco in this Agreement or any Transaction Document required to be performed by Pubco Stockholder or Pubco on or prior to the Closing Date or by Pubco Stockholder after the Closing Date.

 

7.3 Matters Involving Third Parties .

 

(a) If any third party shall notify any Priveco Indemnified Parties (the “ Indemnified Party ”) with respect to any matter (a “ Third Party Claim ”) which may give rise to a claim for indemnification against Pubco Stockholder (the “ Indemnifying Party ”) under this Article XII , then the Indemnified Party shall promptly notify each Indemnifying Party thereof in writing; provided, however, that no delay on the part of the Indemnified Party in notifying any Indemnifying Party shall relieve the Indemnifying Party from any obligation hereunder unless (and then solely to the extent) the Indemnifying Party is thereby prejudiced.

 

(b) Any Indemnifying Party will have the right to defend the Indemnified Party against the Third Party Claim with counsel of its choice reasonably satisfactory to the Indemnified Party so long as (A) the Indemnifying Party notifies the Indemnified Party in writing within fifteen (15) days after the Indemnified Party has given notice of the Third Party Claim that the Indemnifying Party will indemnify the Indemnified Party from and against the entirety of any Damages the Indemnified Party may suffer resulting from, arising out of, relating to, in the nature of, or caused by the Third Party Claim, (B) the Indemnifying Party provides the Indemnified Party with evidence acceptable to the Indemnified Party that the Indemnifying Party will have the financial resources to defend against the Third Party Claim and fulfill its indemnification obligations hereunder, (C) the Third Party Claim involves only money damages and does not seek an injunction or other equitable relief, (D) settlement of, or an adverse judgment with respect to, the Third Party Claim is not, in the good faith judgment of the Indemnified Party, likely to establish a precedential custom or practice adverse to the continuing business interests of the Indemnified Party, and (E) the Indemnifying Party conducts the defense of the Third Party Claim actively and diligently.

 

 
28
 

 

(c) So long as the Indemnifying Party is conducting the defense of the Third Party Claim in accordance with Section 7.3(b) above, (A) the Indemnified Party may retain separate co-counsel at its sole cost and expense and participate in the defense of the Third Party Claim, (B) the Indemnified Party will not consent to the entry of any judgment or enter into any settlement with respect to the Third Party Claim without the prior written consent of the Indemnifying Party (not to be withheld unreasonably), and (C) the Indemnifying Party will not consent to the entry of any judgment or enter into any settlement with respect to the Third Party Claim without the prior written consent of the Indemnified Party (not to be withheld unreasonably).

 

(d) In the event any condition in Section 7.3(b) above is or becomes unsatisfied, however, (A) the Indemnified Party may defend against, and consent to the entry of any judgment or enter into any settlement with respect to, the Third Party Claim in any manner it reasonably may deem appropriate (and the Indemnified Party need not consult with, or obtain any consent from, any Indemnifying Party in connection therewith), (B) the Indemnifying Parties will reimburse the Indemnified Party promptly and periodically for the costs of defending against the Third Party Claim (including reasonable attorneys’ fees and expenses), and (C) the Indemnifying Parties will remain responsible for any Damages the Indemnified Party may suffer resulting from, arising out of, relating to, in the nature of, or caused by the Third Party Claim to the fullest extent provided in this Article 7 .

 

ARTICLE 8

COVENANTS OF THE PARTIES

 

8.1 Corporate Examinations and Investigations . Prior to the Closing, each Party shall be entitled, through its employees and representatives, to make such investigations and examinations of the books, records and financial condition of Priveco and Pubco as each party may request. In order that each Party may have the full opportunity to do so, Priveco, Pubco, Priveco Stockholders and Pubco Stockholder shall furnish each Party and its representatives during such period with all such information concerning the affairs of Priveco or Pubco as each Party or its representatives may reasonably request and cause Priveco or Pubco and their respective officers, employees, consultants, agents, accountants and attorneys to cooperate fully with each Party’s representatives in connection with such review and examination and to make full disclosure of all information and documents requested by each Party and/or its representatives. Any such investigations and examinations shall be conducted at reasonable times and under reasonable circumstances, it being agreed that any examination of original documents will be at each Party’s premises, with copies thereof to be provided to each Party and/or its representatives upon request.

 

 
29
 

 

8.2 Cooperation; Consents . Upon the terms and subject to the conditions set forth in this Agreement, each of the Parties agrees to use its best efforts to take, or cause to be taken, all actions, and to do, or cause to be done, and to assist and cooperate with the other Parties in doing, all things necessary, proper or advisable to consummate and make effective, in the most expeditious manner practicable, the Share Exchange and the other transactions contemplated by this Agreement. Pubco and Priveco and their respective representatives will use their best efforts and cooperate with one another: (i) in promptly determining whether any filings are required to be made or consents, approvals, waivers, permits or authorizations are required to be obtained (or, which if not obtained, would result in an event of default, termination or acceleration of any agreement or any put right under any agreement) under any applicable law or regulation or from any governmental authorities or third parties, in promptly making any such filings and in furnishing information required in connection therewith and in timely seeking to obtain any such consents, approvals, permits or authorizations and (ii) in facilitating each other’s due diligence investigations. The Parties shall mutually cooperate in order to facilitate the achievement of the benefits reasonably anticipated from the Share Exchange.

 

8.3 Conduct of Business . Subject to the provisions hereof, from the date hereof through the Closing, each Party shall (i) conduct its business in the ordinary course and in such a manner so that the representations and warranties contained herein shall continue to be true and correct in all material respects as of the Closing as if made at and as of the Closing and (ii) not enter into any material transactions or incur any material liability not required or specifically contemplated hereby, without first obtaining the written consent of Priveco and Priveco Stockholders on the one hand, and Pubco and Pubco Stockholder on the other hand. Without the prior written consent of Priveco, Priveco Stockholders, Pubco or Pubco Stockholder, except as required or specifically contemplated hereby, each party shall not undertake or fail to undertake any action if such action or failure would render any of said warranties and representations untrue in any material respect as of the Closing.

 

8.4 Litigation . From the date hereof through the Closing, each Party shall promptly notify the representative of the other Parties of any lawsuits, claims, Proceedings or investigations which after the date hereof are threatened or commenced against such Party or any of its Affiliates or any officer, director, employee, consultant, agent or stockholder thereof, in their capacities as such, which, if decided adversely, could reasonably be expected to have a Material Adverse Effect on such Party.

 

8.5 Notice of Default . From the date hereof through the Closing, each Party shall give to the representative of the other Parties prompt written notice of the occurrence or existence of any event, condition or circumstance occurring which would constitute a violation or breach of this Agreement by such party or which would render inaccurate in any material respect any of such Party’s representations or warranties herein.

 

8.6 Confidentiality; Access to Information .

 

(a) Confidentiality . Any confidentiality agreement or letter of intent previously executed by the Parties shall be superseded in its entirety by the provisions of this Agreement. Each party agrees to maintain in confidence any non-public information received from the other party, and to use such non-public information only for purposes of consummating the transactions contemplated by this Agreement. Such confidentiality obligations will not apply to (i) information which was known to the one party or their respective agents prior to receipt from the other party; (ii) information which is or becomes generally known; (iii) information acquired by a party or their respective agents from a third party who was not bound to an obligation of confidentiality; and (iv) disclosure required by law. In the event this Agreement is terminated as provided in Article 10 hereof, each party will return or cause to be returned to the other all documents and other material obtained from the other in connection with the Transaction contemplated hereby.

 

 
30
 

 

(b) Access to Information . Pubco will afford Priveco and its financial advisors, underwriters, accountants, counsel and other representatives reasonable access during normal business hours, upon reasonable notice, to the properties, books, records and personnel of Pubco during the period prior to the Closing to obtain all information concerning the business, including the status of product development efforts, properties, results of operations and personnel of Pubco, as Priveco may reasonably request. No information or Knowledge obtained by Priveco in any investigation pursuant to this Section 8.6 will affect or be deemed to modify any representation or warranty contained herein or the conditions to the obligations of the Parties to consummate the Transaction.

 

8.7 Public Disclosure . Except to the extent previously disclosed or to the extent the Parties believe that they are required by applicable law or regulation to make disclosure, prior to Closing, no party shall issue any statement or communication to the public regarding the transaction contemplated herein without the consent of the other party, which consent shall not be unreasonably withheld. To the extent a Party believes it is required by law or regulation to make disclosure regarding the Transaction, it shall, if possible, immediately notify the other party prior to such disclosure.

 

8.8 Assistance with Post-Closing SEC Reports and Inquiries . Upon the reasonable request of Priveco, after the Closing Date, Pubco Stockholder shall use its reasonable best efforts to provide such information available to it, including information, filings, reports, financial statements or other circumstances of Pubco occurring, reported or filed prior to the Closing, as may be necessary or required by Pubco for the preparation of the post-Closing Date reports that Pubco is required to file with the SEC to remain in compliance and current with its reporting requirements under the Securities Act, or filings required to address and resolve matters as may relate to the period prior to the Closing and any SEC comments relating thereto or any SEC inquiry thereof.

 

8.9 Designation of New Officers and Directors . On the Closing Date, Pubco shall accept the resignation of Michael Hlavsa as President, Treasurer, Secretary and sole director to be effective on the Closing Date. On the Closing Date, Pubco shall also appoint Robert Davidson, William Yuan and Charles Berman as new members of Pubco’s board of directors. In addition, effective on the Closing Date, Pubco shall appoint the following new officers of Pubco: Robert Davidson as the Chief Executive Officer, Edward Maliski as President and Chief Scientific Officer, Mark Udell as Chief Financial Officer, Treasurer and Secretary and Wayne Nasby as Chief Operating Officer.

 

8.10 Pa yment of Pubco Liabilities . Pubco and Pubco Stockholder agree to pay, on or before the Closing Date, all of the liabilities of Pubco in their entirety and all of Pubco’s expenses through the Closing Date that are related to the transactions contemplated by this Agreement.

 

 
31
 

 

8.11 Shares Cancellations . In connection with the Cancellation Agreements and immediately prior to the Closing, Pubco Stockholder and Pubco each agrees to execute and deliver or cause the execution and delivery of any and all agreements, documents and instruments reasonably necessary to effect the Shares Cancellations, including originally executed stock certificate(s) and stock power(s) with proper endorsements and/or medallion certified signatures (or equivalent) as may be required by Pubco’s transfer agent for the Shares Cancellations.

 

8.12 Reserved.

 

8.13 Equity Incentive Plan . After the Closing Date, Pubco will develop and approve an equity incentive plan for the employees and management of the Company (the “Equity Incentive Plan”) which will include 3,490,010 shares of Pubco’s common stock reserved for issuance in connection with the Equity Incentive Plan. Pubco agrees to seek the approval of its stockholders in compliance with the Securities Act and applicable Nevada Revised Statutes to approve the Equity Incentive Plan.

 

ARTICLE 9

CONDITIONS TO CLOSING

 

9.1 Conditions to Obligations of Priveco, Priveco Stockholders and Priveco Noteholders . The obligations of Priveco, Priveco Stockholders and Priveco Noteholders under this Agreement shall be subject to each of the following conditions:

 

(a) Closing Deliveries . At the Closing, Pubco and Pubco Stockholder shall have delivered or caused to be delivered to Priveco and Priveco Stockholders the following:

 

(i) this Agreement duly executed by Pubco’s duly authorized signatory and by Pubco Stockholder;

 

(ii) the Cancellation Agreements duly executed by Pubco’s duly authorized signatory and by the Cancelling Stockholders;

 

(iii) letter of resignation from Pubco’s current executive officer as follows: (1) letter of resignation of Michael Hlavsa as to all of the offices he currently holds with Pubco to be effective on the Closing Date and confirming that he has no claim against Pubco in respect of any outstanding remuneration or fees of whatever nature as of the Closing Date;

 

(iv) letter of resignation from Pubco’s current sole director as follows: (a) letter of resignation of Michael Hlavsa as sole director, with resignation to be effective on the Closing Date and confirming that he has no claim against Pubco in respect of any outstanding remuneration or fees of whatever nature as of the Closing Date;

 

 
32
 

 

(v) resolutions duly adopted by the board of directors of Pubco approving the following events or actions, as applicable:

 

(A) the execution, delivery and performance of this Agreement;

 

(B) the Share Exchange and the terms thereof;

 

(C) the Conversion and the terms thereof;

 

(D) the Shares Cancellations and the terms thereof;

 

(E) the change of Pubco’s fiscal year end from March 31 to December 31;

 

(F) the appointment of Robert Davidson, William Yuan and Charles Berman to Pubco’s board of directors, effective on the Closing Date; and

 

(G) the appointment of the following person/s as officer/s of Pubco, with the titles set forth opposite his name, effective on the Closing Date:

 

Robert Davidson

 

Chief Executive Officer

Edward Maliski

 

President and Chief Scientific Officer

 

Mark Udell

 

Chief Financial Officer, Treasurer and Secretary

Wayne Nasby

 

Chief Operating Officer

 

(vi) a certificate of good standing for Pubco from its jurisdiction of incorporation, dated not earlier than three calendar (3) days prior to the Closing Date (the “ Good Standing Certificate ”);

 

(vii) an instruction letter signed by the President of Pubco addressed to Pubco’s transfer agent of record, in a form reasonably acceptable to Priveco and Pubco’s transfer agent and consistent with the terms of this Agreement, instructing the transfer agent to issue stock certificates representing the Exchange Shares and Conversion Shares to be delivered pursuant to this Agreement registered in the names set forth in the attached Signature Pages of Priveco Stockholders and Signature Pages of Priveco Noteholders;

 

(viii) a certificate of the Secretary of Pubco, dated as of the Closing Date, certifying as to (a) the incumbency of officers of Pubco executing this Agreement and all exhibits and schedules hereto and all other documents, instruments and writings required pursuant to this Agreement (the “ Transaction Documents ”), (b) a copy of the Articles of Incorporation and Bylaws of Pubco, as in effect on and as of the Closing Date, and (c) a copy of the resolutions of the board of directors of Pubco authorizing and approving Pubco’s execution, delivery and performance of the Transaction Documents, all matters in connection with the Transaction Documents, and the transactions contemplated thereby;

 

 
33
 

 

(ix) a stockholder list of Pubco as certified by Pubco’s transfer agent, dated within three (3) calendar days of the Closing Date;

 

(x) all corporate records, Organizational Documents, agreements, seals and any other information reasonably requested by Priveco’s representatives with respect to Pubco;

 

(xi) evidence satisfactory to Priveco of the delivery by Pubco Stockholder to Pubco of the original stock certificates representing the Cancellation Shares, accompanied by a stock power(s) with proper endorsements and/or medallion certified signatures (or equivalent) as may be required by Pubco’s transfer agent for the cancellation and any and all other agreements, documents and instruments required by the transfer agent for the Shares Cancellations as described in Section 8.11 herein;

 

(xii) such other documents as Priveco and/or Priveco Stockholders may reasonably request in connection with the transactions contemplated hereby.

 

(b) Representations and Warranties to be True . The representations and warranties of Pubco and Pubco Stockholder herein contained shall be true in all material respects at the Closing with the same effect as though made at such time. Pubco and Pubco Stockholder shall have performed in all material respects all obligations and complied in all material respects with all covenants and conditions required by this Agreement to be performed or complied with by them at or prior to the Closing.

 

(c) No Assets, Subsidiaries and Liabilities . At the Closing, Pubco shall have no liabilities, debts, Liens or payables (direct or indirect, matured or unmatured, accrued, absolute, contingent or otherwise), no tax obligations, no assets, no Subsidiaries, and except as contemplated in this Agreement, no material changes to its business or financial condition shall have occurred since June 30, 2016. At the Closing, Pubco shall provide evidence of the extinguishment of all Pubco pre-Closing liabilities, including but not limited to Pubco’s debts, liabilities, Liens, payables (direct or indirect, matured or unmatured, accrued, absolute, contingent or otherwise) and tax obligations as requested by Priveco.

 

(d) SEC Filings . At the Closing, Pubco will be current in all SEC filings that Pubco is required to file.

 

(e) Outstanding Capital Stock . Pubco shall have at least 75,000,000 shares of its Common Stock authorized and shall have no more than 24,984,000 shares of its Common Stock issued and outstanding immediately prior to the Closing.

 

(f) No Adverse Effect . The business and operations of Pubco will not have suffered any Material Adverse Effect.

 

 
34
 

 

9.2 Conditions to Obligations of Pubco . The obligations of Pubco and Pubco Stockholder under this Agreement shall be subject to each of the following conditions:

 

(a) Closing Deliveries . On the Closing Date, Priveco and/or Priveco Stockholders shall have delivered to Pubco the following:

 

(i) this Agreement duly executed by Priveco, Priveco Stockholders and Priveco Noteholders;

 

(ii) resolutions duly adopted by the board of directors of Priveco authorizing and approving the execution, delivery and performance of this Agreement;

 

(iii) certificates representing the Priveco Shares to be delivered pursuant to this Agreement duly endorsed or accompanied by duly executed stock powers, instruments of transfer or other executed instruments of like tenor;

 

(iv) the Notes to be delivered for cancellation pursuant to this Agreement; and

 

(v) such other documents as Pubco may reasonably request in connection with the transactions contemplated hereby.

 

(b) Representations and Warranties True and Correct . The representations and warranties of Priveco, Priveco Stockholders and Priveco Noteholders herein contained shall be true in all material respects at the Closing with the same effect as though made at such time. Priveco, Priveco Stockholders and Priveco Noteholders shall have performed in all material respects all obligations and complied in all material respects with all covenants and conditions required by this Agreement to be performed or complied with by them at or prior to the Closing.

 

(c) No Adverse Effect . The business and operations of Priveco will not have suffered any Material Adverse Effect.

 

ARTICLE 10

SEC FILING; TERMINATION

 

10.1 Termination . This Agreement may be terminated at any time prior to the Closing:

 

(a) by mutual written agreement of the Parties hereto;

 

(b) by either Pubco, Priveco or Priveco Stockholders if the Transaction shall not have been consummated for any reason by November 15, 2016;

 

 
35
 

 

(c) by either Pubco, Priveco or Priveco Stockholders if a governmental entity shall have issued an order, decree or ruling or taken any other action, in any case having the effect of permanently restraining, enjoining or otherwise prohibiting the Transaction, which order, decree, ruling or other action is final and non-appealable;

 

(d) by Priveco: (i) if Priveco is not satisfied with the results of its due diligence investigation and Priveco so notifies Pubco or its representatives before November 14, 2016, 2016, or (ii) if Pubco or Pubco Stockholder shall have breached in any material respect any of its representations, warranties, covenants or other agreements contained in this Agreement, and the breach cannot be or has not been cured before November 14, 2016.

 

10.2 Notice of Termination; Effect of Termination . Any termination of this Agreement under Section 10.1 above will be effective immediately upon the delivery of written notice of the terminating Party to the other Parties. In the event of the termination of this Agreement as provided in Section 10.1 , this Agreement shall be of no further force or effect and the Transaction shall be abandoned, except as set forth in Section 10.1 , Section 10.2 and Article 11 (General Provisions), each of which shall survive the termination of this Agreement.

 

ARTICLE 11

GENERAL PROVISIONS

 

11.1 Notices . Any and all notices and other communications hereunder shall be in writing and shall be deemed duly given to the party to whom the same is so delivered, sent, transmitted or mailed at addresses and contact information set forth on the signature pages hereof (or at such other address for a party as shall be specified by like notice). Any notices or other communications required or permitted hereunder shall be in writing, delivered via facsimile, email, U.S. nationally recognized overnight courier or by hand-delivery and shall be deemed sufficiently given, received and effective on the earliest of: (i) the date of transmission, if such notice or communication is delivered via confirmed facsimile at the applicable facsimile number set forth on the signature pages attached hereto prior to 5:30 p.m. (Pacific Standard Time) on a Trading Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via confirmed facsimile at the applicable facsimile number set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (Pacific Standard Time) on any Trading Day, (iii) the date of transmission, if such notice or communication is delivered via email at the applicable email address set forth on the signature pages attached hereto prior to 5:30 p.m. (Pacific Standard Time) on a Trading Day (provided that such sent email is kept on file (whether electronically or otherwise) by the sending party and the sending party does not immediately receive an automatically generated message from the recipient’s email server that such email could not be delivered to such recipient), (iv) the next Trading Day after the date of transmission, if such notice or communication is delivered via email at the applicable email address set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (Pacific Standard Time) on any Trading Day (provided that such sent email is kept on file (whether electronically or otherwise) by the sending party and the sending party does not immediately receive an automatically generated message from the recipient’s email server that such email could not be delivered to such recipient), (v) the second Trading Day following the date of mailing, if sent to the applicable address set forth in the signature pages hereto by internationally recognized overnight courier service, or (vi) the date of actual receipt by the party to whom such notice or communication is required or permitted to be given, if such notice or communication is hand-delivered to such party.

 

 
36
 

 

11.2 Interpretation . The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. References to Sections and Articles refer to sections and articles of this Agreement unless otherwise stated.

 

11.3 Severability . If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated and the Parties shall negotiate in good faith to modify this Agreement to preserve each party’s anticipated benefits under this Agreement.

 

11.4 Miscellaneous . This Agreement (together with all other documents and instruments referred to herein): (a) constitutes the entire agreement and supersedes all other prior agreements and undertakings, both written and oral, among the Parties with respect to the subject matter hereof; (b) except as expressly set forth herein, is not intended to confer upon any other person any rights or remedies hereunder and (c) shall not be assigned by operation of law or otherwise, except as may be mutually agreed upon by the Parties.

 

11.5 Separate Counsel . Each Party hereby expressly acknowledges that it has been advised to seek its own separate legal counsel for advice with respect to this Agreement.

 

11.6 Governing Law . All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Nevada, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a Party or its respective affiliates, directors, officers, stockholders, employees or agents) shall be commenced exclusively in the state courts sitting in the County of Ventura, California or in the United States District Court in the Western Division of the Central District of California. Each Party hereby irrevocably submits to the exclusive jurisdiction of the state courts sitting in the County of Ventura, California or in the United States District Court in the Western Division of the Central District of California for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of the Agreement), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each Party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via internationally recognized overnight courier service (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any Party shall commence an action or proceeding to enforce any provisions of the Agreement, then the prevailing Party in such action or proceeding shall be reimbursed by the other Party(s) for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

 

 
37
 

 

11.7 Counterparts and Facsimile Signatures . This Agreement may be executed simultaneously in two or more counterparts, any one of which need not contain the signatures of more than one party, but all such counterparts taken together will constitute one and the same Agreement. This Agreement, to the extent delivered by means of a facsimile machine or electronic mail (any such delivery, an “ Electronic Delivery ”), shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of any Party, each other Party shall re-execute original forms hereof and deliver them in person to all other Parties. No Party shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and each such Party forever waives any such defense, except to the extent such defense related to lack of authenticity.

 

11.8 Amendment . This Agreement may be amended, modified or supplemented only by an instrument in writing executed by Priveco, Pubco, Pubco Stockholder, holders of at least a majority of the aggregate number of the Conversion Shares issued or to be issued to the Priveco Noteholders and holders of at least a majority of the aggregate number of the Exchange Shares issued or to be issued to the Priveco Stockholders; provided that, the consent of any Priveco Stockholder or Pubco Stockholder that is a party to this Agreement shall be required if the amendment or modification would disproportionately affect such stockholder (other than by virtue of their ownership of Priveco or Exchange Shares, as applicable).

 

11.9 Parties in Interest . Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective heirs, legal representatives, successors and assigns of the Parties.

 

11.10 Waiver . No waiver by any party of any default or breach by another party of any representation, warranty, covenant or condition contained in this Agreement shall be deemed to be a waiver of any subsequent default or breach by such party of the same or any other representation, warranty, covenant or condition. No act, delay, omission or course of dealing on the part of any party in exercising any right, power or remedy under this Agreement or at law or in equity shall operate as a waiver thereof or otherwise prejudice any of such party’s rights, powers and remedies. All remedies, whether at law or in equity, shall be cumulative and the election of any one or more shall not constitute a waiver of the right to pursue other available remedies.

 

11.11 Expenses . At or prior to the Closing, the Parties shall pay all of their own expenses relating to the transactions contemplated by this Agreement, including, without limitation, the fees and expenses of their respective counsel and financial advisers.

 

11.12 Third Party Beneficiaries. This Agreement is strictly between Pubco, Pubco Stockholder, Priveco, Priveco Stockholders and Priveco Noteholders, and, except as specifically provided, no director, officer, stockholder (other than Priveco Stockholders), employee, agent, independent contractor or any other Person or entity shall be deemed to be a third party beneficiary of this Agreement.

 

[ Remainder of Page Left Blank Intentionally ]

 

 
38
 

 

IN WITNESS WHEREOF, the Parties have executed this Share Exchange Agreement as of the date first written above.

 

PUBCO:

 

MAKKANOTTI GROUP CORP.,

a Nevada corporation

 

     
By: /s/ Michael Hlavsa

Name:

Michael Hlavsa  
Title: President  

 

Address for Notices:

 

 

 

 

Phone:

 

 

Fax:

 

 

Email:

 

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.

SIGNATURE PAGE FOR PUBCO STOCKHOLDER FOLLOWS.]

 

 
39
 

 

SIGNATURE PAGE OF PUBCO STOCKHOLDER

 

PUBCO STOCKHOLDER:

 

AUREUS FIDUCIARY NEVIS LIMITED

 

     
By:

/s/ Milan Patel

Name:

Milan Patel  

Title:

 

 

Address for Notices:

 

 

 

 

 

 

 

Phone:

 

 

Fax:

 

 

Email:

 

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.

SIGNATURE PAGE FOR PRIVECO FOLLOWS.]

 

 
40
 

 

SIGNATURE PAGE OF PRIVECO

 

PRIVECO:

 

CURE PHARMACEUTICAL CORPORATION,

a California corporation

 

     
By:

/s/ Robert Davidson

Name:

Robert Davidson  

Title:

Chief Executive Officer  

 

Address for Notices:

 

 

1620 Beacon Place

Oxnard, CA 93033

Tel: (805) 824-0410

Fax: (805) 487-7163

Email: RDavidson@curepharmaceutical.com

 

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.

SIGNATURE PAGES OF PRIVECO STOCKHOLDERS AND SIGNATURE PAGES OF PRIVECO NOTEHOLDERS FOLLOW.]

 

 
41
 

 

SIGNATURE PAGES OF PRIVECO STOCKHOLDERS

( Please use this Signature Page for Priveco Stockholders that are Entities )

 

PRIVECO STOCKHOLDER:

 

[ INSERT PRIVECO STOCKHOLDER ENTITY NAME HERE ]

 

     
By:

Name:

 
Title:  

 

Number of Priveco Shares Owned by

Priveco Stockholder

Exchange Shares to be Received in

Exchange for Priveco Shares

 

 

Address for Notices:

 

 

 

 

 

 

 

 

 

 

Phone:

 

 

Fax:

 

 

Email:

 

 

Check One:

 

This Priveco Stockholder hereby certifies that it is:

 

 

¨ an “Accredited Investor” under Regulation D of the Securities Act (see Section 3.4(a) and Annex I of this Agreement); or

 

 

 

 

¨ a “Sophisticated Investor,” as described in Rule 506(b)(2)(ii) promulgated under the Securities Act, that hereby confirms that the representations and warranties in Section 3.4(b) of this Agreement are true and correct as to such Priveco Stockholder; or

 

 

 

 

¨

a Non-U.S. Person, that hereby confirms that the representations and warranties in Section 3.4(c) of this Agreement are true and correct as to such Priveco Stockholder, and hereby accepts and agrees to comply with the covenants in Section 3.4(c).

 

 
42
 

 

SIGNATURE PAGES OF PRIVECO STOCKHOLDERS

( Please use this Signature Page for Priveco Stockholders that are Individuals )

 

PRIVECO STOCKHOLDER:

 

 

Name:

 

 

 

Number of Priveco Shares Owned by

Priveco Stockholder

Exchange Shares to be Received in

Exchange for Priveco Shares

 

 

Address for Notices:

 

 

 

 

 

 

 

 

 

 

Phone:

 

 

Fax:

 

 

Email:

 

 

Check One:

 

This Priveco Stockholder hereby certifies that it is:

 

 

¨ an “Accredited Investor” under Regulation D of the Securities Act (see S ection 3.4(a) and Annex I of this Agreement); or

 

 

 

 

¨ a “Sophisticated Investor,” as described in Rule 506(b)(2)(ii) promulgated under the Securities Act, that hereby confirms that the representations and warranties in Section 3.4(b) of this Agreement are true and correct as to such Priveco Stockholder; or

 

 

 

 

¨ a Non-U.S. Person, that hereby confirms that the representations and warranties in Section 3.4(c) of this Agreement are true and correct as to such Priveco Stockholder, and hereby accepts and agrees to comply with the covenants in Section 3.4(c).

 

 
43
 

 

SIGNATURE PAGES OF PRIVECO NOTEHOLDERS

( Please use this Signature Page for Priveco Noteholders that are Entities )

 

PRIVECO NOTEHOLDER:

 

[ INSERT PRIVECO NOTEHOLDER ENTITY NAME HERE ]

 

     
By:

Name:

 
Title:  

 

Principal Amount of Note Held by

Priveco Noteholder ($)

Conversion Shares to be Received for

Cancellation of Note

 

 

Address for Notices:

 

 

 

 

 

 

 

 

 

 

Phone:

 

 

Fax:

 

 

Email:

 

 

Check One:

 

This Priveco Noteholder hereby certifies that it is:

 

 

¨ an “Accredited Investor” under Regulation D of the Securities Act (see Section 4.4(a) and Annex I of this Agreement); or

 

 

 

 

¨ a Non-U.S. Person, that hereby confirms that the representations and warranties in Section 4.4(b) of this Agreement are true and correct as to such Priveco Noteholder, and hereby accepts and agrees to comply with the covenants in Section 4.4(b).

 

 
44
 

 

SIGNATURE PAGES OF PRIVECO NOTEHOLDERS

( Please use this Signature Page for Priveco Noteholders that are Individuals )

 

PRIVECO NOTEHOLDER:

 

 

Name:

 

 

 

Principal Amount of Note Held by

Priveco Noteholder ($)

Conversion Shares to be Received for

Cancellation of Note

 

 

Address for Notices:

 

 

 

 

 

 

 

 

 

 

Phone:

 

 

Fax:

 

 

Email:

 

 

Check One:

 

This Priveco Noteholder hereby certifies that it is:

 

 

¨ an “Accredited Investor” under Regulation D of the Securities Act (see Section 4.4(a) and Annex I of this Agreement); or

 

 

 

 

¨ a Non-U.S. Person, that hereby confirms that the representations and warranties in Section 4.4(b) of this Agreement are true and correct as to such Priveco Noteholder, and hereby accepts and agrees to comply with the covenants in Section 4.4(b).

 

 
45
 

 

EXHIBIT A

TO

SHARE EXCHANGE AGREEMENT

 

[ FORM OF SHARE CANCELLATION AGREEMENT ]

 

 

 

 

 
46
 

 

EXHIBIT B

TO

SHARE EXCHANGE AGREEMENT

 

[ FORM OF SHARE CANCELLATION AGREEMENT ]

 

 

 

 

 
47
 

 

ANNEX I

 

ACCREDITED INVESTOR DEFINITION

 

Category A The undersigned is a natural person (not a partnership, corporation, etc.) whose individual net worth, or joint net worth with his or her spouse, excluding the value of the primary residence of such natural person, presently exceeds $1,000,000.

 

 

Category B The undersigned is a natural person (not a partnership, corporation, etc.) who had an income in excess of $200,000 in each of the two most recent years, or joint income with his or her spouse in excess of $300,000 in each of those years (in each case including foreign income, tax exempt income and full amount of capital gains and losses but excluding any income of other family members and any unrealized capital appreciation) and has a reasonable expectation of reaching the same income level in the current year.

 

 

Category C The undersigned is a director or executive officer of the company which is issuing and selling the securities.

 

 

Category D The undersigned is a bank; a savings and loan association; insurance company; registered investment company; registered business development company; licensed small business investment company (“ SBIC ”); or employee benefit plan within the meaning of Title 1 of ERISA and (a) the investment decision is made by a plan fiduciary which is either a bank, savings and loan association, insurance company or registered investment advisor, or (b) the plan has total assets in excess of $5,000,000 or (c) is a self-directed plan with investment decisions made solely by persons that are accredited investors.

 

 

Category E The undersigned is a private business development company as defined in section 202(a)(22) of the Investment Advisors Act of 1940.

 

 

Category F The undersigned is either a corporation, partnership, Massachusetts business trust, or non-profit organization within the meaning of Section 501(c)(3) of the Internal Revenue Code, in each case not formed for the specific purpose of acquiring the Securities and with total assets in excess of $5,000,000.

 

 

Category G The undersigned is a trust with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Securities, where the purchase is directed by a “sophisticated investor” as defined in Regulation 506(b)(2)(ii) under the Act.

 

 

Category H The undersigned is an entity (other than a trust) in which all of the equity owners are “accredited investors” within one or more of the above categories. If relying upon this Category alone, each equity owner must complete a separate copy of this Agreement.

 

 
48
 

 

DISCLOSURE SCHEDULES

TO

SHARE EXCHANGE AND CONVERSION AGREEMENT

(MAKKANOTTI GROUP CORP.)

 

(Note: Capitalized terms used herein and not defined shall have the same meanings as set forth in the Share Exchange Agreement attached hereto.)

 

[DISCLOSURES SCHEDULES COMMENCE ON THE FOLLOWING PAGE]

 

 

 

 

 
49
 

 

Schedule 2.4 – Authorization and Validity of this Agreement

 

Landlord’s consent is required under the following leases:

 

Standard Industrial/Commercial Single Tenant Lease dated January 11, 2012 by and between Priveco and George Stern

 

Standard Industrial/Commercial Single Tenant Lease dated July 10, 2012 by and between Priveco and Fiske Industrial LLC

 
 
50
 

 

Schedule 2.7 – Capitalization

 

Authorized Shares : 10,000,000 shares of common stock, no par value.

 

Outstanding Shares : 2,718,253 shares of common stock.

 

Warrants : Pursuant to that certain Engagement Letter dated October 26, 2015 by and between Priveco and Colorado Financial Service Corporation (“Colorado Financial”), which acted as placement agent in connection with the 2016 Convertible Promissory Note Offering, Colorado Financial is entitled to receive warrants with a five (5) year term to purchase the same security as Priveco Noteholders at $1.00 per share in an amount equal to 6% of the capital received by Priveco in the 2016 Convertible Promissory Note Offering, excluding capital received from Priveco Noteholders introduced to Colorado Financial by Priveco for which no warrants shall be issued. “2016 Convertible Promissory Note Offering” refers to the sale by Priveco, and purchase by Priveco Noteholders, of Priveco’s Convertible Promissory Notes in aggregate principal amount of $6,106,463. In satisfaction of Priveco’s above-described warrant obligation under the Engagement Letter, Colorado Financial has agreed to accept a warrant to be issued directly by Pubco concurrently with the closing of the Transaction for the purchase of up to 141,142 shares of Pubco’s common stock at an exercise price of $1.00 per share and with a five (5) year term.

 

 
51
 

 

Schedule 2.9 – Compliance with Laws and Other Instruments

 

Leases

 

Pursuant to the Standard Industrial/Commercial Single Tenant Lease dated January 11, 2012 by and between Priveco and George Stern, Priveco is required to:

 

 

1. Add the landlord as an additional insured under Priveco’s commercial general liability policy;

 

 

 

 

2. Obtain loss of income insurance; and

 

 

 

 

3. Obtain public liability insurance in the amount of $5,000,000 naming the landlord as an additional insured.

 

Priveco has not complied with the above requirements, but the landlord has not taken any action with respect to this non-compliance.

 

Pursuant to the Standard Industrial/Commercial Single Tenant Lease dated July 10, 2012 by and between Priveco and Fiske Industrial LLC, Priveco is required to obtain the necessary loss of income insurance. Priveco has not complied with this requirement, but the landlord has not taken any action with respect to this non-compliance.

 

Both of the abovementioned leases have expired and are currently month to month leases.

 

21 st Century Note

 

Priveco received a Notice of Default and Notice of Acceleration dated October 15, 2015 (“Notice”) from the attorney representing 21 st Century Brands Distributing LLC (“21 st Century”) declaring Priveco to be in default for non-payment of the monthly payments due under the 5% Secured Promissory Note issued to 21 st Century Brands, LLC dated May 7, 2015 (“21 st Century Note”). The 21 st Century Note was assigned to 21 st Century on June 8, 2015. The Notice states that as of October 15, 2015, the balance due under the 21 st Century Note was $282,878.04 and unless full payment is made within 10 days of the Notice, 21 st Century’s intent was to proceed with enforcement of the 21 st Century Note.

 

Priveco and 21 st Century subsequently entered into a Letter Agreement dated October 30, 2015 pursuant to which 21 st Century agreed to conditionally rescind exercising the Notice and take no action in respect of Priveco’s failure to pay the principal of and accrued interest on the 21 st Century Note due prior to the date thereof if Priveco delivered to 21 st Century payment of not less than $140,000 (“Partial Payment”) by no later than November 6, 2015 (“Partial Payment Deadline”) and no other Event of Default arises under the 21 st Century Note. Priveco failed to make the Partial Payment under the 21 st Century Note and entered into another Letter Agreement dated November 29, 2015 (“Second Letter Agreement”) with 21 st Century pursuant to which 21 st Century agreed to conditionally rescind the Notice and take no action in respect of Priveco’s failure to pay the principal of and accrued interest on the 21 st Century Note due prior to the date thereof if Priveco delivered to 21 st Century payment of not less than $5,000 each week (“Weekly Payments”) by the last business day of each week beginning with the payment due on November 27, 2015 and no other Event of Default arises under the 21st Century Note. Priveco acknowledged under the Second Letter Agreement that $221,061.45 was due and owing to 21 st Century under the 21 st Century Note as of November 24, 2015, and that the 21 st Century Note bore interest at the default rate of 10% per annum, compounded monthly, and has borne interest at such rate since the date of the Default Notice.

 
 
52
 

 

Priveco has been meeting its obligation to make the Weekly Payments under the Second Letter Agreement and anticipates making its final payment to complete all payments due under the 21 st Century Note on October 14, 2016.

 

Insurance

 

Pursuant to the Manufacturing and Supply Agreement dated December 1, 2011 by and between Priveco and 21 st Century, Priveco is required to add 21 st Century as an additional insured under its product liability insurance policy in the amount of $2,000,000 per occurrence and $5,000,000 in the aggregate. 21 st Century has not been added as an additional insured to the policy and Priveco’s product liability insurance only covers up to $2,000,000 in the aggregate.

 

Tax

 

Priveco has filed its Federal and State corporate tax returns for the fiscal years ending December 31, 2011, 2012 and 2013 only. Priveco is in the process of completing the audits for the years ending December 31, 2014 and 2015. Upon completion of the audits, Priveco will be required to amend the tax returns filed for the years ending December 31, 2011, 2012 and 2013 and file corporate tax returns for the years ended December 31, 2014 and 2015.

 
 
53
 

 

Schedule 2.12 – Title to and Condition of Properties

 

Security interests in certain or all of Priveco’s assets were granted pursuant to the following agreements:

 

Promissory Notes

 

5% Secured Promissory Note dated May 7, 2015 by and between Priveco and 21st Century Brands, LLC

 

Secured Promissory Note dated May 7, 2015 by and between Priveco and Hollingsworth, Mendenhall & McFadden, LLC

 

Convertible Notes: All outstanding principal amounts owed under each of the following Convertible Promissory Notes, together with accrued and unpaid interest due thereon, will have been repaid and/or converted into shares of common stock of Priveco (“Termination Event”) prior to the Closing. Any and all security interests granted pursuant to such Convertible Promissory Notes will be terminated with the occurrence of the Termination Event, and Priveco shall request that the relevant noteholders terminate any UCC financing statements which may have been filed by such noteholders.

 

Secured Convertible Promissory Note with Restricted Transferability dated June 8, 2012 issued by Priveco to Michael Krimbill

 

Secured Convertible Promissory Note with Restricted Transferability dated June 8, 2012 issued by Priveco to David A. Krimbill GST Trust

 

Secured Convertible Promissory Note with Restricted Transferability dated June 8, 2012 issued by Priveco to Mike and Sherry Fine

 

Secured Convertible Promissory Note with Restricted Transferability dated June 8, 2012 issued by Priveco to Mike and Sherry Fine

 

Secured Convertible Promissory Note with Restricted Transferability dated June 8, 2012 issued by Priveco to Michael Krimbill

 

Secured Convertible Promissory Note with Restricted Transferability dated June 8, 2012 issued by Priveco to Limerick Capital LLC

 

Secured Convertible Promissory Note with Restricted Transferability dated June 8, 2012 issued by Priveco to Paul Mannion (Assigned to Lisa Mannion)

 

Secured Convertible Promissory Note with Restricted Transferability dated June 8, 2012 issued by Priveco to Paul Mannion (Assigned to Lisa Mannion)

 

Secured Convertible Promissory Note with Restricted Transferability dated June 8, 2012 issued by Priveco to Krimbill Enterprises LP

 
 
54
 

 

Secured Convertible Promissory Note with Restricted Transferability dated June 8, 2012 issued by Priveco to Tanya M. Krimbill GST Trust

 

Secured Convertible Promissory Note with Restricted Transferability dated June 8, 2012 issued by Priveco to Michael R. Krimbill GST Trust

 

Secured Convertible Promissory Note with Restricted Transferability dated June 8, 2012 issued by Priveco to Jennifer L. Krimbill GST Trust

 

Secured Convertible Promissory Note with Restricted Transferability dated June 8, 2012 issued by Priveco to Travis J. Krimbill GST Trust

 

Secured Convertible Promissory Note with Restricted Transferability dated June 8, 2012 issued by Priveco to Avenel Financial Group, Inc. as amended by Addendum dated August 8, 2013 (Assigned to Lisa Mannion)

 

Secured Convertible Promissory Note with Restricted Transferability dated June 8, 2012 issued by Priveco to Avenel Financial Group, Inc. as amended by Addendum dated August 8, 2013 (Assigned to Lisa Mannion)

 

Secured Convertible Promissory Note with Restricted Transferability dated June 8, 2012 issued by Priveco to Avenel Financial Group, Inc. as amended by Addendum dated August 8, 2013 (Assigned to Lisa Mannion)

 

Secured Convertible Promissory Note with Restricted Transferability dated June 8, 2012 issued by Priveco to Avenel Financial Group, Inc. as amended by Addendum dated August 8, 2013 (Assigned to Lisa Mannion)

 

3% Secured Convertible Note to The Branstetter Group (“TBG”) (Priveco omitted to issue the 3% Secured Convertible Note documents to TBG, but there is an agreement between TBG and Priveco that the $55,000 owed to TBG shall be converted into a 3% Secured Convertible Note identical to those issued pursuant to the Convertible Note Purchase Agreement dated February 25, 2013 by and between Priveco and Maven Partners, LLC)

 

3% Secured Convertible Note dated June 7, 2013 issued by Priveco to William O. Shields

 

3% Secured Convertible Note dated April 4, 2014 issued by Priveco to William O. Shields

 

3% Secured Convertible Note dated May 17, 2013 issued by Priveco to Donald B. Sallee Revocable Trust

 

3% Secured Convertible Note dated June 25, 2013 issued by Priveco to Frank H. DiCristina, III

 

3% Secured Convertible Note dated August 1, 2013 issued by Priveco to Frank H. DiCristina, III

 
 
55
 

 

3% Secured Convertible Note dated September 1, 2013 issued by Priveco to Frank H. DiCristina, III

 

3% Secured Convertible Note dated October 1, 2013 issued by Priveco to Frank H. DiCristina, III

 

3% Secured Convertible Note dated November 1, 2013 issued by Priveco to Frank H. DiCristina, III

 

3% Secured Convertible Note dated November 27, 2013 issued by Priveco to Frank H. DiCristina, III

 

3% Secured Convertible Note dated May 29, 2013 issued by Priveco to Frank H. DiCristina, III

 

3% Secured Convertible Note dated May, 2013, issued by Priveco to Thomas L. Shields

 

3% Secured Convertible Note dated June 26, 2013, issued by Priveco to Thomas L. Shields

 

3% Secured Convertible Note dated August 1, 2013 issued by Priveco to Thomas L. Shields

 

3% Secured Convertible Note dated September 1, 2013 issued by Priveco to Thomas L. Shields

 

3% Secured Convertible Note dated October 1, 2013 issued by Priveco to Thomas L. Shields

 

3% Secured Convertible Note dated March 21, 2014 issued by Priveco to Patrick M. Shields

 

3% Secured Convertible Note dated March 21, 2014 issued by Priveco to Thomas L. Shields, the 3rd

 

3% Secured Convertible Note dated March 21, 2014 issued by Priveco to Thomas L. Shields

 

3% Secured Convertible Note dated May 16, 2013 issued by Priveco to Fourth Street Fund, LP (Assigned to Lisa Mannion)

 

3% Secured Convertible Note dated March 5, 2014 issued by Priveco to Maven Partners, LLC (Assigned to Leland Martin Capital Partners, LLC)

 

3% Secured Convertible Note dated March 11, 2014 issued by Priveco to Maven Partners, LLC (Assigned to Leland Martin Capital Partners, LLC)

 

3% Secured Convertible Note dated February 25, 2013 issued by Priveco to Maven Partners, LLC (Assigned to Leland Martin Capital Partners, LLC)

 

3% Secured Convertible Note dated April 1, 2013 issued by Priveco to Maven Partners, LLC (Assigned to Leland Martin Capital Partners, LLC)

 
 
56
 

 

3% Secured Convertible Note dated May 1, 2013 issued by Priveco to Maven Partners, LLC (Assigned to Leland Martin Capital Partners, LLC)

 

3% Secured Convertible Note dated May 1, 2013 issued by Priveco to Maven Partners, LLC (Assigned to Leland Martin Capital Partners, LLC)

 

3% Secured Convertible Note dated June 24, 2013 issued by Priveco to Maven Partners, LLC (Assigned to Leland Martin Capital Partners, LLC)

 

3% Secured Convertible Note dated August 1, 2013 issued by Priveco to Maven Partners, LLC (Assigned to Leland Martin Capital Partners, LLC)

 

3% Secured Convertible Note dated September 1, 2013 issued by Priveco to Maven Partners, LLC (Assigned to Leland Martin Capital Partners, LLC)

 

3% Secured Convertible Note dated October 1, 2013 issued by Priveco to Maven Partners, LLC (Assigned to Leland Martin Capital Partners, LLC)

 

3% Secured Convertible Note dated November 1, 2013 issued by Priveco to Maven Partners, LLC (Assigned to Leland Martin Capital Partners, LLC)

 

3% Secured Convertible Note dated November 27, 2013 issued by Priveco to Maven Partners, LLC (Assigned to Leland Martin Capital Partners, LLC)

 

3% Secured Convertible Note dated October 31, 2014 issued by Priveco to Ronick (Rob Davidson)

 

3% Secured Convertible Note dated November 10, 2014 issued by Priveco to Ronick (Rob Davidson)

 

3% Secured Convertible Note dated December 1, 2014 issued by Priveco to Ronick (Rob Davidson)

 

3% Secured Convertible Note dated February 2, 2015 issued by Priveco to Ronick (Rob Davidson)

 

3% Secured Convertible Note dated June 17, 2015 issued by Priveco to Williams Ten, LLC

 

3% Secured Convertible Note dated July 13, 2015 issued by Priveco to Williams Ten, LLC

 

Secured Convertible Promissory Note dated July 24, 2015 issued by Priveco to Pace Wellness, Inc.

 

Secured Convertible Promissory Note dated July 30, 2015 issued by Priveco to Pace Wellness, Inc.

 
 
57
 

 

Secured Convertible Promissory Note dated August 14, 2015 issued by Priveco to Pace Wellness, Inc.

 

Secured Convertible Promissory Note dated August 31, 2015 issued by Priveco to Pace Wellness, Inc.

 

Secured Convertible Promissory Note dated September 14, 2015 issued by Priveco to Pace Wellness, Inc.

 

Secured Convertible Promissory Note dated September 18, 2015 issued by Priveco to Pace Wellness, Inc.

 

Secured Convertible Promissory Note dated October 15, 2015 issued by Priveco to Pace Wellness, Inc.

 

3% Secured Convertible Note dated December 31, 2015 issued by Priveco to Robert Davidson

 

3% Secured Convertible Note dated December 31, 2015 issued by Priveco to Wayne Nasby

 

3% Secured Convertible Note dated December 31, 2015 issued by Priveco to Edward Maliski

 

3% Secured Convertible Note dated December 31, 2015 issued by Priveco to Jon Turman

 

UCC Financing Statements

 

UCC Financing Statement filed with the California Secretary of State on July 12, 2012 listing holders of Secured Convertible Promissory Notes with Restricted Transferability dated June 8, 2012 as secured parties

 

UCC Financing Statement filed with the California Secretary of State on February 28, 2013 listing Paul Mannion as secured party

 

UCC Financing Statement filed with the California Secretary of State on October 26, 2015 listing 21 st Century Brands Distributing LLC as secured party

 

UCC Financing Statement filed with the California Secretary of State on November 3, 2015 listing Pace Wellness, Inc. as secured party

 
 
58
 

 

Schedule 5.5

Exemption Pursuant to which the Shares Were Issued

 

The shares issued by the Company were issued pursuant to Section 4(a)(2) of the Securities Act of 1933.

 

Schedule 5.6

Capitalizations

 

Total Outstanding Shares: 24,984,000

 

Schedule 5.14

Officer, Director, and/or Employee Transactions with Makkanotti

 

None.

 

Schedule 5.16

Finder’s Fees or Commissions

 

None.

 

Schedule 5.22

Tax Deficiencies

None.

 

Schedule 5.25

Accounting Firm

 

RBSM LLP

 

Schedule 5.33

Undisclosed Liabilities

 

None.

 

 

59

 

EXHIBIT 3.3

 

AMENDMENTS TO THE BYLAWS OF

MAKKANOTTI GROUP CORP.

 

1. Subsections .01, .02, .03 and .07 of Section I of the Bylaws of Makkanotti Group Corp. (the “ Corporation ”) shall each be amended and restated in their entirety as follows:

 

“.01 Annual Meetings.

 

The annual meeting of the shareholders of this Corporation, for the purpose of election of Directors and for such other business as may properly come before it, shall be held at the registered office of the Corporation, or such other places, either within or without the State of Nevada, as may be designated by the notice of the meeting, and on such date and at such time as is fixed by the Board of Directors and stated in the notice of the meeting.

 

.02 Special Meeting.

 

Special meetings of the shareholders of this Corporation may be called at any time by the holders of twenty-five percent (25%) of the voting shares of the Corporation, or by the President, or by the Chief Executive Officer, or by the Board of Directors or a majority thereof. No business shall be transacted at any special meeting of shareholders except as is specified in the notice calling for said meeting. The Board of Directors may designate any place, either within or without the State of Nevada, as the place of any special meeting called by the President, Chief Executive Officer or the Board of Directors, and special meetings called at the request of shareholders shall be held at such place in the State of Nevada, as may be determined by the Board of Directors and placed in the notice of such meeting.

 

.03 Notice of Meeting.

 

Written notice of annual or special meetings of shareholders stating the place, day, and hour of the meeting and, in the case of a special meeting, the purpose or purposes for which the meeting is called shall be given by the secretary or persons authorized to call the meeting to each shareholder of record entitled to vote at the meeting. Such notice shall be given not less than ten (10) nor more than sixty (60) days prior to the date of the meeting, and such notice shall be deemed to be delivered when deposited in the United States mail addressed to the shareholder at his/her address as it appears on the stock transfer books of the Corporation. Notice of any meeting of shareholders shall not be required to be given to any shareholder who shall attend the meeting, except for the express purpose of objecting at the beginning thereof to the transaction of any business because the meeting is not lawfully called or convened, or who shall submit, either before or after the meeting, a signed waiver of notice. Unless the Board of Directors, after the adjournment of such meeting, shall fix a new record date for an adjourned meeting or unless the adjournment is for more than thirty (30) days, notice of an adjourned meeting need not be given if the place, date and time to which the meeting shall be adjourned is announced at the meeting at which the adjournment is taken.

 

* * *

 

 
1
 

 

.07 Voting of Shares.

 

Except as otherwise provided in the Articles of Incorporation or in these Bylaws, every shareholder of record shall have the right at every shareholder's meeting to one (1) vote for every share standing in his/her name on the books of the Corporation as of the record date, and the affirmative vote of a majority of the shares represented at a meeting and entitled to vote thereat shall be necessary for the adoption of a motion or for the determination of all questions and business which shall come before the meeting.”

 

2. Subsection .09 as set forth below is hereby added to Section I of the Corporation’s Bylaws:

 

.09 Record Date.

 

For the purpose of determining the shareholders entitled to notice of or to vote at any meeting of shareholders or any adjournment thereof, or to express consent to or dissent from any proposal without a meeting, or for the purpose of determining shareholders entitled to receive payment of any dividend or other distribution or the allotment of any rights, or for the purpose of any other action, the Board of Directors may fix in advance, a record date, which shall be not more than sixty (60) nor less than ten (10) days before the date of any such meeting, nor more than sixty (60) days prior to any other action.”

 

3. Paragraph B under Subsection .06 of Section II of the Corporation’s Bylaws shall be amended and restated in its entirety as follows:

 

B. Special Meetings.

 

Special meetings of the Directors shall be called at any time and place upon the call of the President, the Chief Executive Officer or any Director. Notice of the time and place of each special meeting shall be given by the secretary, or the persons calling the meeting, by mail, radio, telegram, or by personal communication by telephone or otherwise at least one (1) day in advance of the time of the meeting. The purpose of the meeting need not be given in the notice. Notice of any special meeting may be waived in writing or by telegram (either before or after such meeting) and will be waived by any Director in attendance at such meeting.”

 

4. Section III of the Corporation’s Bylaws shall be amended and restated in its entirety as follows:

 

III. ACTIONS BY WRITTEN CONSENT.

 

01. By Shareholders

 

Unless otherwise restricted by the Corporation’s Articles of Incorporation or these Bylaws, any action required or permitted to be taken at a meeting of the shareholders may be taken without a meeting if, before or after the action, a written consent thereto is signed by shareholders holding at least a majority of the voting power, except that if a different proportion of voting power is required for such an action at a meeting, then that proportion of written consents shall be required. Whenever such action is taken by written consent, a meeting of shareholders need not be called or notice given. The shareholders’ written consent may be signed in counterparts, including, without limitation, facsimile counterparts, and shall be filed with the minutes of the proceedings of the shareholders.

 

 
2
 

 

.02 By the Board of Directors

 

Unless otherwise restricted by the Corporation’s Articles of Incorporation or these Bylaws, any action required or permitted to be taken at a meeting of the Board of Directors or of any committee thereof may be taken without a meeting if, before or after the action, a written consent thereto is signed by all of the members of the Board of Directors or of the committee. The Board of Directors’ or committee’s written consent may be signed in counterparts, including, without limitation, facsimile counterparts, and such written consent shall be filed with the minutes of proceedings of the Board of Directors or the committee.”

 

5. Subsections .01, .02 and .03 of Section IV of the Corporation’s Bylaws shall be amended and restated in their entirety as follows:

 

“IV. OFFICERS.

 

.01 Officers Designated.

 

The officers of the Corporation shall be chosen by the Board of Directors. There shall be a Chief Executive Officer, a President, a Secretary and a Treasurer, and there may be a Chairman of the Board of Directors, a Chief Operating Officer, a Chief Scientific Officer, one or more Vice Presidents, one or more Assistant Secretaries, and one or more Assistant Treasurers (each an “Officer” and collectively, the ‘Officers”), as the Board of Directors may elect. Any Officer may be held by the same person, except that in the event that the Corporation shall have more than one director, the offices of Chief Executive Officer and Secretary shall be held by different persons.

 

.02 Election, Qualification and Term of Office.

 

Each of the Officers shall be elected by the Board of Directors. Each Officer of the Corporation shall hold office until such Officer’s successor is duly elected and qualified, or until such Officer’s earlier death, resignation or removal. Election or appointment of an Officer or agent shall not of itself create contract rights. All Officers, agents and employees of the Corporation shall respectively have such authority and perform such duties in the conduct and management of the Corporation as may be delegated by the Board of Directors or by these Bylaws.

 

.03 Powers and Duties.

 

The powers and duties of the respective Officers shall be as follows:

 

A. Chief Executive Officer

 

Under the supervision of the Board of Directors, the Chief Executive Officer shall have the general control and management of the Corporation’s business and affairs, subject, however, to the right of the Board of Directors to confer any specific power upon any other officer or officers of the Corporation. In the absence of the President, he shall perform any necessary duties of the President, or delegate same to the Chief Operating Officer, as he may determine. The Chief Executive Officer shall do and perform all acts and things incident to the office of Chief Executive Officer and such other duties as may be assigned to him from time to time by the Board of Directors. In the Chief Executive Officer’s absence, the Chief Executive Officer’s duties shall be attended to by the President.

 

 
3
 

 

B. President.

 

The President shall be executive officer next in authority to the Chief Executive Officer, and, under the supervision of the Chief Executive Officer and the Board of Directors, shall generally supervise and administer the business and affairs of the Corporation. He shall perform all duties incident to the office of President and such other duties as may be prescribed by the Board of Directors.

 

C. Chief Operating Officer

 

The Chief Operating Officer shall in general supervise and control all operations of the Corporation. He shall be responsible for formulation of operations policies and procedures and shall submit such policies to the Board of Directors, as necessary. He shall perform such other duties as usually appertain to the office or as may be prescribed by the Board of Directors.

 

D. Chief Scientific Officer

 

The Chief Scientific Officer generally shall supervise and control all scientific affairs of the Corporation. He shall be responsible for formulation of recommendations to the Board of Directors relating to the various scientific activities of the Corporation, as necessary. He shall perform such other duties as usually appertain to the office or as may be prescribed by the Board of Directors.

 

E. Vice Presidents

 

The Vice Presidents shall perform such of the duties of the President on behalf of the Corporation as may be respectively assigned to them from time to time by the Board of Directors or by the President. The Board of Directors may designate one of the Vice Presidents as the Executive Vice President, and in the absence or inability of the President to act, such Executive Vice President shall have and possess all of the powers and discharge all of the duties of the President, subject to the control of the Board of Directors.

 

F. Secretary.

 

The secretary shall:

 

 

1. Keep the minutes of the shareholder's and of the Board of Directors meetings in one or more books provided for that purpose;

 

 

 

 

2. See that all notices are duly given in accordance with the provisions of these Bylaws or as required by law;

 

 

 

 

3. Be custodian of the corporate records and of the seal of the Corporation and affix the seal of the Corporation to all documents as may be required;

 

 

 

 

4. Keep a register of the postal address and all other contact information of each shareholder which shall be furnished to the secretary by such shareholder;

 
 
4
 

 

 

5. Sign with the president, or a vice president, certificates for shares of the Corporation, the issuance of which shall have been authorized by resolution of the Board of Directors;

 

 

 

 

6. Have general charge of the stock transfer books of the corporation; and

 

 

 

 

7. In general perform all duties incident to the office of secretary and such other duties as from time to time may be assigned to him/her by the President or by the Board of Directors.
  

G. Chief Financial Officer

 

The Chief Financial Officer shall in general supervise and control the financial affairs of the Corporation. He shall formulate and submit to the Board of Directors, if any, matters of general fiscal policy of the Corporation. He shall further develop and maintain procedures necessary for the financial control of business and safeguarding of the assets of the Corporation, direct internal auditing, maintain internal accounting activities, and prepare, or cause to be prepared, for submission to the Board of Directors, the Chief Executive Officer or the President, upon instruction of the Board of Directors or at the request of the Chief Executive Officer, or the President, a statement of financial condition of the Corporation, in such detail as may be required. In the absence of a Treasurer, he shall also perform all of the duties of the Treasurer. The Chief Financial Officer shall perform such other duties as usually appertain to the office or as may be prescribed by the Board of Directors.

 

H. Treasurer

 

The Treasurer shall (a) have charge and custody of and be responsible for all funds and securities of the Corporation; receive and give receipts for moneys due and payable to the Corporation from any source whatsoever and deposit all such moneys in the name of the Corporation in such banks, trust companies or other depositories as shall be selected by the Corporation; (b) prepare, or cause to be prepared, for submission at each regular meeting of the Board of Directors, at each annual meeting of the shareholders, and at such other times as may be required by the Board of Directors, the Chief Financial Officer or the President, a statement of financial condition of the Corporation in such detail as may be required; and (c) in general, perform all the duties incident to the office of Treasurer and such other duties as from time to time may be assigned to him by the President or the Board of Directors or the Chief Financial Officer.

 

I. Assistant Secretaries and Assistant Treasurers.

 

The assistant secretaries, when authorized by the Board of Directors, may sign with the president or a vice president certificates for shares of the Corporation the issuance of which shall have been authorized by a resolution of the Board of Directors. The assistant treasurers shall, respectively, if required by the Board of Directors, give bonds for the faithful discharge of their duties in such sums and with such sureties as the Board of Directors shall determine. The assistant secretaries and assistant treasurers, in general, shall perform such duties as shall be assigned to them by the secretary or the treasurer, respectively, or by the president or the Board of Directors.

 
 
5
 

 

6. Subsection .01 of Section V of the Bylaws of Makkanotti Group Corp. (the “Corporation”) shall be amended and restated in its entirety as follows:

 

V. SHARE CERTIFICATES

 

.01 Form and Execution of Certificates.

 

Certificates for shares of the Corporation shall be in such form as is consistent with the provisions of the Corporation laws of the State of Nevada. They shall be signed by the President or the Chief Executive Officer and by the Secretary, and the seal of the Corporation shall be affixed thereto. Certificates may be issued for fractional shares.”

   

7. Section XIII as set forth below is hereby added to the Corporation’s Bylaws:

 

XIII. ACQUISITION OF CONTROLLING INTEREST

 

The Corporation elects not to be governed by Sections 78.378 through 78.3793 of the Nevada Revised Statutes, inclusive, relating to acquisition of a controlling interest in the Corporation.”

 

 

 

6

 

 

EXHIBIT 10.2

  

FORM OF SHARE CANCELLATION AGREEMENT

 

This SHARE CANCELLATION AGREEMENT (this “ Agreemen t”), dated November 7, 2016 ( the “ Effective Date ”), is entered into by and among (the “ Company ”), Makkanotti Group Corp., a Nevada corporation, (the “ Company ”), [ ·  ] (the “ Cancelling Party ”). The Company and Cancelling Party are also hereinafter individually and jointly referred to as “ P(p)arty ” and/or “ P(p)arties ”.

 

RECITALS

 

WHEREAS , as of the date hereof, the Cancelling Party is the owner of [  · ] shares of the Company’s common stock, par value $0.001per share; and

 

WHEREAS , concurrently herewith, the Parties and Cure Pharmaceutical Corp., a California corporation (“ Cure Pharma ”), are entering into a Share Exchange and Conversion Agreement (the “ Exchange Agreement ”), pursuant to which Cure Pharma will become a wholly owned subsidiary of the Company; and

 

WHEREAS , it is a condition precedent to the consummation of the Exchange Agreement that the Cancelling Party will enter into this Agreement, which will effectuate the cancellation of an aggregate [  · ] shares of the Company’s common stock owned by the Cancelling Party (the “ Cancelled Shares ”);

 

WHEREAS , the Cancelling Party acknowledges that it would benefit from the completion of the transactions contemplated by the Exchange Agreement; and

 

WHEREAS , the Cancelling Party is entering into this Agreement to, amongst other things, induce Cure Pharma to enter into the Exchange Agreement and the Cancelling Party acknowledges that Cure Pharma would not consummate the transactions contemplated by the Exchange Agreement unless the transactions contemplated hereby are effectuated in accordance herewith.

 

AGREEMENT

 

In consideration of the mutual promises herein contained and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:

 

1. Cancellation of Cancelled Shares . On the Effective Date, the Cancelling Party will deliver to the Company the necessary documentation for the cancellation of the stock certificates representing the Cancelled Shares, along with duly executed medallion guaranteed stock powers covering the Cancelled Shares (or such other documents acceptable to the Company’s transfer agent) and hereby irrevocably instructs the Company and the Company’s transfer agent to cancel the Cancelled Shares such that the Cancelled Shares will no longer be outstanding on the stock ledger of the Company and such that the Cancelling Party shall no longer have any interest in the Cancelled Shares whatsoever. The Company shall immediately deliver to the Company’s transfer agent irrevocable instructions providing for the cancellation of the Cancelled Shares. As of the Effective Date, the Cancelling Party hereby waives any and all rights and interests it has, had or may have with respect to the Cancelled Shares.

 
 
1
 

 

2. Consideration for Share Cancellation . At the Closing, as consideration for the cancellation of the Cancelled Shares by the Cancelling Party, the Company shall deliver to the Cancelling Party a warrant for the purchase of up to [  · ] shares of the Company’s common stock (the “ New Warrant ”) with an exercise price per share of $2.00 (subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Company’s common stock that occur after the date of this Agreement) (the “ Exercise Price ”). The New Warrant shall be exercisable for period of four (4) years from its issuance date and shall include a call provision pursuant to which the Company shall have the right to call the exercise of all, or the remaining portion of the New Warrant outstanding and unexercised at the then-current Exercise Price on or at any time after the effective date of the Company’s listing of its common stock for trading on any of the following markets or exchanges: the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the NYSE MKT LLC exchange or any other national securities exchange registered with the U.S. Securities and Exchange Commission (the “ SEC ”) under Section 6(a) of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”). The shares of Company’s common stock issuable upon exercise of New Warrant are herein referred to as the “New Warrant Shares” and the New Warrant and the New Warrant Shares are herein together referred to as the “Securities.”

  

3. Effective Date . This Agreement shall become effective upon the execution of this Agreement. The transactions to occur at such place and time with respect to this Agreement are referred to herein as the “ Closing ”.

 

4. Release of Claims. At and subsequent to the Closing, the Cancelling Party, on behalf of its directors, shareholders, officers, legal representatives, affiliates and related entities hereby releases and forever discharges the Company, and its respective past, present and future officers, directors, partners, principals, agents, employees, affiliates, related entities, successors and assigns from any and all claims, demands, obligations, losses, causes of action, costs, expenses, attorneys’ fees and liabilities whatsoever, whether based on contract, tort, statutory or other legal or equitable theories of recovery, and whether known or unknown, asserted or unasserted, which in any way are based upon, arise out of or relate to the Cancelled Shares. The Parties intend that this Agreement cover all claims or possible claims based upon, arising out of or related to those matters referred to in the foregoing release, whether such claims or possible claims are known, unknown or hereafter discovered.

 

5. Representations by the Cancelling Party .

 

(a) The Cancelling Party owns the Cancelled Shares of record and beneficially free and clear of all liens, claims, charges, security interests, and/or encumbrances of any kind whatsoever. The Cancelling Party has sole control over the Cancelled Shares and/or sole discretionary authority over any account in which they are held. Except for this Agreement, no person/entity has any option or right to purchase or otherwise acquire the Cancelled Shares, whether by contract of sale or otherwise, nor is there a “short position” as to the Cancelled Shares.

 
 
2
 

 

(b) The Cancelling Party has full right, power and authority to execute, deliver and perform this Agreement and to carry out the transactions contemplated hereby. This Agreement has been duly and validly executed and delivered by the Cancelling Party and constitutes a valid, binding obligation of the Cancelling Party, enforceable against it in accordance with its terms (except as such enforceability may be limited by laws affecting creditor's rights generally).

 

(c) Cancelling Party represents and warrants that it has the requisite authority and capacity to enter into this Agreement, as well as carry out the terms/conditions referenced herein. Additionally, Cancelling Party represents and warrants that its compliance with the terms and conditions of this Agreement and will not violate any instrument relating to the conduct of its business, or any other agreement which it may be a party, or any federal and state rules or regulations applicable to either Party.

 

(d) Cancelling Party is, and on the date which it exercises the New Warrant it will be, an “accredited investor” within the meaning of Rule 501 under the Securities Act of 1933, as amended (the “ Securities Act ”), and was not organized for the specific purpose of acquiring the Securities. Cancelling Party has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Cancelling Party is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment. Cancelling Party has had the opportunity to ask questions and receive answers concerning the terms and conditions of its purchase of the Securities and to obtain any additional information from the Company that is necessary to verify the information furnished in the Company’s periodic, current and other reports required to be filed by it under the Exchange Act made with the SEC.

 

(e) Cancelling Party is (i) purchasing the New Warrant and (ii) upon exercise of the New Warrant will acquire the New Warrant Shares issuable upon exercise thereof, for investment purposes for its own account only and not with a view to, or for resale in connection with, any public sale or “distribution” thereof within the meaning of the Securities Act. Cancelling Party understands that the Securities have not been registered under the Securities Act or registered or qualified under the applicable securities law of any other jurisdiction in reliance on specific exemptions therefrom, which exemptions may depend upon, among other things, the bona fide nature of Cancelling Party’s investment intent as expressed herein.

 

6. Representations and Warranties of the Company . The Company represents and warrants to Cancelling Party as of the date hereof as follows:

 

(a) Corporate Authorization; Enforceability . The execution, delivery and performance by the Company of this Agreement are within the corporate powers and have been, duly authorized by all necessary corporate action on the part of the Company. This Agreement has been duly executed and delivered by the Company and constitutes the valid and binding agreement of the Company, enforceable against the Company in accordance with its terms, except to the extent that its enforceability may be subject to applicable bankruptcy, insolvency, reorganization, moratorium and similar laws affecting the enforcement of creditors’ rights generally and by general equitable principles.

 
 
3
 

 

(b) Governmental Authorization . The execution, delivery and performance by the Company of this Agreement requires no consent, approval, order, authorization or action by or in respect of, or filing with, any governmental authority.

 

(c) Non-Contravention; Consents . The execution, delivery and performance by the Company of this Agreement and the consummation of the transactions contemplated hereby do not (i) violate the articles of incorporation or bylaws of the Company, or (ii) violate any applicable law or order.

 

7. Restrictions on Transfer of Securities; Registrable Securities.

 

(a) Restrictions on Transferability . The Securities shall not be offered, sold, resold, pledged, assigned or otherwise transferred from Cancelling Party to a transferee (any such transferee, a “Holder”) other than (i) if such Securities have been registered for sale pursuant to an effective registration statement under the Securities Act or (ii) (A) in accordance with the provisions of Section 7 and Section 12 hereof, (B) in accordance with the applicable provisions of the New Warrant, and (C) where Cancelling Party shall have delivered to the Company an opinion of counsel, in a form acceptable to the Company and from counsel reasonably acceptable to the Company, to the effect that such Securities to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration. Cancelling Party will be required to notify any subsequent purchaser of any then-existing resale restrictions as set forth above. The Company shall be entitled to give stop transfer instructions to the transfer agent with respect to the Securities to enforce the foregoing restrictions.

 

(b) Restrictive Legends . Cancelling Party understands that the Securities have been issued (or will be issued in the case of the New Warrant Shares) pursuant to an exemption from registration or qualification under the Securities Act and applicable state securities laws, and the Securities (or any other securities issued in respect of the Securities upon any stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or otherwise) shall (unless otherwise permitted by the provisions hereof or the Warrants) be stamped or otherwise imprinted with a legend substantially in the following form (in addition to any legend required under applicable federal or state securities laws):

 

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

 

(c) Limitation on Transfer . Notwithstanding the other applicable provisions of this Agreement to the contrary, Cancelling Party agrees that it shall not transfer the Warrants to more than ten (10) holders, and each holder to whom all or part of any Warrant shall be transferred, by executing the assignment agreement attached to the Warrant, cannot transfer such Warrant to more than one holder.

 
 
4
 

 

8. Further Assurances . Each Party to this Agreement will use its best efforts to take all action and to do all things necessary, proper, or advisable in order to consummate and make effective the transactions contemplated by this Agreement including, but not limited to the execution and delivery of such other documents and agreements as may be necessary to effectuate the cancellation of the Cancelled Shares.

 

9. Notices . Any and all notices and other communications hereunder shall be in writing and shall be deemed duly given to the party to whom the same is so delivered, sent, transmitted or mailed at addresses and contact information set forth on the signature pages hereof (or at such other address for a party as shall be specified by like notice). Any notices or other communications required or permitted hereunder shall be in writing, delivered via facsimile, email, U.S. nationally recognized overnight courier or by hand-delivery and shall be deemed sufficiently given, received and effective on the earliest of: (i) the date of transmission, if such notice or communication is delivered via confirmed facsimile at the applicable facsimile number set forth on the signature pages attached hereto prior to 5:30 p.m. (Pacific Standard Time) on a Trading Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via confirmed facsimile at the applicable facsimile number set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (Pacific Standard Time) on any Trading Day, (iii) the date of transmission, if such notice or communication is delivered via email at the applicable email address set forth on the signature pages attached hereto prior to 5:30 p.m. (Pacific Standard Time) on a Trading Day (provided that such sent email is kept on file (whether electronically or otherwise) by the sending party and the sending party does not immediately receive an automatically generated message from the recipient’s email server that such email could not be delivered to such recipient), (iv) the next Trading Day after the date of transmission, if such notice or communication is delivered via email at the applicable email address set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (Pacific Standard Time) on any Trading Day (provided that such sent email is kept on file (whether electronically or otherwise) by the sending party and the sending party does not immediately receive an automatically generated message from the recipient’s email server that such email could not be delivered to such recipient), (v) the second Trading Day following the date of mailing, if sent to the applicable address set forth in the signature pages hereto by internationally recognized overnight courier service, or (vi) the date of actual receipt by the party to whom such notice or communication is required or permitted to be given, if such notice or communication is hand-delivered to such party.

 

10. Entire Agreement; Amendments . This Agreement contains the entire understanding of the Parties with respect to the matters covered herein and therein and, except as specifically set forth herein, neither the Company nor the Cancelling Party makes any representation, warranty, covenant or undertaking with respect to such matters. No amendment, modification, termination or waiver of any provision of this Agreement, and no consent to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by both Parties. Any such waiver or consent shall be effective only in the specific instance and for the specific purpose for which it was given.

 
 
5
 

 

11. Survival of Agreements, Representations and Warranties, etc . All representations and warranties contained herein shall survive the execution and delivery of this Agreement.

  

12. Successors and Assigns . This Agreement shall bind and inure to the benefit of and be enforceable by the Parties and their respective successors and assigns. Cancelling Party may assign its rights under this Agreement to any person to whom Cancelling Party assigns or transfers any Securities, provided: (i) such transferor agrees in writing with the transferee or assignee for the assignment of such rights, and a copy of such agreement is furnished to the Company after such assignment, (ii) the Company is furnished with written notice of the name and address of such transferee or assignee, (iii) such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions hereof that apply to the “Cancelling Party,” and (iv) such transfer shall have been made in accordance with the applicable requirements of this Agreement and with all laws applicable thereto.

 

13. Governing Law . All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Nevada, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a Party or its respective affiliates, directors, officers, stockholders, employees or agents) shall be commenced exclusively in the state courts sitting in the County of Ventura, California or in the United States District Court in the Western Division of the Central District of California. Each Party hereby irrevocably submits to the exclusive jurisdiction of the state courts sitting in the County of Ventura, California or in the United States District Court in the Western Division of the Central District of California for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of the Agreement), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each Party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via internationally recognized overnight courier service (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any Party shall commence an action or proceeding to enforce any provisions of the Agreement, then the prevailing Party in such action or proceeding shall be reimbursed by the other Party(s) for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

 
 
6
 

 

14. Severability . In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof.

 

15. Miscellaneous . This Agreement embodies the entire agreement and understanding between the Parties hereto and supersedes all prior agreements and understandings relating to the subject matter hereof. If any provision of this Agreement shall be held invalid or unenforceable for whatever reason, the remainder of this Agreement shall not be affected thereby and every remaining provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. This Agreement may be executed in any number of counterparts and by the Parties hereto on separate counterparts but all such counterparts shall together constitute but one and the same instrument. This Agreement, to the extent delivered by means of a facsimile machine or electronic mail (any such delivery, an “ Electronic Delivery ”), shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of any Party, each other Party shall re-execute original forms hereof and deliver them in person to all other Parties. No Party shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and each such Party forever waives any such defense, except to the extent such defense related to lack of authenticity.

 

[ Signature page follows ]

 

 
7
 

 

IN WITNESS WHEREOF , the Parties hereto have executed this Agreement as of the date first above written.

 

 

MAKKANOTTI GROUP CORP.,

a Nevada corporation

       
By: /s/ Michael Hlavsa

 

Name:

Michael Hlavsa  
 

Title:

President  

 

 

 

 

 

 

Address for Notices:

 

________________________________________

________________________________________

Phone:  __________________________________

Fax:_____________________________________

Email:  ___________________________________

 

 

 

 

 

 

 

 

 

 

· ]

 

 

 

 

 

 

By:

 

 

 

Name:  

 

 

Title:  

 

 

 

 

 

 

 

Address for Notices:

 

________________________________________

________________________________________

Phone:  __________________________________

Fax:_____________________________________

Email:  ___________________________________

 

 

 

8

 

 

EXHIBIT 10.3

   

NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THESE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT SECURED BY SUCH SECURITIES.

 

MAKKANOTTI GROUP CORP.

 

FORM OF WARRANT TO PURCHASE COMMON STOCK

 

Warrant No. [  · ]

Original Issue Date: November 7, 2016

 

Makkanotti Group Corp. , a Nevada corporation (the “Company” ), hereby certifies that, for value received, [  · ] or its registered assigns (the “Holder” ), is entitled to purchase from the Company up to a total of [  · ]   shares of Common Stock (each such share, a “Warrant Share” and all such shares, the “Warrant Shares” ), as determined in accordance with the terms herewith, at the Exercise Price (as defined below), at any time and from time to time from, on or after November 7, 2016 (the “ Commencement Date ”), and through and including 5:30 P.M., U.S. Pacific Standard Time, on November 7, 2020 (the “Expiration Date” ), and subject to the following terms and conditions:

 

1. Definitions . As used in this Warrant, the following terms shall have the respective definitions set forth in this Section 1 .

 

“Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 144.

 

“Business Day” means any day except Saturday, Sunday and any day which is a federal legal holiday or a day on which banking institutions in the State of California are authorized or required by law or other governmental action to close.

 

 
1
 

 

“California Courts” means (i) the state or federal courts sitting in Ventura County, California; or (ii) if such court does not have jurisdiction, then the United States District Court for the Central District of California.

 

“Common Stock” means the common stock of the Company, $0.001 par value per share, and any securities into which such common stock may hereafter be reclassified or for which it may be exchanged as a class.

 

“Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

National Trading Market ” means the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the NYSE MKT, LLC or the New York Stock Exchange (or any successors to any of the foregoing).

 

“Original Issue Date” means the Original Issue Date first set forth on the first page of this Warrant.

 

“Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Rule 144” means Rule 144 promulgated by the Securities and Exchange Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Securities and Exchange Commission having substantially the same effect as such Rule.

 

“Securities Act” means the Securities Act of 1933, as amended.

 

“Subsidiary” means any “significant subsidiary” as defined in Rule 1-02(w) of Regulation S-X promulgated by the Securities and Exchange Commission under the Exchange Act.

 

“Trading Day” means (i) a day on which the Common Stock is traded on a Trading Market, or (ii) if the Common Stock is not quoted on any Trading Market, a day on which the Common Stock is quoted in the over-the-counter market as reported by the OTC Markets Group, Inc. (or any similar organization or agency succeeding to its functions of reporting prices); provided, that in the event that the Common Stock is not listed or quoted as set forth in (i) or (ii) hereof, then Trading Day shall mean a Business Day.

 
 
2
 

 

“Trading Market” means whichever of the following markets, exchanges or quotation systems on which the Common Stock is listed or quoted for trading on the date in question: New York Stock Exchange, the NYSE MKT, LLC, the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market, OTC Bulletin Board, or the OTCQX, OTCQB or OTC Pink tiers of the OTC Markets Group, Inc. quotation system (or any successors to any of the foregoing).

 

Uplisting ” means listing of the Company’s common stock for trading on a National Trading Market.

 

“Warrant Shares” means the shares of Common Stock issuable upon exercise of this Warrant.

 

2. Exercise Price . For purposes of this Warrant, the “ Exercise Price ” means $2.00 per share of Common Stock, subject to adjustment as provided herein.

 

3. Registration of Warrant . The Company shall register this Warrant upon records to be maintained by the Company for that purpose (the “Warrant Register” ), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

4. Registration of Transfers . The Company shall register the transfer of all or any portion of this Warrant in the Warrant Register, upon (i) surrender of this Warrant, with the Form of Assignment attached as Schedule 2 hereto duly completed and signed, to the Company’s transfer agent or to the Company at its address specified herein, (ii) delivery, at the request of the Company, of an opinion of counsel reasonably satisfactory to the Company to the effect that the transfer of such portion of this Warrant may be made pursuant to an available exemption from the registration requirements of the Securities Act and all applicable state securities or blue sky laws and (iii) delivery by the transferee of a written statement to the Company, in form and substance reasonably acceptable to the Company, certifying that the transferee is an “accredited investor” as defined in Rule 501(a) under the Securities Act and making the representations and certifications as the Company may reasonably request to procure an exemption from section 5 of the Securities Act. Upon any such registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a “ New Warrant ”) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations of a Holder of this Warrant.

 

5. Exercise and Duration of Warrants .

 

(a) All or any part of this Warrant shall be exercisable by the registered Holder at any time and from time to time from and after the Commencement Date, and through and including 5:30 P.M., U.S. Pacific Standard Time, on the Expiration Date. At 5:30 P.M., U.S. Pacific Standard time on the Expiration Date, the portion of this Warrant not exercised prior thereto shall be and become void and of no value. This Warrant shall also be subject to the Call Rights provision set forth in Section 17 below.

 
 
3
 

 

(b) The Holder may exercise this Warrant by delivering to the Company (i) an exercise notice, in the form attached as Schedule 1 hereto (the “ Exercise Notice ”), appropriately completed and duly signed, (ii) payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being, and the date such items are delivered to the Company (as determined in accordance with the notice provisions hereof) is an “ Exercise Date .” The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares.

 

6. Delivery of Warrant Shares . Upon exercise of this Warrant, the Company shall promptly issue or cause to be issued and cause to be delivered to or upon the written order of the Holder and in such name or names as the Holder may designate a certificate for the Warrant Shares issuable upon such exercise, with an appropriate restrictive legend. The Holder, or any Person permissibly so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date. This Warrant is exercisable, either in its entirety or, from time to time, for a portion of the number of Warrant Shares. Upon surrender of this Warrant following one or more partial exercises, the Company shall issue or cause to be issued, at its expense, a New Warrant evidencing the right to purchase the remaining number of Warrant Shares.

 

7. Charges, Taxes and Expenses . Issuance and delivery of Warrant Shares upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, withholding tax, transfer agent fee or other incidental tax or expense in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; provided, however, that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or Warrants in a name other than that of the Holder. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.

 

8. Replacement of Warrant . If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity (which shall not include a surety bond), if requested. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company’s obligation to issue the New Warrant.

 

9. Reservation of Warrant Shares . The Company covenants that it will at all times reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares which are then issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of Persons other than the Holder (taking into account the adjustments and restrictions of Section 10 ). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and nonassessable.

 
 
4
 

 

10. Certain Adjustments . The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this Section 10 .

 

(a) Stock Dividends and Splits . If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital stock that is payable in shares of Common Stock, (ii) subdivides outstanding shares of Common Stock into a larger number of shares, or (iii) combines outstanding shares of Common Stock into a smaller number of shares, then in each such case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, and any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the effective date of such subdivision or combination.

 

(b) Fundamental Transactions . If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation of the Company with or into another Person, in which the Company is not the survivor, (ii) the Company effects any sale of all or substantially all of its assets or a majority of its Common Stock is acquired by a third party, in each case, in one or a series of related transactions, (iii) any tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which all or substantially all of the holders of Common Stock are permitted to tender or exchange their shares for other securities, cash or property, or (iv) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by Section 10(a) above), then the Holder shall have the right thereafter to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant (the “Alternate Consideration” ). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. The Company shall use its reasonable best efforts to ensure that at the Holder’s option and request, any successor to the Company or surviving entity in such Fundamental Transaction shall issue to the Holder a new warrant substantially in the form of this Warrant and consistent with the foregoing provisions and evidencing the Holder’s right to purchase the Alternate Consideration for the aggregate Exercise Price upon exercise thereof. The Company shall use its reasonable best efforts to ensure that the terms of any agreement pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this paragraph (b) and ensuring that the Warrant (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction.

 
 
5
 

 

(c) Number of Warrant Shares . Simultaneously with any adjustment to the Exercise Price pursuant to this Section 10 , the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the adjusted number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment to the Exercise Price and the number of Warrant Shares.

  

(d) Calculations . All calculations under this Section 10 shall be made to the nearest cent or the nearest 1/100 th of a share, as applicable. The number of shares of Common Stock outstanding at any given time shall not include shares owned or held by or for the account of the Company, and the disposition of any such shares shall be considered an issue or sale of Common Stock.

 

(e) Notice of Adjustments . Upon the occurrence of each adjustment pursuant to this Section 10 , the Company at its expense will promptly compute such adjustment in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company’s Transfer Agent.

 

(f) Notice of Corporate Events . If the Company (i) declares a dividend or any other distribution of cash, securities or other property in respect of its Common Stock, including without limitation any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any Subsidiary, (ii) authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, then the Company shall deliver to the Holder a notice describing the material terms and conditions of such transaction (but only to the extent such disclosure would not result in the dissemination of material, non-public information to the Holder) at least 10 calendar days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction, and the Company will take all steps reasonably necessary in order to ensure that the Holder is given the practical opportunity to exercise this Warrant prior to such time so as to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice.

 

11. Payment of Exercise Price . The Holder may pay the Exercise Price in immediately available funds.

 
 
6
 

 

12. Limitations on Exercise . The Company shall not effect the exercise of this Warrant, and the Holder shall not have the right to exercise this Warrant, to the extent that after giving effect to such exercise, the Holder (together with such Holder’s affiliates and any Persons acting as a group together with the Holder or any Holder’s affiliates) would beneficially own in excess of 9.99% (“ Maximum Percentage ”) of the shares of Common Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Holder and its affiliates, and any Persons acting as a group together with such Holder and such Holder’s affiliates, shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon (A) exercise of the remaining, unexercised portion of this Warrant beneficially owned by such Holder and its affiliates, and any Persons acting as a group together with such Holder and such Holder’s affiliates and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such Holder and its affiliates, and any Persons acting as a group together with such Holder and such Holder’s affiliates (including, without limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act. The Warrant Agent shall not be responsible for calculating beneficial ownership in accordance with the provisions of this Section 12 . To the extent that the limitation contained in this Section 12 applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any affiliate, and any persons acting as a group together with such Holder and such Holder’s affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and Holder’s submission of an Exercise Notice shall be deemed to be the Holder’s determination of whether a Warrant is exercisable (in relation to any other securities owned by the Holder together with any affiliates, and any persons acting as a group together with such Holder and such Holder’s affiliates) and of which portion of a Warrant is exercisable, in each case subject to the Maximum Percentage, and the Company shall have no obligation to verify or confirm the accuracy of such determination. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (1) the Company’s most recent Form 10-K, Form 10-Q, Current Report on Form 8-K or other public filing with the Securities and Exchange Commission, as the case may be, (2) a more recent public announcement by the Company or (3) any other notice by the Company setting forth the number of shares of Common Stock outstanding. For any reason at any time, upon the written or oral request of the Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and its affiliates, and any Persons acting as a group together with such Holder and such Holder’s affiliates, since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, Holder may remove the limitations on exercises provided in this Section 12 entirely; provided that (i) any such removal will not be effective until the 61st day after such notice is delivered to the Company, and (ii) any such removal will apply only to the Holder sending such notice and not to any other holder of Warrants. For purposes of clarity, the shares of Common Stock issuable pursuant to this Warrant in excess of the Maximum Percentage for the Holder shall not be deemed to be beneficially owned by such Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the Exchange Act. No prior inability to exercise this Warrant pursuant to this Section 12 shall have any effect on the applicability of the provisions of this paragraph with respect to any subsequent determination of exercisability. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 12 to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended beneficial ownership limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

 
 
7
 

 

13. No Fractional Shares . No fractional shares of Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares which would, otherwise be issuable, the Company shall pay cash equal to the product of such fraction multiplied by the closing price of one Warrant Share as reported by the applicable Trading Market on the date of exercise.

 

14. Notices . All notices and other communications hereunder shall be in writing and shall be deemed given if delivered personally or by overnight courier service or sent via facsimile (receipt confirmed) or via electronic mail transmission (“email”) to the parties at the following addresses or facsimile numbers:

 

If to the Company :

 

1620 Beacon Place

Oxnard, CA 93033

Tel: (805) 824-0410

Fax: (805) 487-7163

Email: RDavidson@curepharmaceutical.com

 

If to the Holder :

 

· ]

 

with all such notices and other communications becoming effective (a) if sent via facsimile, when transmitted and confirmation is received, provided such notice is sent on or before 5:00 P.M. Pacific Standard Time on a Business Day and, if not, on the next Business Day, (b) if sent via email, when transmitted on or before 5:00 P.M. Pacific Standard Time on a Business Day, and if not, on the next Business Day (provided that such sent email is kept on file (whether electronically or otherwise) by the sending party and the sending party does not immediately receive an automatically generated message from the recipient’s electronic mail server that such email could not be delivered to such recipient), (c) if sent via overnight courier service, one Business Day after deposit with an overnight courier service, or (d) if personally delivered, upon delivery. The addresses or facsimile number of a party for such notices or communications may be changed by such party by two Trading Days’ prior notice to the other party in accordance with this Section 14 .

 
 
8
 

 

15. Warrant Agent . The Company shall serve as warrant agent under this Warrant. Upon 10 calendar days’ notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause a written notice of its succession as warrant agent to be delivered in accordance with Section 14 herein to the Holder.

 

16. Market Standoff Agreement . The Holder and each transferee of this Warrant (or any replacement issued hereunder) agrees in connection with any registration of the Company’s securities, upon notice by the Company or the underwriters managing any underwritten public offering of the Company’s securities, not to sell, make any short sale of, loan, pledge (or otherwise encumber or hypothecate), grant any option for the purchase of, or otherwise directly or indirectly dispose of this Warrant or any Warrant Shares without the prior written consent of the Company and such managing underwriters for such period of time as the Board of Directors establishes pursuant to its good faith negotiations with such managing underwriters, which period shall not exceed 180 days. The Holder agrees to execute such additional agreements as the managing underwriters may require to effect the intent of this provision. The Holder hereby consents to the placement of stop transfer orders with the Company’s transfer agent in order to enforce the foregoing provision. Notwithstanding the foregoing, the obligations described in this Section 16 shall not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms which may be promulgated in the future, or a registration relating solely to an SEC Rule 145 transaction on Form S-4 or similar forms which may be promulgated in the future.

 

17. Call Rights . The Company shall have the right to call the exercise of all, or the remaining portion of this Warrant outstanding and unexercised at the then-current Exercise Price at any time after the effective date of the Company’s Uplisting (the “ Call Condition ”). In the event the Call Condition is satisfied and the Company desires to exercise its call rights under this Section 17 , the Company shall deliver a notice to each registered Holder of the Warrants setting forth the number of Warrants held by Holder being called for exercise (the “ Call Amount ”) and the dollar amount due to exercise the Warrants (the “ Call Notice ”). Each Holder shall have fifteen (15) calendar days from the receipt of the Call Notice to exercise the Call Amount of the Warrants (the “ Call Period ”). The date on which the Call Amount is exercised is referred to herein as the “ Forced Exercise Date .” Upon the expiration of the Call Period, any remaining portion of this Warrant which had been called but remained unexercised shall automatically expire. Notwithstanding anything herein to the contrary, (a) in connection with the Company’s exercise of its call rights under this Section 17 , the Maximum Percentage limitation on exercise set forth in Section 12 herein shall not apply; and (b) if, after the call right under this Section 17is exercised, the stated Expiration Date of this Warrant would occur prior to the last day of the Call Period, the “Expiration Date” hereof shall be extended to last day of the Call Period solely to the extent necessary to enable this Warrant to be exercised for the Call Amount on the Forced Exercise Date.

 
 
9
 

 

18. Miscellaneous .

 

(a) This Warrant shall be binding on and inure to the benefit of the parties hereto and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder and their successors and assigns.

 

(b) All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of this Warrant and the transactions herein contemplated ( “Proceedings” ) (whether brought against a party hereto or its respective Affiliates, employees or agents) shall be commenced exclusively in the California Courts. Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the California Courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any Proceeding, any claim that it is not personally subject to the jurisdiction of any California Court, or that such Proceeding has been commenced in an improper or inconvenient forum. Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Each party hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Warrant or the transactions contemplated hereby. If either party shall commence a Proceeding to enforce any provisions of this Warrant, then the prevailing party in such Proceeding shall be reimbursed by the other party for its attorney’s fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Proceeding.

 

(c) If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.

 

(d) The Holder, by acceptance hereof, acknowledges and agrees that the Warrant Shares acquired upon the exercise of this Warrant will have restrictions upon resale imposed by state and federal securities laws.

 

(e) The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.

 

(f) In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby and the parties will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant.

 

(g) Prior to exercise of this Warrant, the Holder hereof shall not, by reason of being a Holder, be entitled to any rights of a stockholder with respect to the Warrant Shares.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK, SIGNATURE PAGE FOLLOWS]

 

 
10
 

 

IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.

 

 

MAKKANOTTI GROUP CORP.

       
By: /s/ Robert Davidson

 

 

Robert Davidson  
    Chief Executive Officer  

  
 
11
 

   

SCHEDULE 1

 

FORM OF EXERCISE NOTICE

 

(To be executed by the Holder to exercise the right to purchase shares

of Common Stock under the foregoing Warrant)

 

The undersigned is the Holder of Warrant No. __ (the “ Warrant ”) issued by Makkanotti Group Corp., a Nevada corporation (the “ Company ”). Capitalized terms used herein and not otherwise defined have the respective meanings set forth in the Warrant.

 

(1)

The undersigned Holder hereby exercises its right to purchase _________________ Warrant Shares pursuant to the Warrant.

 

(2)

The holder shall pay the sum of $____________ to the Company in accordance with the terms of the Warrant.

 

(3)

Pursuant to this Exercise Notice, the Company shall deliver to the holder _______________ Warrant Shares in accordance with the terms of the Warrant.

 

(4)

By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 12 of this Warrant to which this notice relates.

 

Dated: ____________, ______

 

Name of Holder (Print):  _______________________________________________

 

By: _________________________________________

Name: _______________________________________

Title: ________________________________________

 

(Signature must conform in all respects to name of holder as specified on the face of the Warrant)

 

 
12
 

 

SCHEDULE 2

 

FORM OF ASSIGNMENT

 

[To be completed and signed only upon transfer of Warrant]

 

FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto _______________________ (the “ Transferee ”) the right represented by the within Warrant to purchase __________________ shares of Common Stock of Makkanotti Group Corp. (the “ Company ”) to which the within Warrant relates and appoints ____________________ attorney to transfer said right on the books of the Company with full power of substitution in the premises. In connection therewith, the undersigned represents, warrants, covenants and agrees to and with the Company that:

 

(a) the offer and sale of the Warrant contemplated hereby is being made in compliance with Section 4(1) of the United States Securities Act of 1933, as amended (the “ Securities Act ”) or another valid exemption from the registration requirements of Section 5 of the Securities Act and in compliance with all applicable securities laws of the states of the United States;

 

(b) the undersigned has not offered to sell the Warrant by any form of general solicitation or general advertising, including, but not limited to, any advertisement, article, notice or other communication published in any newspaper, magazine or similar media or broadcast over television or radio, and any seminar or meeting whose attendees have been invited by any general solicitation or general advertising;

 

(c) the undersigned has read the Transferee’s written statement included herewith, and to its actual knowledge, the statements made therein are true and correct; and

 

(d) the undersigned understands that the Company may condition the transfer of the Warrant contemplated hereby upon the delivery to the Company by the undersigned or the Transferee, as the case may be, of a written opinion of counsel (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that such transfer may be made without registration under the Securities Act and under applicable securities laws of the states of the United States.

 

Dated: ____________, ______

 

Name of Holder (Print): _______________________________________________

 

By: ___________________________________________

Name: _________________________________________

Title: __________________________________________

 

(Signature must conform in all respects to name of holder as specified on the face of the Warrant)

 

  

Address of Transferee:

 

 

Transferee Fax No.:

 

 

Transferee Email Address:

 

 

 

 

 

13

 

 

EXHIBIT 21.1

 

SUBSIDIARIES

 

Cure Pharmaceutical Corporation, a California corporation

 

EXHIBIT 99.1

 

FINANCIAL STATEMENTS

Cure Pharmaceutical Corporation

 

Report of Independent Registered Public Accounting Firm

 

F-2

Balance Sheets

 

F-3

Statements of Operations

 

F-4

Statement of Stockholders’ Deficit

 

F-5

Statements of Cash Flows

 

F-6

Notes to Financial Statements

 

F-7

 
 
F-1
 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Stockholders of

CURE Pharmaceutical Corporation

 

We have audited the accompanying balance sheets of CURE Pharmaceutical Corporation as of December 31, 2015 and 2014, and the related statements of operations, stockholders’ deficit, and cash flows for each of the years in the two-year period ended December 31, 2015. CURE Pharmaceutical Corporation’s management is responsible for these financial statements. Our responsibility is to express an opinion on these financial statements based on our audits.

 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements , assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

 

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of CURE Pharmaceutical Corporation as of December 31, 2015 and 2014, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2015, in conformity with accounting principles generally accepted in the United States of America.

 

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered losses from operations, which raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

 

RBSM, LLP

 

Henderson, Nevada

 

November 10, 2016

 

 
F-2
 

 

Cure Pharmaceutical Corporation

Balance Sheets

(Audited)

 

 

 

December 31,

2015

 

 

December 31,
2014

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash

 

$ 13,352

 

 

$ 4,206

 

Restricted cash

 

 

49,980

 

 

 

-

 

Accounts receivable (less allowance of $100,000 for 2014)

 

 

1,907

 

 

 

114,798

 

Note receivable

 

 

17,948

 

 

 

-

 

Inventory

 

 

191,465

 

 

 

178,483

 

Prepaid expenses and other assets

 

 

38,122

 

 

 

44,241

 

Total current assets

 

 

312,774

 

 

 

341,728

 

Property and equipment, net

 

 

381,830

 

 

 

311,721

 

Intangibles, net

 

 

949,725

 

 

 

924,954

 

Other assets

 

 

177,820

 

 

 

286,204

 

Total assets

 

$ 1,822,149

 

 

$ 1,864,607

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders' Deficit

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$ 614,250

 

 

$ 322,665

 

Accrued expenses

 

 

297,905

 

 

 

272,307

 

Current portion of loan payable

 

 

17,188

 

 

 

17,186

 

Current portion of notes payable

 

 

402,874

 

 

 

50,000

 

Current portion of capital lease payable

 

 

11,362

 

 

 

10,064

 

Current portion of related party convertible promissory notes

 

 

412,212

 

 

 

-

 

Current portion of convertible promissory notes

 

 

3,114,889

 

 

 

216,889

 

Deferred revenue

 

 

215,519

 

 

 

622,123

 

Total current liabilities

 

 

5,086,199

 

 

 

1,511,234

 

License Fees

 

 

560,000

 

 

 

200,000

 

Capital lease payable

 

 

9,453

 

 

 

20,815

 

Convertible promissory notes

 

 

-

 

 

 

2,363,000

 

Total liabilities

 

 

5,655,652

 

 

 

4,095,049

 

 

 

 

 

 

 

 

 

 

Stockholders' Deficit:

 

 

 

 

 

 

 

 

Common stock: $0.0001 par value; authorized 10,000,000 shares; 2,000,000 shares issued and outstanding as of December 31, 2015 and 2014

 

 

200

 

 

 

200

 

Additional paid-in capital

 

 

2,727,531

 

 

 

2,727,531

 

Accumulated deficit

 

 

(6,561,234 )

 

 

(4,958,173 )

Total stockholders' deficit

 

 

(3,833,503 )

 

 

(2,230,442 )

Total liabilities and stockholders' deficit

 

$ 1,822,149

 

 

$ 1,864,607

 

 

The accompanying notes are an integral part of these financial statements

 
 
F-3
 

 

Cure Pharmaceutical Corporation

Statements of Operations

(Audited)

 

 

 

For the Year Ended December 31,

2015

 

 

For the Year Ended December 31,
2014

 

Revenue

 

 

 

 

 

 

Net product sales

 

$ 150,439

 

 

$ 235,676

 

Consulting research & development income

 

 

25,225

 

 

 

990,798

 

Shipping and other sales

 

 

7,766

 

 

 

16,156

 

Total revenues

 

 

183,430

 

 

 

1,242,630

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

 

117,012

 

 

 

205,117

 

Gross profit

 

 

66,418

 

 

 

1,037,513

 

 

 

 

 

 

 

 

 

 

Research and development expenses

 

 

681,699

 

 

 

663,899

 

Selling, general and administrative expenses

 

 

920,247

 

 

 

914,736

 

Total costs and expenses

 

 

1,601,946

 

 

 

1,783,752

 

Net loss from operations

 

 

(1,535,528 )

 

 

(541,122 )

Other income (expense):

 

 

 

 

 

 

 

 

Interest income

 

 

199

 

 

 

10,913

 

Other income

 

 

177,892

 

 

 

36,390

 

Loss on Disposal of PP&E

 

 

-

 

 

 

(6,396 )

Other expense

 

 

(72,160 )

 

 

(68,871 )

Interest expense

 

 

(173,464 )

 

 

(95,753 )

Other income (expense)

 

 

(67,533 )

 

 

(123,717 )

Net loss before income taxes

 

 

(1,603,061 )

 

 

(664,839 )

Provision for income taxes

 

 

-

 

 

 

-

 

Net loss

 

$ (1,603,061 )

 

$ (664,839 )

Net loss per share, basic and diluted

 

$ (0.80 )

 

$ (0.33 )

Weighted average shares outstanding, basic and diluted

 

 

2,000,000

 

 

 

2,000,000

 

 

The accompanying notes are an integral part of these financial statements

 

 
F-4
 

 

Cure Pharmaceutical Corporation

Statement of Stockholders’ Deficit

(Audited)

 

 

 

Common stock

 

 

Additional Paid in

 

 

Accumulated

 

 

Total
Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Deficit

 

Balance as of December 31, 2013

 

 

2,000,000

 

 

$ 200

 

 

$ 2,727,531

 

 

$ (4,293,334 )

 

$ (1,565,603 )

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(664,839 )

 

 

(664,839 )

Balance as of December 31, 2014

 

 

2,000,000

 

 

 

200

 

 

 

2,727,531

 

 

 

(4,958,173 )

 

 

(2,230,442 )

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(1,603,061 )

 

 

(1,603,061 )

Balance as of December 31, 2015

 

 

2,000,000

 

 

$ 200

 

 

$ 2,727,531

 

 

$ (6,561,234 )

 

$ (3,833,503 )

 

The accompanying notes are an integral part of these financial statements

 

 
F-5
 

 

Cure Pharmaceutical Corporation

Statements of Cash Flows

(Audited)

 

 

 

For the Year Ended

 

 

For the Year Ended

 

 

 

December 31,
2015

 

 

December 31,
2014

 

Cash flows from operating activities

 

 

 

 

 

 

Net loss

 

$ (1,603,061 )

 

$ (664,839 )

Adjustment to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and Amortization

 

 

157,546

 

 

 

151,201

 

Loss on Disposal of PP&E

 

 

-

 

 

 

6,396

 

Change in other assets and liabilities:

 

 

 

 

 

 

 

 

Restricted cash

 

 

(49,980 )

 

 

-

 

Accounts receivable

 

 

112,891

 

 

 

(53,481 )

Inventory

 

 

(12,982 )

 

 

352

 

Prepaid expenses and other assets

 

 

6,119

 

 

 

(9,818 )

Other assets

 

 

108,384

 

 

 

(116,324 )

Accounts payable

 

 

291,585

 

 

 

(67,029 )

Accrued expenses

 

 

348,810

 

 

 

170,481

 

Deferred revenue

 

 

(121,404 )

 

 

64,147

 

License fees

 

 

360,000

 

 

 

200,000

 

Net cash used in operating activities

 

 

(402,092 )

 

 

(318,914 )

Cash flows from investing activities

 

 

 

 

 

 

 

 

Advanced on note receivable

 

 

(17,948 )

 

 

-

 

Purchases on intangible assets

 

 

(66,031 )

 

 

(203,790 )

Acquisition of property and equipment, net

 

 

(186,395 )

 

 

(47,179 )

Net cash used in investing activities

 

 

(270,374 )

 

 

(250,969 )

Cash flows from financing activities

 

 

 

 

 

 

 

 

Proceeds from loan

 

 

813,009

 

 

 

507,009

 

Loan repayments

 

 

(121,333 )

 

 

(20,272 )

Capital lease payments

 

 

(10,064 )

 

 

(8,915 )

Net cash provided by financing activities

 

 

681,612

 

 

 

477,822

 

 

 

 

 

 

 

 

 

 

Net increase (decrease) in cash and cash equivalents

 

 

9,146

 

 

 

(92,061 )

Cash and cash equivalents, beginning of period

 

 

4,206

 

 

 

96,267

 

Cash and cash equivalents, end of period

 

$ 13,352

 

 

$ 4,206

 

Supplemental cash flow information

 

 

 

 

 

 

 

 

Cash paid for interest and income taxes:

 

 

 

 

 

 

 

 

Interest

 

$ 67,211

 

 

$ 5,415

 

Income taxes

 

$ -

 

 

$ -

 

Non-cash financing activities:

 

 

 

 

 

 

 

 

Accrued expenses converted to related party convertible

 

 

 

 

 

 

 

 

promissory notes

 

$ 323,212

 

 

$ -

 

Deferred revenue converted to note payable

 

$ 285,200

 

 

$ -

 

 

The accompanying notes are an integral part of these financial statements

 

 
F-6
 

 

CURE PHARMACEUTICAL CORPORATION.

NOTES TO FINANCIAL STATEMENTS

 

Note 1 - Nature of the Business

 

Cure Pharmaceutical Corporation (“Cure”, “we”, “us”, “our” or the “Company”) is a specialty pharmaceutical and bioscience company with a focus in drug delivery technologies. Cure leverages novel drug delivery technologies to develop and commercialize new applications of proven therapeutics through Oral Thin Film (“OTF”) via our proprietary patented CureFilm™ Technology as well as through transdermal applications. Our micro encapsulation of drug actives in our CureFilm™ Technology allows for a higher volume of an active and if required, multiple actives to be produced on a single oral thin film strip.

 

The Company is focused on partnering with pharmaceutical and biotech companies seeking to deliver drug actives utilizing and benefitting from our proprietary OTF and transdermal applications and when preferable to take our own products from clinical process to commercialization. We are focused on both the human and veterinary prescription, OTC and nutraceutical markets. Cure represents the complete solution for OTF drug delivery therapeutics from inception to finished product utilizing our CGMP/FDA registered manufacturing facility and processes.

 

Note 2 - Summary of Significant Accounting Policies

 

Use of Estimates

 

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. At December 31, 2015 and 2014 included in these estimates are assumptions about collection of accounts receivable, and useful life of fixed and intangible assets.

 

Cash and Cash Equivalents

 

The Company considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid investments with maturities of three months or less, when purchased, to be cash and cash equivalents. As of December 31, 2015 and 2014 the Company had no cash equivalents. The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (“FDIC”) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. At December 31, 2015 and 2014, the company does not have any uninsured balances.

 

Restricted Cash

 

Restricted cash consists $49,980 of total funds received in an escrow account from accredited investors. These funds are in relation to convertible promissory notes issued to these accredited investors. The funds held in the escrow account will remain in there until all obligations are met in relation to the convertible promissory notes.

 

Capitalization of Property and Equipment

 

The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one year for: (1) assets purchased; (2) existing assets that are replaced, improved or the useful lives have been extended; or (3) all land, regardless of cost. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs, including any planned major maintenance activities, are expensed as incurred.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with the Financial Accounting Standards Board’s (“FASB”), Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. The Company believes that these criteria are satisfied upon shipment from our facility. Freight billed to customers is presented as revenues, and the related freight costs are presented as cost of goods sold. Deferred revenue is recognized when earned and all significant obligations have been satisfied.

 

Accounts receivable

 

Accounts receivable are generally unsecured. The Company establishes an allowance for doubtful accounts receivable based on the age of outstanding invoices and management’s evaluation of collectability. Accounts are written off after all reasonable collection efforts have been exhausted and management concludes that likelihood of collection is remote. Any future recoveries are applied against the allowance for doubtful accounts.

 
 
F-7
 

 

Advertising Expense

 

The Company expenses marketing, promotions and advertising costs as incurred. Such costs are included in general and administrative expense in the accompanying statements of operations. The Company recorded advertising costs of $1,813 for the year ended December 31, 2015. No advertising costs were recorded for the year ended December 31, 2014.

 

Research and Development

 

Costs incurred in connection with the development of new products and processes and are charged to research and development expenses as incurred.

 

Income Taxes

 

The Company utilizes FASB ASC 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized.

 

The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of 100% has been established due to the uncertainty of the Company’s realization of the net operating loss carry forward prior to its expiration.

 

Basic and diluted loss per share

 

Basic loss per share is computed by dividing the net loss to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed by dividing the net loss for the period by the weighted average number of common and dilutive common equivalent shares outstanding during the period. Common equivalent shares, which consist of stock options and warrants, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.

 

Going Concern

 

The Company’s financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit at December 31, 2015 of $6,561,234. The Company had a working capital deficit of $4,773,425 as of December 31, 2015. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it establishes a revenue stream and becomes profitable. The Company is continually analyzing its current costs and is attempting to make additional cost reductions where possible. We expect that we will continue to generate losses from operations throughout 2016.

 

In order to continue as a going concern and to develop a reliable source of revenues, and achieve a profitable level of operations the Company will need, among other things, additional capital resources. Management’s plans to continue as a going concern include raising additional capital through borrowing and/or sales of equity and debt securities. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.

 

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.

 

Fair Value Measurements

 

The Company measures and discloses the fair value of assets and liabilities required to be carried at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value, establishes a framework for measuring fair value, and enhances fair value measurement disclosure.

 
 
F-8
 

 

ASC 825 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825 establishes three levels of inputs that may be used to measure fair value:

 

Level 1 - Quoted prices for identical assets or liabilities in active markets to which we have access at the measurement date.

 

Level 2 - Inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly.

 

Level 3 - Unobservable inputs for the asset or liability.

 

The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

 

As of December 31, 2015 and 2014, the Company has determined that there were no assets or liabilities measured at fair value.

 

Inventory

 

Inventory consists of raw materials, packaging components, work-in-process and finished goods. The Company’s inventory is stated at the lower of cost (FIFO cost basis) or market. Finished goods include the cost of labor to assemble the items.

 

Long-lived Assets

 

Long-lived assets include equipment and intangible assets other than those with indefinite lives. We assess the carrying value of our long-lived asset groups when indicators of impairment exist and recognize an impairment loss when the carrying amount of a long-lived asset is not recoverable when compared to undiscounted cash flows expected to result from the use and eventual disposition of the asset.

 

Indicators of impairment include significant underperformance relative to historical or projected future operating results, significant changes in our use of the assets or in our business strategy, loss of or changes in customer relationships and significant negative industry or economic trends. When indications of impairment arise for a particular asset or group of assets, we assess the future recoverability of the carrying value of the asset (or asset group) based on an undiscounted cash flow analysis. If carrying value exceeds projected, net, undiscounted cash flows, an additional analysis is performed to determine the fair value of the asset (or asset group), typically a discounted cash flow analysis, and an impairment charge is recorded for the excess of carrying value over fair value. As of December 31, 2015 and 2014, our qualitative analysis of long-lived assets did not indicate any impairment.

 

Concentrations of Credit Risk

 

In the normal course of business, the Company provided credit terms to its customers; however, collateral was not required. Accordingly, the Company performed credit evaluations of its customers and maintained allowances for possible losses which, when realized, were within the range of management’s expectations. From time to time, a higher concentration of credit risk existed on outstanding accounts receivable for a select number of customers due to individual buying patterns.

 

Cost of Sales

 

Cost of sales includes the purchase cost of products sold and all costs associated with getting the products to our customers, including transportation costs.

 

Shipping Costs

 

Shipping and handling costs billed to customers are recorded in sales. Shipping costs incurred by the company are recorded in selling, general and administrative expenses.

 
 
F-9
 

 

Related parties

 

Parties are considered to be related to the Company if the parties that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. All transactions with related parties shall be recorded at fair value of the goods or services exchanged.

 

Segment Reporting

 

Segment identification and selection is consistent with the management structure used by the Company’s chief operating decision maker to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company’s management structure and method of internal reporting, the Company has one operating segment. The Company’s chief operating decision maker does not review operating results on a disaggregated basis; rather, the chief operating decision maker reviews operating results on an aggregate basis.

 

Recent Accounting Pronouncements

 

ASU 2015-03

 

In April 2015, the FASB issued Accounting Standards Update (“ASU”) No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. The amendments are effective for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The amendments are to be applied on a retrospective basis, wherein the balance sheet of each individual period presented is adjusted to reflect the period-specific effects of applying the new guidance. The Company is evaluating the possible effect of this guidance on its financial statements.

 

ASU 2015-01

 

In January 2015, the FASB issued ASU No. 2015-01, “Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items.” This ASU eliminates from U.S. GAAP the concept of extraordinary items. ASU 2015-01 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. A reporting entity may apply the amendments prospectively. We do not expect the adoption of ASU 2015-01 to have a material effect on our financial position, results of operations or cash flows.

 

ASU 2014-16

 

In November 2014, the FASB issued ASU 2014-16, “Derivatives and Hedging (Topic 815).” ASU 2014-16 addresses whether the host contract in a hybrid financial instrument issued in the form of a share should be accounted for as debt or equity. ASU 2014-16 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. We do not currently have issued, nor are we investors in, hybrid financial instruments. Accordingly, we do not expect the adoption of ASU 2014-16 to have any effect on our financial position, results of operations or cash flows.

 

ASU 2014-15

 

In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40)”. ASU 2014-15 provides guidance related to management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosure. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and for interim and annual periods thereafter. Early application is permitted. We do not expect the adoption of ASU 2014-15 to have a material effect on our financial position, results of operations or cash flows.

 

 
F-10
 

 

ASU 2014-09

 

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 affects any entity using U.S. GAAP that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). ASU 2014-09 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. We are still evaluating the effect of the adoption of ASU 2014-09. In August 2015, the FASB issued ASU 2015-14, which defers the effective date of ASU 2014-09 by one year for all entities and permits early adoption on a limited basis. ASU 2014-09 will be effective for the Company in the first quarter of 2018, and early adoption permitted in the first quarter of 2017. The Company does not believe the adoption of this ASU will have a material impact on its financial statements.

 

ASU 2014-08

 

In April 2014, the FASB issued ASU No. 2014-08, “Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360) and Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity.” ASU 2014-08 amends the definition for what types of asset disposals are to be considered discontinued operations, as well as amending the required disclosures for discontinued operations and assets held for sale. ASU 2014-08 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2014. The adoption of ASU 2014-08 did not have any effect on our financial position, results of operations or cash flows.

 

ASU 2015-11

 

On July 22, 2015, the FASB issued ASU 2015-11, which requires entities to measure most inventory “at the lower of cost and net realizable value,” thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market (market in this context is defined as one of three different measures). ASU 2015-11 will not apply to inventories that are measured by using either the last-in, first-out (LIFO) method or the retail inventory method (RIM). ASU 2015-11 is effective prospectively for annual periods beginning after December 15, 2016, and interim periods thereafter. Early application of the ASU is permitted. Upon transition, entities must disclose the nature of and reason for the accounting change. The Company does not believe the adoption of this ASU will have a material impact on its financial statements.

 

There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

 

The Company has not filed its 2015 and 2014 Federal and State income tax returns. Such income tax returns remain subject to examination by federal and most state tax authorities.

 

Note 3 - Accounts Receivable

 

Accounts receivable, net of allowances for sales returns and doubtful accounts, consisted of the following:

 

 

 

December 31,
2015

 

 

December 31,
2014

 

Trade accounts receivable

 

$ 1,907

 

 

$ 214,798

 

Less allowances

 

 

-

 

 

 

(100,000 )

Total accounts receivable, net

 

$ 1,907

 

 

$ 114,798

 

 

Note 4 - Concentration of Credit Risk

 

Accounts receivable

 

As of December 31, 2015, one customer accounted for 100% of the Company’s accounts receivable.

 

Major customers

 

For the year ended December 31, 2015, four customers accounted for approximately 81% of the Company’s revenues. Substantially all of the Company’s business is with companies in the United States.

 

 
F-11
 

 

Note 5 - Inventory

 

Inventory consists of raw materials, packaging components, work-in-process and finished goods. The Company’s inventory is stated at the lower of cost (FIFO cost basis) or market.

 

The carrying value of inventory consisted of the following:

 

 

 

December 31,
2015

 

 

December 31,
2014

 

Raw Materials

 

$ 75,800

 

 

$ 89,958

 

Packaging Components

 

 

88,454

 

 

 

62,392

 

Work-In-Process

 

 

27,211

 

 

 

53,770

 

Finished Goods

 

 

-

 

 

 

2,615

 

 

 

 

191,465

 

 

 

208,735

 

Reserve for Obsolescence

 

 

-

 

 

 

(30,252 )

Total inventory

 

$ 191,465

 

 

$ 178,483

 

 

Note 6 – Property and Equipment and Intangible Assets

 

As of December 31, 2015 and 2014, property and equipment and intangible assets consisted of the following:

 

 

 

December 31,
2015

 

 

December 31,
2014

 

 

 

 

 

 

 

 

Manufacturing equipment

 

$ 488,733

 

 

$ 488,733

 

Computer and other equipment

 

 

58,767

 

 

 

57,756

 

Leasehold improvements

 

 

30,616

 

 

 

30,616

 

Construction in progress

 

 

224,969

 

 

 

39,585

 

Less accumulated depreciation

 

 

(421,255 )

 

 

(304,969 )

Property and Equipment, net

 

$ 381,830

 

 

$ 311,721

 

 

Depreciation expense for the years ended December 31, 2015 and 2014 was $116,286 and $140,005, respectively, which includes depreciation of $8,640 for capitalized leased assets for the years ended December 31, 2015 and 2014. The total amount of property held under a under a capital lease was $43,201 as of December 31, 2015 and 2014. Accumulated depreciation for property held under capital leases were $19,897 and $11,256 as December 31, 2015 and 2014, respectively.

 

 

 

December 31,
2015

 

 

December 31,

2014

 

 

 

 

 

 

 

 

Intellectual Property

 

$ 814,582

 

 

$ 814,582

 

Patents

 

 

186,173

 

 

 

121,445

 

Less accumulated amortization

 

 

(51,030 )

 

 

(11,073 )

Intangible assets, net

 

$ 949,725

 

 

$ 924,954

 

 

Amortization expense for the years ended December 31, 2015 and 2014 was $41,260 and $11,196, respectively.

 

The estimated aggregate amortization expense over each of the next five years is as follows:

 

2016

 

$ 42,663

 

2017

 

 

42,663

 

2018

 

 

42,663

 

2019

 

 

42,663

 

2020

 

 

42,663

 

Thereafter

 

 

585,589

 

Total Amortization

 

$ 798,904

 

 
 
F-12
 

 

Note 7 – Note Receivable

 

Note receivable consists of the following at December 31, 2015 and 2014:

 

 

 

2015

 

 

2014

 

 

 

 

 

 

 

 

 

 

The note receivable is a promissory note with a company bearing an interest rate of 8% per annum, principal and accrued and unpaid interest is payable on demand of the Company any time before November 11, 2016 or by November 11, 2016 if no demand is made prior to such date

 

 

17,948

 

 

 

-

 

 

 

 

17,948

 

 

 

-

 

Current portion of note receivable

 

 

17,948

 

 

 

-

 

Note receivable, less current portion

 

$ -

 

 

$ -

 

 

Note 8 - Related Party Transactions

 

On October 3, 2014, the Company obtained a short-term loan from Jonathan Turman in the amount of $1,000. This loan is non-interest bearing, unsecured and has no fixed terms of repayment.

 

On October 22, 2014, the Company obtained a short-term loan from Jonathan Turman in the amount of $1,000. This loan is non-interest bearing, unsecured and has no fixed terms of repayment.

 

On various dates from October 31, 2014 to February 2, 2015, the Company issued convertible promissory notes to Ronick totaling $89,000 that are due on February 25, 2016. Robert Davidson is a shareholder of Ronick. Interest is payable at 3% per annum and is secured by technology and patent rights. Principal and accrued interest is convertible into common stock at $4.00 per share. This conversion is subject to an adjustment if the Company sells stock or grants conversion rates at a lower price; however, Ronick has subsequently agreed to waive these conversion rights and will convert at $4.00 per share.

 

On April 15, 2015, the Company obtained a short-term loan from Jonathan Turman in the amount of $20,000. This loan is non-interest bearing, unsecured and has no fixed terms of repayment.

 

On May 6, 2015, the Company obtained a short-term loan from Jonathan Turman in the amount of $4,000. This loan is non-interest bearing, unsecured and has no fixed terms of repayment.

 

On December 31, 2015, the Company converted $100,150 of accrued payroll for Robert Davidson into a convertible promissory note. (see Note 12).

 

On December 31, 2015, the Company converted $94,312 of accrued payroll for Wayne Nasby into a convertible promissory note. (see Note 12).

 

On December 31, 2015, the Company converted $77,250 of accrued payroll for Edward Maliski into a convertible promissory note. (see Note 12).

 

On December 31, 2015, the Company converted $51,500 of accrued payroll for Jonathan Turman into a convertible promissory note. (see Note 12).

 

At December 31, 2015, Robert Davidson and Mark Udell had $50,772 and $12,377, respectively, due to them and are included in accounts payable. At December 31, 2014, Robert Davidson had $24,126 due to him and is included in accounts payable.

 

 
F-13
 

 

Note 9 – Capital Lease Obligations

 

In 2013, the Company entered into a capital lease agreement for manufacturing equipment. The following is a schedule by years of future minimum lease payments under capital leases together with the present value of the net minimum lease payments as of December 31, 2015:

 

Years Ending December 31

 

 

 

2016

 

$ 13,278

 

2017

 

 

9,906

 

 

 

 

 

 

Total Minimum Lease Payments

 

 

23,184

 

 

 

 

 

 

Less: Amount Representing Interest

 

 

(2,369 )

 

 

 

 

 

Present Value of Net Minimum Lease Payments

 

 

20,815

 

 

 

 

 

 

Less: Current Obligations

 

 

(11,362 )

 

 

 

 

 

Non-Current Obligations Under Capital Leases

 

$ 9,453

 

 

Note 10 – Loan Payable

 

Loan payable consist of the following at December 31, 2015 and 2014:

 

 

 

2015

 

 

2014

 

 

 

 

 

 

 

 

Note to a company due September 29, 2016 including interest at 11.49% per annum; unsecured; interest due monthly

 

$ 17,188

 

 

$ 17,186

 

 

 

 

 

 

 

 

 

 

 

 

 

17,188

 

 

 

17,186

 

Current portion of loan payable

 

 

17,188

 

 

 

17,186

 

Loan payable, less current portion

 

$ -

 

 

$ -

 

 

Note 11 – Notes Payable

 

Notes payable consist of the following at December 31, 2015 and 2014:

 

 

 

2015

 

 

2014

 

 

 

 

 

 

 

 

Note to an individual, non-interest bearing, unsecured and has no fixed terms of repayment

 

$ 50,000

 

 

$ 50,000

 

Note to a company due October 14, 2016; interest payable at 5% per annum, secured by all assets of the company (excluding patents and intellectual property); principal and interest totaling $5,000 due weekly

 

 

197,874

 

 

 

-

 

Note to a company with no fixed maturity date; interest payable at 10% per month, secured by certain equipment of the company; accrued and unpaid interest due monthly

 

 

70,000

 

 

 

-

 

Note to a company due November 9, 2016; interest payable at 5% per annum, unsecured; principal and accrued and unpaid interest payable any time before November 9, 2016

 

 

85,000

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

402,874

 

 

 

50,000

 

Current portion of loan payable

 

 

402,874

 

 

 

50,000

 

Loan payable, less current portion

 

$ -

 

 

$ -

 

 
 
F-14
 

 

Note 12 – Convertible Promissory Notes

 

Convertible promissory notes consist of the following at December 31, 2015 and 2014:

 

 

2015

 

2014

 

Convertible promissory notes totaling $2,372,000 due February 25, 2016; interest payable at 3% annum; technology and patent rights; principal and accrued interest convertible into common stock at $4.00 per share (subject to adjustment if the Company sells stock or grants conversion rates at a lower price; however, holders of notes have subsequently agreed to waive these conversion rights and will convert at $4.00 per share); accrued interest due on February 25, 2016 (maturity date has been extended to August 31, 2016, but now is in default), on October 6, 2016 a portion of these notes were converted to common stock and the remaining portion of these notes were converted on October 17, 2016.

 

$

2,283,000

 

$

2,363,000

 

Convertible promissory notes totaling $250,000 to a company due February 25, 2016 including interest at 5% per annum; secured by technology and patent rights; principal and accrued interest convertible into common stock at $4.00 per share (subject to adjustment if the Company sells stock or grants conversion rates at a lower price; however, holders of notes have subsequently agreed to waive these conversion rights and will convert at $4.00 per share); accrued interest due February 25, 2016 (maturity date has been extended to August 31, 2016, but now is in default), on October 6, 2016 a portion of these notes were converted to common stock and the remaining portion of these notes were converted on October 17, 2016.

 

250,000

 

-

 

Convertible promissory notes totaling $235,000 due on various dates from November 10, 2016 to December 30, 2016; interest payable at 1% annum; unsecured; principal and accrued interest automatically convertible into common stock at $1.00 per share upon closing of a merger; accrued interest due on various dates from November 16, 2016 to December 30, 2016 (if on or prior to the maturity date, the Company completes a merger, then all accrued and unpaid interest due under these notes shall be waived).

 

285,000

 

-

 

Convertible promissory notes of $194,135 due June 7, 2013 (in default) and $22,754 due August 8, 2014 (in default); interest payable at 8% annum and a default rate of 12% per annum; secured by technology and patent rights; principal and accrued interest convertible into common stock at $5.50 per share, however, holders of these notes have subsequently agreed to convert at $4.00 per share; accrued interest due on June 7, 2013 not paid (13 holders) and accrued interest due on August 8, 2014 (4 holders), on October 6, 2016 these notes were converted to common stock.

 

216,889

 

216,889

 

Convertible promissory notes totaling $80,000 to a company due February 25, 2016 including interest at 3% per annum; secured by technology and patent rights; principal and accrued interest convertible into common stock at $4.00 per share (subject to adjustment if the Company sells stock or grants conversion rates at a lower price; however, holders of notes have subsequently agreed to waive these conversion rights and will convert at $4.00 per share); accrued interest due February 25, 2016 (maturity date has been extended to August 31, 2016, but now is in default), on October 6, 2016 a portion of these notes were converted to common stock and the remaining portion of these notes were converted on October 17, 2016

 

80,000

 

-

 

3,114,889

 

2,579,889

 

Current portion of convertible promissory notes

 

3,114,889

 

216,889

 

Convertible promissory notes, less current portion

 

$

-

 

$

2,363,000

 

 

 
F-15
 

 

Note 13 - Related Party Convertible Promissory Notes

 

Related party convertible promissory notes consist of the following at December 31, 2015 and 2014: 

 

 

2015

 

2014

 

Convertible promissory notes totaling $323,212 to related parties due December 31, 2016 including interest at 3% per annum; secured by technology and patent rights; principal and accrued interest convertible into common stock at $4.00 per share (subject to adjustment if the Company sells stock or grants conversion rates at a lower price; however, holders of notes have subsequently agreed to waive these conversion rights and will convert at $4.00 per share); accrued interest due December 31, 2016, on October 6, 2016 a portion of these notes were converted to common stock and the remaining portion of these notes converted as of October 17, 2016.

 

323,212

 

-

 

Convertible promissory note totaling $89,000 due February 25, 2016; interest payable at 3% annum; secured by technology and patent rights; principal and accrued interest convertible into common stock at $4.00 per share (subject to adjustment if the Company sells stock or grants conversion rates at a lower price; however, holders of notes have subsequently agreed to waive these conversion rights and will convert at $4.00 per share); accrued interest due on February 25, 2016 (maturity date has been extended to August 31, 2016, but now is in default), on October 6, 2016 a portion of these notes were converted to common stock and the remaining portion of these notes converted as of October 17, 2016.

 

89,000

 

-

 

412,212

 

-

 

Current portion of related party convertible promissory notes

 

412,212

 

-

 

Related party convertible promissory note, less current portion

 

$

-

 

$

-

 

Note 14 - Stockholders’ Deficit

 

The total number of shares of all classes of capital stock which the Company is authorized to issue is 10,000,000 shares of common stock with $0.0001 par value.

 

 As of December 31, 2015 and 2014, there were 2,000,000 shares of the Company’s common stock issued and outstanding.

 

Note 15 - Income Taxes

 

The Company utilizes FASBASC740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized.

 

The Company generated a deferred tax asset through net operating loss carry-forwards. Based upon Management’s evaluation, a valuation allowance of 100% has been established due to the uncertainty of the Company’s realization of the benefit derived from net operating loss carry-forwards.

 

Deferred income taxes arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or noncurrent depending on the periods in which the temporary differences are expected to reverse. The Company does not have any uncertain tax positions.

 

The Company does not have any income tax expense for the years ended December 31, 2015 and 2014.

 

The total deferred tax asset is calculated by multiplying a domestic (US) 34 percent marginal tax rate by the cumulative Net Operating Loss Carryforwards (“NOL”). The Company currently has net operating loss carryforwards approximately aggregating $6,600,135, which expire through 2035. The deferred tax asset related to the NOL carryforwards Management has determined based on all the available information that a 100% Valuation reserve is required.

 

Note 16 - Commitments and Contingencies

 

Litigation:

 

From time to time the Company may become a party to litigation in the normal course of business. Management believes that there are no current legal matters that would have a material effect on the Company’s financial position or results of operations.

 

 
F-16
 

 

Operating leases

 

The Company maintains its corporate offices and manufacturing facility at 1620 Beacon Place, Oxnard, California 93033, which contains approximately 25,000 square feet. The Company is currently on a month-to-month lease.

 

The Company also leases additional office and warehouse space at 1610 and 1612 Fiske Place, Oxnard, California 93033, which contains approximately 6,547 square feet. The Company is currently on a month-to-month lease.

 

Total rent expense for the years ended December 31, 2015 and 2014 was $247,326 and $263,797, respectively.

 

Note 17 - Subsequent Events

 

On various dates in 2016, the Company and its convertible promissory note holders totaling $2,918,889 have agreed to waive their conversion rights of converting their convertible notes at the lower of $4.00 per share or 80% of the price per share at which the Company issues common stock, or if the Company issues securities convertible or exchangeable into common stock, then 80% of the conversion or exchange price of such securities, in any offering in which the Company raises minimum gross proceeds of at least $1,000,000. All convertible promissory note holders have agreed to convert their convertible promissory notes at $4.00 per share.

 

On various dates in 2016, the holders of the convertible promissory notes totaling $2,918,889 have agreed to extend the maturity date from February 25, 2016 to August 31, 2016. No other terms from the original convertible promissory notes have changed.

 

From January 1, 2016 to September 8, 2016, the Company has issued convertible promissory notes totaling $5,821,463. These convertible promissory notes issued in 2016 are due on various dates from January 4, 2017 to September 8, 2017. Interest is payable at 1% annum; unsecured and principal and accrued interest automatically convertible into common stock at $1.00 per share upon closing of a merger. Accrued interest is due on various dates from January 4, 2017 to September 8, 2017. If on or prior to the maturity date, the Company completes a merger, then all accrued and unpaid interest due under these notes shall be waived. The Company formally closed its convertible note offering on October 6, 2016. The Company agreed to issue a warrant to purchase 141,142 shares of common stock at $1.00 per share exercisable within five years to Colorado Financial Service Corporation as part compensation for services rendered in connection to the Company’s convertible note offering.

 

On January 8, 2016, the Company received 50% ownership in Cure Innovations, Inc (“CI”). CI was created in 2015 by IncuBrands Studio, Inc (“IncuBrands”). The Company and IncuBrands each own 50% of the common stock of CI. The Company and IncuBrands entered into a Joint Venture agreement in 2013 to distribute several OTF products utilizing IncuBrands marketing and contacts in the various industries as well as utilize the Company’s technology and capabilities of manufacturing OTF’s.

 

On October 6, 2016, various convertible promissory note holders that total to $216,889 converted their convertible promissory notes along with unpaid accrued interest into common stock shares of the Company at $4.00 per share. As a result of the conversion, a total of 77,785 common stock shares were issued on October 6, 2016.

 

On October 6, 2016, various convertible promissory note holders that total to $3,025,212 converted a portion of their convertible promissory notes along with unpaid accrued interest into common stock shares of the Company at $4.00 per share. As a result of the conversion, a total of 361,691 common stock shares were issued on October 6, 2016.

 

On October 17, 2016, various convertible promissory note holders that total to $3,025,212 converted their remaining portion of their convertible promissory notes along with unpaid accrued interest into common stock shares of the Company at $4.00 per share. As a result of the conversion, a total of 278,776 common stock shares were issued on October 17, 2016.

 

 

F-17

 

EXHIBIT 99.2

   

FINANCIAL STATEMENTS

Cure Pharmaceutical Corporation

 

Condensed Balance Sheets (unaudited)

 

F-2

Condensed Statements of Operations (unaudited)

 

F-3

Condensed Statements of Cash Flows (unaudited)

 

F-4

Notes to Condensed Financial Statements (unaudited)

 

F-5

 

 
F-1
 

 

Cure Pharmaceutical Corporation

Condensed Balance Sheets 

 

 

June 30,

2016

 

December 31,

2015

 

(unaudited)

 

Assets

Current assets:

 

Cash

 

$

2,025,787

 

$

13,352

 

Restricted Cash

 

99,980

 

49,980

 

Accounts receivable

 

228

 

1,907

 

Notes receivable

 

36,238

 

17,948

 

Inventory

 

178,490

 

191,465

 

Prepaid expenses and other assets

 

741,960

 

38,122

 

Total current assets

 

3,082,683

 

312,774

 

Property and equipment, net

 

373,275

 

381,830

 

Intangibles, net

 

953,920

 

949,725

 

Other assets

 

168,962

 

177,820

 

Total assets

 

$

4,578,840

 

$

1,822,149

 

Liabilities and Stockholders' Deficit

Current liabilities:

 

Accounts payable

 

$

348,568

 

$

614,250

 

Accrued expenses

 

344,728

 

297,905

 

Current portion of loan payable

 

5,894

 

17,188

 

Current portion of notes payable

 

124,915

 

402,874

 

Current portion of capital lease payable

 

12,072

 

11,362

 

Current portion of convertible promissory notes

 

7,486,852

 

3,114,889

 

Current portion of related party convertible promissory notes

 

412,212

 

412,212

 

Deferred revenue

 

186,980

 

215,519

 

Total current liabilities

 

8,922,221

 

5,086,199

 

License fees

 

560,000

 

560,000

 

Capital lease payable

 

3,234

 

9,453

 

Total liabilities

 

9,485,455

 

5,655,652

 

Stockholders' Deficit:

 

Common stock: $0.0001 par value; authorized 10,000,000 shares;

 

2,000,000 shares issued and outstanding as of

 

June 30, 2016 and December 31, 2015

 

200

 

200

 

Additional paid-in capital

 

2,727,531

 

2,727,531

 

Accumulated deficit

 

(7,634,346

)

 

(6,561,234

)

Total stockholders' deficit

 

(4,906,615

)

 

(3,833,503

)

Total liabilities and stockholders' deficit

 

$

4,578,840

 

$

1,822,149

  

The accompanying notes are an integral part of these unaudited condensed financial statements

 
 
F-2
 

 

Cure Pharmaceutical Corporation

Condensed Statements of Operations

(Unaudited)

 

 

 

For the Three Months Ended June 30,

 

 

For the Six Months Ended June 30,

 

 

 

2016

 

 

2015

 

 

2016

 

 

2015

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Net product sales

 

$ 14,151

 

 

$ 19,950

 

 

$ 42,662

 

 

$ 98,722

 

Consulting research & development income

 

 

-

 

 

 

7,725

 

 

 

-

 

 

 

17,225

 

Shipping and other sales

 

 

3,000

 

 

 

-

 

 

 

3,098

 

 

 

4,573

 

Total revenues

 

 

17,151

 

 

 

27,675

 

 

 

45,760

 

 

 

120,520

 

Costs and expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

 

10,579

 

 

 

19,025

 

 

 

37,744

 

 

 

84,479

 

Gross profit

 

 

6,572

 

 

 

8,650

 

 

 

8,016

 

 

 

36,041

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expenses

 

 

171,447

 

 

 

171,098

 

 

 

298,799

 

 

 

384,970

 

Selling, general and administrative expenses

 

 

296,098

 

 

 

226,933

 

 

 

579,463

 

 

 

429,076

 

Total costs and expenses

 

 

467,545

 

 

 

398,031

 

 

 

878,262

 

 

 

814,046

 

Net loss from operations

 

 

(460,973 )

 

 

(389,381 )

 

 

(870,246 )

 

 

(778,005 )

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

45

 

 

 

-

 

 

 

412

 

 

 

6

 

Other income

 

 

-

 

 

 

145,406

 

 

 

-

 

 

 

145,406

 

Loss on disposal of Plant, Property & Equipment

 

 

-

 

 

 

-

 

 

 

(3,323 )

 

 

-

 

Other expense

 

 

(88,491 )

 

 

(18,640 )

 

 

(100,634 )

 

 

(36,480 )

Interest expense

 

 

(47,603

)

 

 

(35,971 )

 

 

(99,321 )

 

 

(60,941 )

Other income (expense)

 

 

(136,049 )

 

 

90,795

 

 

 

(202,866 )

 

 

47,991

 

Net loss before income taxes

 

 

(597,022 )

 

 

(298,586 )

 

 

(1,073,112 )

 

 

(730,014 )

Provision for income taxes

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Net loss

 

$ (597,022 )

 

$ (298,586 )

 

$ (1,073,112 )

 

$ (730,014 )

Net loss per share, basic and diluted

 

$ (0.29 )

 

$ (0.15 )

 

$ (0.53 )

 

$ (0.36 )

Weighted average shares outstanding, basic and diluted

 

 

2,000,000

 

 

 

2,000,000

 

 

 

2,000,000

 

 

 

2,000,000

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements

 
 
F-3
 

 

Cure Pharmaceutical Corporation

Condensed Statements of Cash Flows

(Unaudited)

 

 

 

For the Six Months

Ended

June 30, 2016

 

 

For the Six Months

Ended

June 30, 2015

 

 

 

 

 

 

 

 

Net loss

 

$ (1,073,112 )

 

$ (730,014 )

Adjustment to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

75,394

 

 

 

86,606

 

Loss on disposal of Property and Equipment

 

 

3,323

 

 

 

-

 

Change in other assets and liabilities:

 

 

 

 

 

 

 

 

Restricted cash

 

 

(50,000 )

 

 

-

 

Accounts receivable

 

 

1,679

 

 

 

113,998

 

Inventory

 

 

12,975

 

 

 

19,719

 

Prepaid expenses and other assets

 

 

(703,838 )

 

 

15,537

 

Other assets

 

 

8,858

 

 

 

56,591

 

Accounts payable

 

 

(265,682 )

 

 

119,901

 

Accrued expenses

 

 

46,823

 

 

 

213,320

 

Deferred revenue

 

 

(28,539 )

 

 

(145,052 )

License fees

 

 

-

 

 

 

360,000

 

Net cash (used in) provided by operating activities

 

 

(1,972,119 )

 

 

110,913

 

 

 

 

 

 

 

 

 

 

Cash flows from investing activities

 

 

 

 

 

 

 

 

Purchase in intangible assets

 

 

(25,527 )

 

 

(40,210 )

Advances made to note receivable

 

 

(18,290 )

 

 

-

 

Acquisition of property and equipment, net

 

 

(48,830 )

 

 

(186,395 )

Net cash used in investing activities

 

 

(92,647 )

 

 

(226,911 )

 

 

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

 

 

Proceeds from convertible promissory notes

 

 

4,371,963

 

 

 

129,000

 

Loan and notes payable repayments

 

 

(289,253 )

 

 

(11,296 )

Capital lease payments

 

 

(5,509 )

 

 

(4,879 )

Net cash provided by financing activities

 

 

4,077,201

 

 

 

112,825

 

 

 

 

 

 

 

 

 

 

Net increase (decrease) in cash and cash equivalents

 

 

2,012,435

 

 

 

(3,174 )

 

 

 

 

 

 

 

 

 

Cash and cash equivalents, beginning of period

 

 

13,352

 

 

 

4,206

 

Cash and cash equivalents, end of period

 

$ 2,025,787

 

 

$ 1,032

 

 

 

 

 

 

 

 

 

 

Supplemental cash flow information

 

 

 

 

 

 

 

 

Cash paid for interest and income taxes:

 

 

 

 

 

 

 

 

Interest

 

$ 9,112

 

 

$ 9,564

 

Income taxes

 

$ -

 

 

$ -

 

Non-cash investing and financing activities:

 

 

 

 

 

 

 

 

Deferred revenue converted to note payable

 

$ -

 

 

$ 285,200

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 
 
F-4
 

 

CURE PHARMACEUTICAL CORPORATION.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Note 1 - Nature of the Business

 

Cure Pharmaceutical Corporation (“Cure”, “we”, “us”, “our” or the “Company”) is a specialty pharmaceutical and bioscience company with a focus in drug delivery technologies. Cure leverages novel drug delivery technologies to develop and commercialize new applications of proven therapeutics through Oral Thin Film (“OTF”) via our proprietary patented matrix technology as well as through transdermal applications. Our micro encapsulation of drug actives in our matrix technology allows for a higher volume of an active and if required, multiple actives to be produced on a single oral thin film strip.

 

The Company is focused on partnering with pharmaceutical and biotech companies seeking to deliver drug actives utilizing and benefitting from our proprietary OTF and transdermal applications and when preferable to take our own products from clinical process to commercialization. We are focused on both the human and veterinary prescription, OTC and nutraceutical markets. Cure represents the complete solution for OTF drug delivery therapeutics from inception to finished product utilizing our CGMP/FDA registered manufacturing facility and processes.

 

Basic of Presentation of the Condensed Financial Statements

 

The accompanying unaudited condensed financial statements of the Company are prepared by management on the accrual basis of accounting and in accordance with principles generally accepted in the United States of America ("GAAP") for interim financial information as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC"), and in conjunction with rules and regulations of the SEC. Certain information and footnote disclosures required for annual financial statements have been condensed or excluded pursuant to SEC rules and regulations. Accordingly, the unaudited condensed financial statements do not include all of the information and footnotes required by the US GAAP for complete financial statements. The unaudited condensed financial statements include accounts and related adjustments, which are, in the opinion of management, of a normal recurring nature and necessary for a fair presentation of the Company's financial position, results of operations and cash flows for the interim period. Operating results for the three and six months ended June 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. These unaudited condensed financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's Annual Report for the year ended December 31, 2015.

 

The balance sheet as of December 31, 2015 contained herein has been derived from the audited financial statements as of December 31, 2015.

 

Note 2 - Summary of Significant Accounting Policies

 

Use of Estimates

 

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. At June 30, 2016 and December 31, 2015 included in these estimates are assumptions about collection of accounts receivable, and useful life of fixed and intangible assets.

 
 
F-5
 

 

Cash and Cash Equivalents

 

The Company considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid investments with maturities of three months or less, when purchased, to be cash and cash equivalents. As of June 30, 2016 and December 31, 2015, the Company had no cash equivalents. The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (FDIC) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. At June 30, 2016 and December 31, 2015, the Company does not have any uninsured balances.

 

Restricted Cash

 

Restricted cash consists $99,980 of total funds received in an escrow account from accredited investors. These funds are in relation to convertible promissory notes issued to these accredited investors. The funds held in the escrow account will remain in there until all obligations are met in relation to the convertible promissory notes.

  

Investment in Associates

 

An associate is an entity over which the Company has significant influence through a joint venture. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or joint control over those policies.

 

The results and assets and liabilities of associates are incorporated in the consolidated financial statements using the equity method of accounting. Under the equity method, investments in associates are carried in the consolidated balance sheet at cost as adjusted for post-acquisition changes in the Company’s share of the net assets of the associate, less any impairment in the value of the investment. Losses of an associate in excess of the Company’s interest in that associate are not recognized. Additional losses are provided for, and a liability is recognized, only to the extent that the Company has incurred legal or constructive obligations or made payments on behalf of the associate.

 

Any excess of the cost of acquisition over the Company’s share of the net fair value of the identifiable assets, liabilities and contingent liabilities of the associate recognized at the date of acquisition is recognized as goodwill. The goodwill is included within the carrying amount of the investment.

 

On January 8, 2016, the Company received 50% ownership in Cure Innovations, Inc (“CI”). CI was created in 2015 by IncuBrands Studio, Inc (“IncuBrands”). The Company and IncuBrands each own 50% of the common stock of CI. The Company and IncuBrands entered into a Joint Venture agreement in 2013 to distribute several OTF products utilizing IncuBrands marketing and contacts in various industries as well as utilize the Company’s technology and capabilities of manufacturing OTF’s.

 

Capitalization of Property and Equipment

 

The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one year for: (1) assets purchased; (2) existing assets that are replaced, improved or the useful lives have been extended; or (3) all land, regardless of cost. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs, including any planned major maintenance activities, are expensed as incurred.

 
 
F-6
 

 

Revenue Recognition

 

The Company recognizes revenue in accordance with the Financial Accounting Standards Board’s (“FASB”), Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. The Company believes that these criteria are satisfied upon shipment from our facility. Freight billed to customers is presented as revenues, and the related freight costs are presented as cost of goods sold. Deferred revenue is recognized when earned and all significant obligations have been satisfied.

 

Accounts receivable

 

Accounts receivable are generally unsecured. The Company establishes an allowance for doubtful accounts receivable based on the age of outstanding invoices and management’s evaluation of collectability. Accounts are written off after all reasonable collection efforts have been exhausted and management concludes that likelihood of collection is remote. Any future recoveries are applied against the allowance for doubtful accounts.

 

Advertising Expense

 

The Company expenses marketing, promotions and advertising costs as incurred. Such costs are included in general and administrative expense in the accompanying statements of operations. No advertising costs were recorded for the three and six month periods ended June 30, 2016. The Company recorded advertising costs of $582 and $0 for the three and six month periods ended June 30, 2015, respectively.

 

Research and Development

 

Costs incurred in connection with the development of new products and processes and are charged to research and development expenses as incurred.

 

Income Taxes

 

The Company utilizes FASB ASC 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized.

 

The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of 100% has been established due to the uncertainty of the Company’s realization of the net operating loss carry forward prior to its expiration.

 

The Company has not filed its Federal and State income tax returns. Such income tax returns remain subject to examination by federal and most state tax authorities.

 
 
F-7
 

 

Basic and diluted loss per share

 

Basic loss per share is computed by dividing the net loss to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed by dividing the net loss for the period by the weighted average number of common and dilutive common equivalent shares outstanding during the period. Common equivalent shares, which consist of stock options and warrants, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.

 

Going Concern

 

The Company’s financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit at June 30, 2016 of $7,634,346. The Company had a working capital deficit of $5,839,538 as of June 30, 2016. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it establishes a revenue stream and becomes profitable. The Company is continually analyzing its current costs and is attempting to make additional cost reductions where possible. We expect that we will continue to generate losses from operations throughout 2016.

 

In order to continue as a going concern and to develop a reliable source of revenues, and achieve a profitable level of operations the Company will need, among other things, additional capital resources. Management’s plans to continue as a going concern include raising additional capital through borrowing and/or sales of equity and debt securities. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.

 

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.

 

Fair Value Measurements

 

The Company measures and discloses the fair value of assets and liabilities required to be carried at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value, establishes a framework for measuring fair value, and enhances fair value measurement disclosure.

 

ASC 825 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825 establishes three levels of inputs that may be used to measure fair value:

   

Level 1 - Quoted prices for identical assets or liabilities in active markets to which we have access at the measurement date.

 

Level 2 - Inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly.

 

Level 3 - Unobservable inputs for the asset or liability.

 
 
F-8
 

 

The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

 

As of June 30, 2016 and 2015, the Company has determined that there were no assets or liabilities measured at fair value.

 

Inventory

 

Inventory consists of raw materials, packaging components, work-in-process and finished goods. The Company’s inventory is stated at the lower of cost (FIFO cost basis) or market. Finished goods include the cost of labor to assemble the items.

 

Long-lived Assets

 

Long-lived assets include equipment and intangible assets other than those with indefinite lives. We assess the carrying value of our long-lived asset groups when indicators of impairment exist and recognize an impairment loss when the carrying amount of a long-lived asset is not recoverable when compared to undiscounted cash flows expected to result from the use and eventual disposition of the asset.

 

Indicators of impairment include significant underperformance relative to historical or projected future operating results, significant changes in our use of the assets or in our business strategy, loss of or changes in customer relationships and significant negative industry or economic trends. When indications of impairment arise for a particular asset or group of assets, we assess the future recoverability of the carrying value of the asset (or asset group) based on an undiscounted cash flow analysis. If carrying value exceeds projected, net, undiscounted cash flows, an additional analysis is performed to determine the fair value of the asset (or asset group), typically a discounted cash flow analysis, and an impairment charge is recorded for the excess of carrying value over fair value. As of June 30, 2016 and December 31, 2015, our qualitative analysis of long-lived assets did not indicate any impairment.

 

Concentrations of Credit Risk

 

In the normal course of business, the Company provided credit terms to its customers; however, collateral was not required. Accordingly, the Company performed credit evaluations of its customers and maintained allowances for possible losses which, when realized, were within the range of management’s expectations. From time to time, a higher concentration of credit risk existed on outstanding accounts receivable for a select number of customers due to individual buying patterns.

 

Cost of Sales

 

Cost of sales includes the purchase cost of products sold and all costs associated with getting the products to our customers, including transportation costs.

 

Shipping Costs

 

Shipping and handling costs billed to customers are recorded in sales. Shipping costs incurred by the company are recorded in selling, general and administrative expenses.

 

 
F-9
 

 

Related parties

 

Parties are considered to be related to the Company if the parties that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. All transactions with related parties shall be recorded at fair value of the goods or services exchanged.

 

Segment Reporting

 

Segment identification and selection is consistent with the management structure used by the Company’s chief operating decision maker to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company’s management structure and method of internal reporting, the Company has one operating segment. The Company’s chief operating decision maker does not review operating results on a disaggregated basis; rather, the chief operating decision maker reviews operating results on an aggregate basis.

 

Recent Accounting Pronouncements

 

ASU 2016-01

 

In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities. The purpose is to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information. This ASU is effective for the Company in the first quarter of 2018. Early adoption is not permitted except for limited provisions. The Company does not expect the adoption of this amendment to have a material effect on its financial condition and results of operations.

 

There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.

 

Note 3 – Notes Receivable

 

Note receivable consists of the following:

 

 

 

June 30,

2016

 

 

December 31,

2015

 

 

 

 

 

 

 

 

 

 

The note receivable is a promissory note with a company bearing an interest rate of 8% per annum, principal and accrued and unpaid interest is payable on demand of the Company any time before November 11, 2016 or by November 11, 2016 if no demand is made prior to such date

 

 

17,948

 

 

 

17,948

 

The note receivable is a promissory note with a company bearing an interest rate of 8% per annum, principal and accrued and unpaid interest is payable on demand of the Company any time before March 30, 2017 or by March 30, 2017 if no demand is made prior to such date

 

 

18,290

 

 

 

0

 

 

 

 

36,238

 

 

 

17,948

 

Current portion of note receivable

 

 

36,238

 

 

 

17,948

 

Note receivable, less current portion

 

$ -

 

 

$ -

 

 

 
F-10
 

  

Note 4 - Inventory

 

Inventory consists of raw materials, packaging components, work-in-process and finished goods. The Company’s inventory is stated at the lower of cost (FIFO cost basis) or market.

 

The carrying value of inventory consisted of the following:

 

 

 

June 30,

2016

 

 

December 31,

2015

 

 

 

 

 

 

 

 

 

 

Raw materials

 

$ 74,593

 

 

$ 75,800

 

Packaging components

 

 

84,203

 

 

 

88,454

 

Work-in-process

 

 

19,694

 

 

 

27,211

 

Finished goods

 

 

-

 

 

 

-

 

 

 

 

178,490

 

 

 

191,465

 

Reserve for obsolescence

 

 

-

 

 

 

-

 

Total inventory

 

$ 178,490

 

 

$ 191,465

 

 

Note 5 – Prepaid Expenses and Other Assets

 

Prepaid expenses and other assets consist of the following:

 

 

 

June 30,

2016

 

 

December 31,

2015

 

 

 

 

 

 

 

 

 

 

Prepaid acquisition costs

 

$ 420,000

 

 

$ -

 

Prepaid consulting fees

 

 

232,167

 

 

 

-

 

Prepaid finder fees

 

 

43,333

 

 

 

-

 

Prepaid insurance

 

 

11,300

 

 

 

25,206

 

Prepaid expenses – other

 

 

9,303

 

 

 

5,000

 

Other assets

 

 

25,857

 

 

 

7,916

 

Total prepaid expenses and other assets

 

$ 741,960

 

 

$ 38,122

 

 

Note 6 – Notes Payable

 

Notes payable consist of the following at June 30, 2016 and December 31, 2015:

 

 

 

2016

 

 

2015

 

 

 

 

 

 

 

 

Note to an individual, non-interest bearing, unsecured and has no fixed terms of repayment

 

$ 50,000

 

 

$ 50,000

 

Note to a company due on October 14, 2016; interest payable at 5% per annum, secured by all assets of the company (excluding patents and intellectual property); principal and interest totaling $5,000 due weekly

 

 

74,915

 

 

 

197,874

 

Note to a company with no fixed maturity date; interest payable at 10% per month, secured by certain equipment of the company; accrued and unpaid interest due monthly

 

 

-

 

 

 

70,000

 

Note to a company due on November 9, 2016; interest payable at 5% per annum, unsecured; principal and accrued and unpaid interest payable any time before November 9, 2016

 

 

-

 

 

 

85,000

 

 

 

 

 

 

 

 

 

 

 

 

 

124,915

 

 

 

402,874

 

Current portion of loan payable

 

 

124,915

 

 

 

402,874

 

Loan payable, less current portion

 

$ -

 

 

$ -

 

 
F-11
 

 

Note 7 – Convertible Promissory Notes

 

Convertible promissory notes consist of the following at June 30, 2016 and December 31, 2015:

 

 

 

2016

 

2015

 

Convertible promissory notes totaling $2,372,000 due February 25, 2016; interest payable at 3% per annum; secured by technology and patent rights; principal and accrued interest convertible into common stock at $4.00 per share (subject to adjustment if the Company sells stock or grants conversion rates at a lower price; however, holders of notes have subsequently agreed to waive these conversion rights and will convert at $4.00 per share); accrued interest due on February 25, 2016 (maturity date has been extended to August 31, 2016, but now is in default), on October 6, 2016 a portion of these notes were converted to common stock and the remaining portion of these notes converted as of October 17, 2016.

 

$

2,283,000

 

$

2,283,000

 

Convertible promissory notes totaling $250,000 to a company due February 25, 2016 including interest at 5% per annum; secured by technology and patent rights; principal and accrued interest convertible into common stock at $4.00 per share (subject to adjustment if the Company sells stock or grants conversion rates at a lower price; however, holders of notes have subsequently agreed to waive these conversion rights and will convert at $4.00 per share); accrued interest due February 25, 2016 (maturity date has been extended to August 31, 2016, but now is in default), on October 6, 2016 a portion of these notes were converted to common stock and the remaining portion of these notes converted as of October 17, 2016.

 

250,000

 

250,000

 

Convertible promissory notes totaling $4,556,963 due on various dates from November 16, 2016 to June 29, 2017; interest payable at 1% per annum; unsecured; principal and accrued interest automatically convertible into common stock at $1.00 per share upon closing of a merger; accrued interest due on various dates from November 10, 2016 to December 30, 2016 (if on or prior to the maturity date, the Company completes a merger, then all accrued and unpaid interest due under these notes shall be waived).

 

4,656,963

 

285,000

 

Convertible promissory notes of $194,135 due June 7, 2013 (in default) and $22,754 due August 8, 2014 (in default); interest payable at 8% per annum and a default rate of 12% per annum; secured by technology and patent rights; principal and accrued interest convertible into common stock at $5.50 per share, however, holders of these notes have subsequently agreed to convert at $4.00 per share; accrued interest due on June 7, 2013 not paid (13 holders) and accrued interest due on August 8, 2014 (4 holders), on October 6, 2016 these notes were converted to common stock.

 

216,889

 

216,889

 

Convertible promissory notes totaling $80,000 to a company due February 25, 2016 including interest at 3% per annum; secured by technology and patent rights; principal and accrued interest convertible into common stock at $4.00 per share (subject to adjustment if the Company sells stock or grants conversion rates at a lower price; however, holders of notes have subsequently agreed to waive these conversion rights and will convert at $4.00 per share); accrued interest due February 25, 2016 (maturity date has been extended to August 31, 2016, but now is in default), on October 6, 2016 a portion of these notes were converted to common stock and the remaining portion of these notes converted as of October 17, 2016.

 

80,000

 

80,000

 

7,486,852

 

3,114,889

 

Current portion of convertible promissory notes

 

7,486,852

 

3,114,889

 

Convertible promissory notes, less current portion

 

$

-

 

$

-

 

 
F-12
 

 

Note 8 - Related Party Convertible Promissory Notes

 

Related party convertible promissory notes consist of the following at June 30, 2016 and December 31, 2015:

 

 

 

2016

 

2015

 

Convertible promissory notes totaling $323,212 to related parties due December 31, 2016 including interest at 3% per annum; secured by technology and patent rights; principal and accrued interest convertible into common stock at $4.00 per share (subject to adjustment if the Company sells stock or grants conversion rates at a lower price; however, holders of notes have subsequently agreed to waive these conversion rights and will convert at $4.00 per share); accrued interest due December 31, 2016, on October 6, 2016 a portion of these notes were converted to common stock and the remaining portion of these notes converted as of October 17, 2016.

 

$

323,212

 

$

323,212

 

Convertible promissory note totaling $89,000 due February 25, 2016; interest payable at 3% annum; secured by technology and patent rights; principal and accrued interest convertible into common stock at $4.00 per share (subject to adjustment if the Company sells stock or grants conversion rates at a lower price; however, holders of notes have subsequently agreed to waive these conversion rights and will convert at $4.00 per share); accrued interest due on February 25, 2016 (maturity date has been extended to August 31, 2016, but now is in default), on October 6, 2016 a portion of these notes were converted to common stock and the remaining portion of these notes converted as of October 17, 2016.

 

$

89,000

 

$

89,000

 

412,212

 

412,212

 

Current portion of related party convertible promissory notes

 

412,212

 

412,212

 

Related party convertible promissory note, less current portion

 

$

-

 

$

-

 

Note 9 - Commitments and Contingencies

 

Litigation:

 

From time to time the Company may become a party to litigation in the normal course of business. Management believes that there are no current legal matters that would have a material effect on the Company’s financial position or results of operations.

 

Operating leases

 

The Company maintains its corporate offices and manufacturing facility at 1620 Beacon Place, Oxnard, California 93033, which contains approximately 25,000 square feet. The Company is currently on a month-to-month lease.

 

The Company also leases additional office and warehouse space at 1610 and 1612 Fiske Place, Oxnard, California 93033, which contains approximately 6,547 square feet. The Company is currently on a month-to-month lease.

 

Total rent expense for the three and six month periods ended June 30, 2016 was $61,897 and $125,427 respectively. Total rent expense for the three and six month periods ended June 30, 2015 was $66,998 and $129,844 respectively.

 
 
F-13
 

 

Note 10 - Subsequent Events

 

From July 6, 2016 to September 8, 2016, the Company has issued convertible promissory notes totaling $1,499,500. These convertible promissory notes issued in 2016 are due on various dates from July 6, 2017 to September 8, 2017. Interest is payable at 1% per annum; unsecured and principal and accrued interest automatically convertible into common stock at $1.00 per share upon closing of a merger. Accrued interest is due on various dates from July 6, 2017 to September 8, 2017. If on or prior to the maturity date, the Company completes a merger, then all accrued and unpaid interest due under these notes shall be waived. The Company formally closed its convertible note offering on October 6, 2016. The Company agreed to issue a warrant to purchase 141,142 shares of common stock at $1.00 per share exercisable within five years to Colorado Financial Service Corporation as part compensation for services rendered in connection to the Company’s convertible note offering.

 

On October 6, 2016, various convertible promissory note holders that total to $216,889 converted their convertible promissory notes along with unpaid accrued interest into common stock shares of the Company at $4.00 per share. As a result of the conversion, a total of 77,785 common stock shares were issued on October 6, 2016.

 

On October 6, 2016, various convertible promissory note holders that total to $3,025,212 converted a portion of their convertible promissory notes along with unpaid accrued interest into common stock shares of the Company at $4.00 per share. As a result of the conversion, a total of 361,691 common stock shares were issued on October 6, 2016.

 

On October 17, 2016, various convertible promissory note holders that total to $3,025,212 converted their remaining portion of their convertible promissory notes along with unpaid accrued interest into common stock shares of the Company at $4.00 per share. As a result of the conversion, a total of 278,776 common stock shares were issued on October 17, 2016.

 

 

 

 

F-14

 

 

EXHIBIT 99.3

 

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

The unaudited condensed consolidated pro forma statements of operations are presented combining Cure Pharmaceutical Corporation’s (“Cure”) condensed audited statement of operations for the year ended December 31, 2015 and Makkanotti Group Corp’s (“the Company” or “Makkanotti”) audited condensed statement of operations for the year ended March 31, 2016 and the unaudited condensed statement of operations for Cure’s six-month period ended June 30, 2016 and the Company’s three month period ended June 30, 2016. The unaudited condensed combined pro forma balance sheet gives effect to the acquisition as if the transaction had taken place on June 30, 2016 and combines Cure’s unaudited condensed balance sheet as of June 30, 2016 with the Company’s condensed balance sheet as of June 30, 2016.

 

The unaudited pro forma condensed combined financial information is for illustrative purposes only. These companies may have performed differently had they actually been combined for the periods presented. You should not rely on the pro forma condensed combined financial information as being indicative of the historical results that would have been achieved had the companies always been combined or the future results that the combined companies will experience after the reverse acquisition. Unaudited pro forma financial information and the notes thereof should be read in conjunction with the accompanying historical financial statements of Cure and Management’s Discussion and Analysis included elsewhere in this report.

 

 
1
 

 

Makkanotti Group Corp.

Unaudited Pro Forma Condensed Consolidated Balance Sheets

June 30, 2016

 

 

 

Makkanotti For the Three Months
Ended
June 30,
2016

 

 

Cure For the
Six Months
Ended
June 30,
2016

 

 

Consolidated

 

 

Pro forma Adjustments

 

 

Reference

 

Consolidated
Pro Forma

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash

 

 

389

 

 

 

2,025,787

 

 

 

2,026,176

 

 

 

 

 

 

 

 

2,026,176

 

Restricted cash

 

 

-

 

 

 

99,980

 

 

 

99,980

 

 

 

 

 

 

 

 

99,980

 

Accounts receivable

 

 

-

 

 

 

228

 

 

 

228

 

 

 

 

 

 

 

 

228

 

Notes receivable

 

 

-

 

 

 

36,238

 

 

 

36,238

 

 

 

 

 

 

 

 

36,238

 

Inventory

 

 

2,484

 

 

 

178,490

 

 

 

180,974

 

 

 

 

 

 

 

 

180,974

 

Prepaid expenses and other assets

 

 

1,100

 

 

 

741,960

 

 

 

743,060

 

 

 

(485,000 )

 

(a)

 

 

258,060

 

Total current assets

 

 

3,973

 

 

 

3,082,683

 

 

 

3,086,656

 

 

 

(485,000 )

 

 

 

 

2,601,656

 

Property and equipment, net

 

 

6,428

 

 

 

373,275

 

 

 

379,703

 

 

 

 

 

 

 

 

 

379,703

 

Intangibles, net

 

 

-

 

 

 

953,920

 

 

 

953,920

 

 

 

 

 

 

 

 

 

953,920

 

Other assets

 

 

-

 

 

 

168,962

 

 

 

168,962

 

 

 

 

 

 

 

 

 

168,962

 

Total assets

 

 

10,401

 

 

 

4,578,840

 

 

 

4,589,241

 

 

 

(485,000 )

 

 

 

 

4,104,241

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders' Deficit

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accounts payable

 

 

-

 

 

 

348,568

 

 

 

348,568

 

 

 

 

 

 

 

 

 

348,568

 

Accrued expenses

 

 

-

 

 

 

344,728

 

 

 

344,728

 

 

 

(257,660 )

 

(b)

 

 

87,068

 

Current portion of loan payable

 

 

-

 

 

 

5,894

 

 

 

5,894

 

 

 

 

 

 

 

 

 

5,894

 

Current portion of notes payable

 

 

-

 

 

 

124,915

 

 

 

124,915

 

 

 

 

 

 

 

 

 

124,915

 

Current portion of capital lease payable

 

 

-

 

 

 

12,072

 

 

 

12,072

 

 

 

 

 

 

 

 

 

12,072

 

Current portion of convertible promissory notes

 

 

-

 

 

 

7,486,852

 

 

 

7,486,852

 

 

 

(2,220,389 )

 

(b)

 

 

5,266,463

 

Current portion of related party convertible promissory notes

 

 

-

 

 

 

412,212

 

 

 

412,212

 

 

 

(364,925 )

 

(b)

 

 

47,287

 

Deferred revenue

 

 

-

 

 

 

186,980

 

 

 

186,980

 

 

 

 

 

 

 

 

 

186,980

 

Total current liabilities

 

 

-

 

 

 

8,922,221

 

 

 

8,922,221

 

 

 

(2,842,974 )

 

 

 

 

6,079,247

 

License fees

 

 

-

 

 

 

560,000

 

 

 

560,000

 

 

 

 

 

 

 

 

 

560,000

 

Capital lease payable

 

 

-

 

 

 

3,234

 

 

 

3,234

 

 

 

 

 

 

 

 

 

3,234

 

Loan payable - related party

 

 

11,032

 

 

 

-

 

 

 

11,032

 

 

 

 

 

 

 

 

 

11,032

 

Total liabilities

 

 

11,032

 

 

 

9,485,455

 

 

 

9,496,487

 

 

 

(2,842,974 )

 

 

 

 

6,653,513

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders' Deficit:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock: $0.001 par value; authorized 75,000,000 shares; 17,122,831 shares issued and outstanding as of June 30, 2016

 

 

24,984

 

 

 

200

 

 

 

25,184

 

 

 

(8,061 )

 

(b) (c) (d)

 

 

17,123

 

Additional paid-in capital

 

 

-

 

 

 

2,727,531

 

 

 

2,727,531

 

 

 

2,825,420

 

 

(b) (c) (e)

 

 

5,552,951

 

Accumulated deficit

 

 

(25,615 )

 

 

(7,634,346 )

 

 

(7,659,961 )

 

 

(459,385 )

 

(a) (e)

 

 

(8,119,346 )

Total stockholders' deficit

 

 

(631 )

 

 

(4,906,615 )

 

 

(4,907,246 )

 

 

2,357,974

 

 

 

 

 

(2,549,272 )

Total liabilities and stockholders' deficit

 

 

10,401

 

 

 

4,578,840

 

 

 

4,589,241

 

 

 

(485,000 )

 

 

 

 

4,104,241

 

 

 
2
 

  

Makkanotti Group Corp.

Unaudited Pro Forma Condensed Consolidated Statement of Operations

For the Year Ended March 31, 2016

 

 

 

Makkanotti For
the Year
Ended
March 31,
2016

 

 

Cure For
the Year
Ended
December 31,
2015

 

 

Pro forma Adjustments

 

Reference

 

Consolidated
Pro Forma

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

Net product sales

 

 

11,395

 

 

 

150,439

 

 

 

 

 

 

 

161,834

 

Consulting research & development income

 

 

-

 

 

 

25,225

 

 

 

 

 

 

 

25,225

 

Shipping and other sales

 

 

-

 

 

 

7,766

 

 

 

 

 

 

 

7,766

 

Total revenues

 

 

11,395

 

 

 

183,430

 

 

 

 

 

 

 

194,825

 

Cost of goods sold

 

 

1,288

 

 

 

117,012

 

 

 

 

 

 

 

118,300

 

Gross Profit

 

 

10,107

 

 

 

66,418

 

 

 

 

 

 

 

76,525

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expenses

 

 

-

 

 

 

681,699

 

 

 

 

 

 

 

681,699

 

Selling, general and administrative expenses

 

 

20,564

 

 

 

920,247

 

 

 

 

 

 

 

940,811

 

Total expenses

 

 

20,564

 

 

 

1,601,946

 

 

 

 

 

 

 

1,622,510

 

Net loss from operations

 

 

(10,457 )

 

 

(1,535,528 )

 

 

 

 

 

 

(1,545,985 )

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-

 

Interest income

 

 

-

 

 

 

199

 

 

 

 

 

 

 

199

 

Other income

 

 

-

 

 

 

177,892

 

 

 

 

 

 

 

177,892

 

Other expense

 

 

-

 

 

 

(72,160 )

 

 

 

 

 

 

(72,160 )

Interest expense

 

 

-

 

 

 

(173,464 )

 

 

 

 

 

 

(173,464 )

Other income (expense)

 

 

-

 

 

 

(67,533 )

 

 

 

 

 

 

(67,533 )

Net loss before income taxes

 

 

(10,457 )

 

 

(1,603,061 )

 

 

 

 

 

 

(1,613,518 )

Provision for income taxes

 

 

-

 

 

 

-

 

 

 

 

 

 

 

-

 

Net loss

 

 

(10,457 )

 

 

(1,603,061 )

 

 

 

 

 

 

(1,613,518 )

Net loss per share, basic and diluted

 

 

(0.00 )

 

 

(0.80 )

 

 

 

 

 

 

(0.09 )

Weighted average shares outstanding, basic and diluted

 

 

6,093,918

 

 

 

2,000,000

 

 

 

 

 

 

 

17,122,831

 

 

 
3
 

 

Makkanotti Group Corp.

Unaudited Pro Forma Condensed Consolidated Statement of Operations

For the Three Months Ended March 31, 2016

 

 

 

Makkanotti For
the Three

Months
June 30,

2016

 

 

Cure For the
Six Months
Ended
June 30,

2016

 

 

Pro forma Adjustments

 

 

Reference

 

Consolidated
Pro Forma

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net product sales

 

 

7,600

 

 

 

42,662

 

 

 

 

 

 

 

 

50,262

 

Shipping and other sales

 

 

-

 

 

 

3,098

 

 

 

 

 

 

 

 

3,098

 

Total revenues

 

 

7,600

 

 

 

45,760

 

 

 

-

 

 

 

 

 

53,360

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

 

829

 

 

 

37,744

 

 

 

 

 

 

 

 

 

38,573

 

Gross Profit

 

 

6,771

 

 

 

8,016

 

 

 

 

 

 

 

 

 

14,787

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expenses

 

 

-

 

 

 

298,799

 

 

 

 

 

 

 

 

 

298,799

 

Selling, general and administrative expenses

 

 

17,439

 

 

 

579,463

 

 

 

485,000

 

 

(a)

 

 

1,081,902

 

Total expenses

 

 

17,439

 

 

 

878,262

 

 

 

485,000

 

 

 

 

 

1,380,701

 

Net loss from operations

 

 

(10,668 )

 

 

(870,246 )

 

 

(485,000 )

 

 

 

 

(1,365,914 )

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

-

 

 

 

412

 

 

 

 

 

 

 

 

 

412

 

Loss on disposal of Plant, Property & Equipment

 

 

-

 

 

 

(3,323 )

 

 

 

 

 

 

 

 

(3,323 )

Other expense

 

 

-

 

 

 

(100,634 )

 

 

 

 

 

 

 

 

(100,634 )

Interest expense

 

 

-

 

 

 

(99,321 )

 

 

-

 

 

 

 

 

(99,321 )

Other income (expense)

 

 

-

 

 

 

(202,866 )

 

 

-

 

 

 

 

 

(202,866 )

Net loss before income taxes

 

 

(10,668 )

 

 

(1,073,112 )

 

 

(485,000 )

 

 

 

 

(1,568,780 )

Provision for income taxes

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

-

 

Net loss

 

 

(10,668 )

 

 

(1,073,112 )

 

 

(485,000 )

 

 

 

 

(1,568,780 )

Net loss per share, basic and diluted

 

 

(0.00 )

 

 

(0.54 )

 

 

 

 

 

 

 

 

(0.09 )

Weighted average shares outstanding, basic and diluted

 

 

24,984,000

 

 

 

2,000,000

 

 

 

 

 

 

 

 

 

17,122,831

 

 

 
4
 

  

MAKKANOTTI GROUP CORP.

NOTES TO CONDENSED PRO FORMA UNAUDITED FINANCIAL STATEMENTS

 

Unaudited Pro Forma Condensed Financial Information .

 

On November 7, 2016, Makkanotti Group Corp. (“the Company” or “Makkanotti”) merged with Cure Pharmaceutical Corporation (“Cure”), a specialty pharmaceutical and bioscience company with a focus in disruptive drug delivery technologies pursuant to a share exchange agreement (the “Agreement”). Under the terms of the Agreement, each share of Cure capital stock was exchanged for 3.31 shares of the Company’s common stock.

 

For accounting purposes, Cure shall be the surviving entity. The transaction is accounted for using the reverse acquisition method of accounting. As a result of the recapitalization and change in control, Cure is considered the accounting acquirer in accordance with ASC 805, Business Combinations. The financial statements of the accounting acquirer became the financial statements of the registrant. The consolidated financial statements after the acquisition include the balance sheets of both companies at historical cost, the historical results of Cure and the results of the Company from the acquisition date. The accumulated earnings of Cure will be carried forward after the completion of the reverse acquisition.

 

The Pro forma Unaudited Condensed Financial Statements have been prepared in order to present consolidated financial position and results of operations of Cure and the Company as if the Merger had occurred as of June 30, 2016 for the pro forma condensed consolidated balance sheet; and to give effect as if the Merger had occurred if the transaction had taken place at April 1, 2015 for the pro forma condensed consolidated statement of operations for the year ended March 31, 2016 and the three months ended June 30, 2016.

 

The following pro forma adjustments are incorporated into the pro forma condensed consolidated balance sheet as of June 30, 2016 and the pro forma condensed consolidated statement of operations for the year ended March 31, 2016 and the three months ended June 30, 2016, respectively.

 

 

(a) To eliminate prepaid consulting fees paid to the Company by Cure

 

(b) To record the conversion of convertible notes and accrued interest totaling $2,842,974 to 710,743 common stock shares of Cure; then the 2,710,743 shares of Cure were exchanged for 8,972,561 shares of the Company

 

(c) To record the cancellation of 16,833,790 shares of the Company

 

(d) To eliminate Cure capital structure.

 

(e) To eliminate the Company’s accumulated deficit and record recapitalization of the Company

 

 

 

 

5